| Excerpt | Reference |
|---|
| "Cervix cancer is uncommon in the white population of North America and Europe with the exception of West Germany, Denmark, Sweden and Yugoslavia." | ( Persaud, V, 1977) |
| "Cancer of the cervix is exceedingly uncommon in the Malaysian Orang Asli (aborigine), despite the presence of factors associated with an increased risk of developing this malignancy." | ( Sumithran, E, 1977) |
| "Cervical cancer is considered to be a preventable disease because of its lengthy preinvasive state, the effectiveness of screening programs, and the availability of effective treatment options for preinvasive lesions." | ( Rubin, M; Yoder, L, 1992) |
| "However, cervical cancer is a relatively drug-resistant disease and prolonged cisplatin treatment appears to induce multiple mechanisms of tumor resistance." | ( Alberts, DS; Garcia, D; Mason-Liddil, N, 1991) |
| "Cancer of the uterine cervix is the leading female malignancy in developing countries such as India." | ( Luthra, UK; Rengachari, R, 1986) |
| "Chemotherapy of cervical cancer is a difficult problem." | ( Guthrie, D, 1985) |
| "Cervical cancer is the most common, accounting for 28% of diagnosed tumours and 47% of genital tumours in women." | ( Séraphin, JJ, 1984) |
| "Cervical cancer is responsive to cisplatin based combination chemotherapy." | ( Atkinson, K; Coppleson, M; Elliott, P; Friedlander, M; Green, D; Houghton, R; Kaye, SB; Russell, P; Solomon, J; Sullivan, A, 1983) |
| "Although cancer of the uterine cervix is found to occur at all ages in Bombay, it is mainly seen during middle age." | ( Jussawalla, DJ; Yeole, BB, 1984) |
| "The risk of cancer of the cervix is linked with sexual behaviour." | ( Fernandez, C; Monks, N; Reed, BD; Sharrard, RM; Talbot, M, 1995) |
| "Cancer of the cervix is the most common cancer among women in India, constituting between one-sixth to one-half of all female cancers with an age-adjusted incidence rate ranging from 19." | ( Anantha, N; Nandakumar, A; Venugopal, TC, 1995) |
| "Cervical cancer is the most common form of cancer among women in India, with an estimated 100,000 new cases developing annually in the country." | ( Anantha, N; Nandakumar, A; Venugopal, TC, 1995) |
| "Drug therapy for cervical cancer is slowly undergoing evaluation in early disease stages, in which it is more likely to make an impact." | ( Muderspach, L; Muggia, FM, 1994) |
| "Cervical cancer is one of the leading malignancies seen in Indian women." | ( Das, DK; Juneja, A; Murthy, NS; Roy, M; Sharma, S; Shukla, DK, 1993) |
| "Cancer of the uterine cervix is the commonest malignancy among females in several regions in India." | ( Mathew, B; Nair, MK; Sankaranarayanan, R; Varghese, C, 1993) |
| "Cervical cancer is the second most common malignancy in women worldwide and remains a significant health problem for women, especially minority and underserved women." | ( Hittelman, WK; Hong, WK; Lotan, R; Mitchell, MF; Nishioka, K; Richards-Kortum, R; Tortolero-Luna, G; Wharton, JT, 1995) |
| "Cervical cancer is the leading cancer among women in many developing countries, and remains a major public health problem worldwide." | ( Brinton, LA; Potischman, N, 1996) |
| "Uterine cervical cancer is the most common malignancy among females in developing countries, including India." | ( Ananth, R; Gajalakshmi, CK; Krishnamurthi, S; Shanta, V, 1996) |
| "Although cancer of the cervix is traditionally considered not to be responsive to steroid hormones, an in vitro study has reported that the addition of oestrogen increased cellular proliferation in a cervix cancer cell line that was inhibited by progesterone." | ( Bhattacharya, D; MacRae, KD; Mittra, I; Redkar, A; Sutaria, U, 1997) |
| "Cancer of the uterine cervix is the commonest cancer among Indian women accounting for 1/5 of the total cancer incidence." | ( Menon, GR; Prabhakar, AK, 1995) |
| "Progression of cervical cancer is associated with excessive circulating levels of cytokines, which are known to be modulators of tumor angiogenesis." | ( Chopra, V; Dinh, TV; Hannigan, EV, 1998) |
| "Globally cervical cancer is the fifth most common cancer and of estimated 460,000 new cases each year three quarters occur in developing countries." | ( Ananth, R, 2000) |
| "Globally, cervical cancer is the fifth most common cancer, and of an estimated 460,000 new cases each year three-quarters occur in developing countries." | ( Ananth, R, 2000) |
| "Cancer of the uterine cervix is one of the leading causes of cancer death among women worldwide." | ( Gajalakshmi, CK; Krishnamurthi, S; Ravichandran, K; Shanta, V; Swaminathan, R, 2000) |
| "Cancer of the uterine cervix is one of the leading causes of cancer death among women worldwide." | ( Gajalakshmi, CK; Krishnamurthi, S; Ravichandran, K; Shanta, V; Swaminathan, R, 2000) |
| "Bone metastasis in cervical cancer is rare." | ( Gupta, R; Julka, PK; Khullar, S; Kumar, R; Malhotra, A; Padhy, AK, 2000) |
| "Cervical cancer is thus considered an important clinical problem in sub-Saharan AFRICA: Recent studies have suggested that epithelial tumors may be regulated by cyclooxygenase (COX) enzyme products." | ( Davis, M; Hinz, S; Hofmeyr, MD; Jabbour, HN; Katz, AA; Millar, RP; Sales, KJ; Soeters, RP, 2001) |
| "Cervical cancer is the most common cancer in women in Mali and the second commonest cause of cancer mortality." | ( Bayo, S; Bosch, FX; Combita, AL; Coursaget, P; de Sanjosé, S; Diaz, M; Dolo, A; Meijer, CJ; Muñoz, N; van den Brule, AJ, 2002) |
| "Cervical cancer is common, as are gonorrhea and pelvic inflammatory disease." | ( Warren, JV, 1984) |
| "While incidence of cervical cancer is declining in industrialized countries, 80% of the 525,000 annual new cases occur in developing countries." | ( , 1997) |
| "Cervical cancer is a major world health problem for women, but the pathophysiology of this disease has received scant attention." | ( Alper, SL; Chiu, WT; Chou, CY; Ellory, JC; Hsu, KF; Hsu, YM; Shen, MR; Tang, MJ, 2003) |
| "Human cervix cancer is caused by high-risk human papillomaviruses encoding E6 and E7 oncoproteins, each of which alter function of distinct targets regulating the cell cycle, apoptosis, and differentiation." | ( Arbeit, JM; Brake, T; Duensing, S; Lambert, PF; Münger, K; Riley, RR, 2003) |
| "Cervical cancer is caused by specific types of the human papilloma virus (HPV), but not all infected women develop cancer." | ( Allan, BR; Carrara, H; Cooper, DD; Denny, LE; du Toit, G; Hoffman, M; Kelly, JP; Rosenberg, L; Shapiro, S; Stander, IA; Williamson, AL, 2003) |
| "The risk of cancer of the cervix is linked with sexual behavior." | ( Chung, BC; Kim, KM; Lee, SH; Yang, YJ, 2003) |
| "Cervical cancer is one of the most common cancers in women." | ( Inciūra, A; Juozaityte, E, 2004) |
| "Cervical cancer is one of the most common cancers affecting a woman's reproductive organs." | ( Pater, A; Shehata, F; Shehata, M, 2004) |
| "Cervical cancer is a leading cause of death by cancer among women worldwide." | ( Brake, T; Lambert, PF, 2005) |
| "Cancer of the cervix is the second most common cause of cancer-related death in women worldwide, and in some low resource countries accounts for the highest cancer mortality in women." | ( Chirenje, ZM, 2005) |
| "Cervical cancer is considered a common yet preventable cause of death in women." | ( Pater, A; Shehata, F; Shehata, M, 2005) |
| "Early stage cervical cancer is treated with surgery or radiation with equivalent results." | ( Gercel-Taylor, C; Spanos, WJ; Taylor, DD; Yashar, CM, 2005) |
| "Cervical cancer is a major cause of morbidity among women." | ( Araújo, Mdo C; Battisti, V; Kaizer, RR; Maldonado, PA; Morsch, VM; Negrini, LA; Schetinger, MR; Zanin, RF, 2006) |
| "Uterine cervix cancer is an important public health problem in developing countries." | ( Eav, S; Kahler, K; Kruy, LS; Lieng, CR; Monchy, D, 2005) |
| "Cancer of the uterine cervix is the second most common cancer among women in the world after breast cancer." | ( Chaudhry, K; Murthy, NS; Saxena, S, 2005) |
| "Nearly all cervical cancers are etiologically attributable to human papillomavirus (HPV) infection and pharmaceutical treatments targeting HPV-infected cells would be of great medical benefit." | ( Baege, AC; Centeno, JA; Disbrow, GL; Hartmann, D; Kierpiec, KA; Schlegel, R; Thibodeaux, CA; Yuan, H, 2005) |
| "Cervical cancer is the 2nd most common cancer among women, behind breast cancer." | ( Bourhis, J; Bruna, A; Castaigne, D; de Crevoisier, R; Haie-Meder, C; Lhommé, C; Morice, P; Pautier, P, 2005) |
| "Cervical cancer is strongly associated with the infection by oncogenic forms of human papillomavirus (HPV)." | ( Cao, Y; Chen, S; Chen, Y; Du, Z; Li, L; Lin, Z; Liu, B; Liu, Z; Wu, Y; Xu, A; Zhang, Y, 2006) |
| "Nearly all cervical cancers are associated with the high-risk subtypes of human papillomavirus (HPV) expressing the E6 and E7 oncoproteins." | ( Aldern, KA; Beadle, JR; Corbeil, J; Hostetler, KY; Rought, S; Trahan, J, 2006) |
| "Cervical cancer is the most frequent gynaecological cancer worldwide." | ( Bruna, A; Castaigne, D; de la Motte Rouge, T; Duvillard, P; Haie-Meder, C; Hamy, AS; Lhommé, C; Morice, P; Pautier, P, 2006) |
| "Cervical cancer is the second leading cause of death from cancer among women in Colombia (16/100,000)." | ( Arboleda-Moreno, YY; Orejuela-Aristizabal, L; Sierra-Torres, CH, 2006) |
| "Cervical cancer is the second most frequently diagnosed cancer in women worldwide." | ( Berkhof, J; Buist, MR; Comans, EF; Hoekstra, OS; Hooft, L; Molthoff, CF; van der Veldt, AA; van Diest, PJ, 2006) |
| "For these reasons, cervical cancer is considered an AIDS-defining neoplasm." | ( De Falco, G; Gichangi, P; Giordano, A; Lazzi, S; Leoncini, L; Leucci, E; Muchiri, L; Nyagol, J; Onnis, A; Pacenti, L; Palummo, N; Petraglia, F; Sanseverino, F; Santopietro, R; Spina, D; Tigli, C; Torriccelli, M, 2006) |
| "Cervical cancer is one of the leading causes of female cancer death worldwide with about 500,000 deaths per year." | ( Kang, YH; Kim, JH; Kim, SH; Lee, KA; Paik, SG; Park, SN; Yang, Y; Yoon, DY, 2007) |
| "Cervical cancer is a disease of middle-aged and elderly but still there are young women diagnosed with advanced disease that is incurable with local treatment and is treated with platinum-based combination chemotherapy." | ( Bamias, A; Bozas, G; Dimopoulos, MA; Gika, D; Kastritis, E; Koutsoukou, V; Papadimitriou, C; Rodolakis, A; Vlahos, G; Voulgaris, Z, 2007) |
| "About 50% of cervical cancers are associated with human papillomavirus type 16 (HPV-16), and since the HPV-16 E6 and E7 oncoproteins are constitutively expressed in the tumor cells, they are attractive targets for cytotoxic T lymphocyte (CTL)-mediated immunotherapy." | ( Akatsuka, Y; Ito, K; Ito, Y; Iwata, K; Kiyono, T; Kodera, Y; Kondo, E; Kuzushima, K; Morishima, S; Morishima, Y; Nakanishi, T; Nawa, A; Takahashi, T; Torikai, H; Tsujimura, K, 2007) |
| "Cancer of the uterine cervix is the commonest gynaecologic cancer in India, with most women presenting with disease extending beyond the cervix." | ( Vallikad, E, 2006) |
| "In India, cervical cancer is a significant problem in terms of incidence, mortality and morbidity." | ( Juneja, A; Pandey, A; Sehgal, A; Sharma, S, 2007) |
| "Cervical cancer is a leading cause of death due to cancer among women worldwide." | ( Brake, T; Lambert, PF; Shai, A; Somoza, C, 2007) |
| "SLN biopsy in cervical cancer is feasible to do, with a low false negative rate." | ( Beiner, M; Covens, A; Ehrlich, L; Harley, I; Hauspy, J; Rasty, G, 2007) |
| "Cervical cancer is the most common cancer in Indian women." | ( Rajappa, M; Saxena, A; Sharma, A; Sharma, M, 2007) |
| "Cervical cancer is an attractive model in which to test gene-specific therapies, because elimination of the HPV oncogenes E6 and E7 may result in cancer cell senescence." | ( Gu, W; Irving, A; McMillan, NA; Putral, LN, 2007) |
| "Cervical cancer is an important health problem in developing countries." | ( Ansink, AC, 2007) |
| "Cervical cancer is the most common cancer in Indian women and is a leading cause of death in women worldwide." | ( Rajappa, M; Saxena, A; Sharma, A; Sharma, M, 2007) |
| "Ovarian and cervical cancers are significant health problems." | ( Arranz, JA; Cassinello, J; del Campo, JM; García-Foncillas, J; González Martín, A; Mendiola, C; Oaknin, A; Ojeda, B; Poveda, A; Rubio, MJ; Salazar, R, 2007) |
| "Cervical cancer is the most common cancer among women in developing countries." | ( Cherian, J; Esmy, PO; Fayette, JM; Muwonge, R; Rajkumar, R; Sankaranarayanan, R; Shanthakumari, S; Swaminathan, R, 2007) |
| "Cervical cancer is both a preventable and a curable disease- preventable because the pre-invasive stage can be detected by screening and curable because the very early stage can be cured." | ( Abudu, OO; Anorlu, RI; Ola, ER, 2007) |
| "Cervical cancer is the second most common female cancer worldwide with high risk Human Papillomavirus (HPV) infection playing an essential aetiological role." | ( Fiander, AN; Rieck, GC, 2008) |
| "Cervical cancer is the second most common malignant neoplasm in women, in terms of incidence and mortality rates worldwide, and is associated with excessive inflammation." | ( Singh, M; Singh, N, 2008) |
| "Cervical cancer is the second most common malignancy among women worldwide and is highly radioresistant, often resulting in local treatment failure." | ( Javvadi, P; Koumenis, C; Segan, AT; Tuttle, SW, 2008) |
| "Cervical cancer is the leading cause of cancer death among women in developing countries." | ( Del Aguila, R; Delgado, JM; Gonzales, M; Lewis, K; Sellors, JW; Tsu, VD; Winkler, JL, 2008) |
| "Cervical cancer is the one of the most common cancers affecting the south Indian women." | ( Majhi, U; Rajkumar, T; Selvaluxmi, G; Vijayalakshmi, N, 2007) |
| "Cervical cancer is a leading cause of cancer-related deaths among women in India." | ( Anand, M; Deshpande, A; Kumar-Sinha, C; Samarth, M; Travasso, CM, 2008) |
| "Cervical cancer is the main cancer among women in sub-Saharan Africa, India and other parts of the developing world." | ( Arbyn, M; Basu, P; Dolo, A; Keita, N; Mbalawa, CG; Muwonge, R; Nouhou, H; Sakande, B; Sankaranarayanan, R; Sharma, A; Shastri, S; Somanathan, T; Wesley, R, 2008) |
| "Cervical cancer is the most common cancer and a leading cause of cancer deaths among women in developing countries." | ( Bharadwaj, M; Das, BC; Hussain, S; Nasare, V, 2008) |
| "Cervical cancer is one of the deadliest cancers in women with a death toll of 230,000 worldwide each year, nearly 80% in developing countries." | ( Dicker, AP; Kamer, S; Ren, Q, 2009) |
| "Cervical cancer is one of the most common neoplastic diseases affecting women, with a combined world wide incidence of almost half a million new cases." | ( Kaur, P; Malekzadeh, K; Shekari, M; Sobti, RC; Suri, V; Tamandani, DM, 2008) |
| "Cervical cancer is a leading cause of cancer death among women in low-income countries, with approximately 25% of cases worldwide occurring in India." | ( Albero, G; Bosch, FX; Clifford, G; de Sanjosé, S; Diaz, M; Goldie, SJ; Kim, JJ, 2008) |
| "Cervical cancer is the second most common cancer of women worldwide and one of the leading cause of death in relative young women." | ( Kamposioras, K; Papaxoinis, G; Pectasides, D; Pectasides, E, 2008) |
| "Cervical cancer is currently the most frequently occurring cancer among women in Mexico." | ( Buonocunto-Vázquez, G; Gurrola-Díaz, CM; Rosales-Quintana, S; Suárez-Rincón, AE; Vázquez-Camacho, G; von Knebel Doeberitz, M; Wentzensen, N, 2008) |
| "Cervical cancer is the second most common cancer among women in the world, with approximately 470,000 new cases and 231,000 deaths occurring each year." | ( Kordi Tamandani, DM; Shekari, M; Sobti, RC, 2008) |
| "Cervical cancer is a relatively neglected disease in terms of advocacy, screening and prevention from professional or public health organizations." | ( Ariyaratne, Y; Ashrafunnessa, KS; Basu, P; Bhatla, N; Esmy, PO; Gravitt, PE; Nene, BM; Sankaranarayanan, R; Shah, A, 2008) |
| "Cervical cancer is the most common reproductive cancer in women in Bangladesh, and most women come for diagnosis and treatment when it is too late." | ( Ahmed, T; Rahman, J, 2008) |
| "Cervical cancer is the second leading cause of cancer death for women in the world." | ( Flowers, L; Horowitz, I; Kowalski, K; Logan, S; Madden, K; Mohammed, SI; Salani, R; Xie, J, 2009) |
| "Cervical cancer is the most common cancer in Indian females and is associated with infection with high risk Human papillomaviruses (HPVs)." | ( Singh, M; Singh, N, 2009) |
| "Cervical cancer is one of the commonest cancers in women worldwide." | ( Khoo, EM; Low, WY; Shuib, R; Wong, LP; Wong, YL, 2009) |
| "Cervical cancer is the second most common female cancer worldwide." | ( Bean, SM; Bentley, RC; Cartwright, PS; Chang, VT; Palmer, GM; Ramanujam, N, 2009) |
| "Cervical cancer is attributable to continuous expression of the E6 and E7 oncoproteins of the high-risk human papillomaviruses." | ( Green, N; Liu, WL; Seymour, LW; Stevenson, M, 2009) |
| "Cervical cancer is one of the most frequently encountered malignancies in pregnancy." | ( Boyd, A; Cowie, V; Gourley, C, 2009) |
| "Cervical cancer is now considered the second leading cause of death among women worldwide, and its incidence has reached alarming levels, especially in developing countries." | ( Acevedo, BE; Alonso, DF; Baladrón, I; Castillo, D; Díaz, A; Gómez, R; González, CA; Herrera, L; López-Saura, P; Perea, SE; Ramos, T; Santana, A; Sigman, H; Solares, AM; Valenzuela, C, 2009) |
| "Cervical cancer is the second most common cause of cancer death in women." | ( Abdelwahab, SI; Abdul, AB; Al-zubairi, AS; Devi, N; Mariod, AA; Mohan, S; Taha, MM, 2010) |
| "Cervical cancer is a major cause of death in women worldwide and is strongly associated with human papillomavirus (HPV) infection." | ( Gray, LJ; Herrington, CS; Jolly, CE; Lain, S; Parish, JL, 2009) |
| "Cervical cancer is a leading cancer among women in developing countries." | ( Andreoli, MA; Cardoso, MA; Costa, MC; Franco, EL; Longatto Filho, A; Tomita, LY; Villa, LL, 2010) |
| "SS in cervical cancer is a feasible and safe pretreatment procedure, and when associated with CT, it improves OS and DFS." | ( Clagnan, WS; de Andrade, JM; Dos Reis, FJ; Garieri, AP; Marana, HR; Tiezzi, DG; Zola, FE, 2009) |
| "Cervical cancer is the second leading cause of cancer mortality in women worldwide, and the leading cause in Africa." | ( Dem, A; Feng, Q; Hawes, SE; Holmes, RS; Kiviat, NB; Touré, P; Weiss, NS, 2009) |
| "Human cervical cancer is an immunogenic tumor with a defined pattern of histopathological and clinical progression." | ( Coleman, DV; Dina, R; Jaafar, F; Lindstrom, V; Linton, C; Lloyd, T; Nohadani, M; Poznansky, J; Poznansky, MC; Righi, E; Stamp, G; Van Noorden, S, 2009) |
| "In India, cervical cancer is a leading cancer among women and almost all cases of cervical cancer show prevalence of High Risk (HR)-HPV infection." | ( Bharti, AC; Das, BC; Hedau, S; Hussain, S; Kumar, R; Mahata, S; Shukla, S, 2009) |
| "The incidence of cervical cancer is declining slowly necessitating concerted and organized control measures." | ( Sehgal, A; Singh, V, 2009) |
| "Cervical cancer is the second-most common cancer in women worldwide causing most cancer related deaths in women in developing countries including India." | ( Bharadwaj, M; Das, BC; Hussain, S; Nasare, V, 2009) |
| "Cervical cancer is the second most common cancer in women worldwide." | ( Bachran, C; Bachran, D; Fuchs, H; Hoffmann, C; Kaufmann, AM; Melzig, MF; Schneider, S; Urban, R; Weng, A, 2010) |
| "Cervical cancer is one of the most common gynecological malignancies in Korea, although the incidence has been declining in recent years." | ( Kim, J; Kim, JH; Kim, MK; Lee, JK; Lee, JM; Lee, JP; Lee, KB; Son, SK; Song, ES; Yun, YM, 2010) |
| "Cervical cancer is the most common cancer in Indian women." | ( Rajappa, M; Satyam, A; Sharma, A; Sharma, M, 2010) |
| "Cervical cancer is the commonest cancer in northern Nigeria." | ( Adewuyi, SA; Oguntayo, AO; Rafindadi, AH; Samaila, MO; Shittu, OS; Zayyan, MS, 2010) |
| "Cervical cancer is the second most common cancer of women in the world." | ( Ahmad, SZ; Asiya, W; Manzoor, NA; Qurieshi, MA; Yasmeen, J, 2010) |
| "Worldwide, cervical cancer is considered to be the second commonest cancer as far as mortality and incidence is concerned and India contributes to about 20–30% of the global burden." | ( Bawaskar, R; Bhavani, M; Chhabra, S; Mahajan, N, 2010) |
| "In Mexico, cervical cancer is the second leading cause of death in women after breast cancer." | ( Aguilar-Durán, M; Arreola-Herrera, Fde A; Cisneros-Pérez, V; Lares-Bayona, EF; Milla-Villeda, RH; Navarrete-Flores, JA; Núñez-Márquez, T; Rueda-Cisneros, DA; Sánchez-Anguiano, LF; Velázquez-Hernández, N, 2010) |
| "Cervical cancer is the most common cancer in Indian females and is associated with infection with high-risk Human papilloma viruses (HPVs) which encode viral oncoprotein E6 and E7." | ( Singh, M; Singh, N, 2011) |
| "Cervical cancer is emerging as a leading cause of morbidity and mortality in women worldwide." | ( Lal, P; Mittal, B; Mittal, RD; Pandey, S; Singh, S; Srivastava, K; Srivastava, M, 2011) |
| "Cervical cancer is one of the most common cancers diagnosed in women worldwide." | ( Chen, CC; Ho, SC; Jan, JS; Lin, JC; Wang, L, 2011) |
| "Cervical cancer is one of the leading causes of morbidity and mortality among women but can be prevented through simple cost-effective measures, such as creating awareness, and regular screening with the Pap smear, both in the premenopausal and postmenopausal age group." | ( Ansari, H; Ansari, M; Arif, SH; Khan, T; Mehdi, G, 2012) |
| "Screening for cervical cancer is well established in resourced countries, but in resource-constrained countries, it is almost non-existent at national level." | ( Cronjé, HS, 2011) |
| "Cervical cancer is a major mortality factor in the female population." | ( Encarnación-Guevara, S; Enríquez-Gasca, Mdel R; Hernández-Ortiz, M; Higareda-Almaraz, JC; Resendis-Antonio, O, 2011) |
| "Cervical cancer is one of the few highly preventable cancers." | ( Begum, N; Hossain, F; Nahar, KN; Nasrin, B; Nessa, A; Shamim, S, 2011) |
| "Cervical cancer is caused by human papilloma virus (HPV) expressing E6 and E7 oncoproteins, which are known to inactivate tumor suppressor proteins p53 and pRb, respectively." | ( Gupta, RC; Kausar, H; Munagala, R; Munjal, C, 2011) |
| "Cervical cancer is unique among cancers in that it can largely be prevented through screening and removal of precursor lesions." | ( Kannika, PS; Senapathy, JG; Umadevi, P, 2011) |
| "Cervical cancer is one of the most common malignant diseases affecting women worldwide." | ( Alam, MS; Ali, A; Batra, S; Mehdi, SJ; Rizvi, MM, 2012) |
| "Cervical cancer is the third most prevalent cancer in females worldwide." | ( Cetina, L; Coronel, J; Dueñas-Gonzalez, A, 2011) |
| "Worldwide, cervical cancer is the second most common causes of cancer in women and represents an important mortality rate." | ( Aguilar-Lemarroy, Adel C; Bravo-Cuellar, A; Castellanos-Esparza, YC; de Celis-Carrillo, R; del Toro-Arreola, S; Dominguez-Rodriguez, JR; Hernandez-Flores, G; Jave-Suarez, LF; Lerma-Diaz, JM; Ortiz-Lazareno, PC, 2011) |
| "Cervical cancer is the third most common cancer in women in peninsular Malaysia and very prevalent worldwide." | ( Lubis, SH; Ni, KA; Rashwan, H, 2011) |
| "Cervical cancer is a major public health problem in resource-limited settings, particularly among HIV-infected women." | ( de Klerk, R; Friedman, HM; Monare, B; Ramogola-Masire, D; Ratshaa, B; Zetola, NM, 2012) |
| "Cervical cancer is rated the second most common malignant tumor globally and is etiologically linked to human papillomavirus infection." | ( Karimi, S; Kordi-Tamandani, DM; MalekZadeh, K; Shekari, M; Sobti, RC; Suri, V, 2012) |
| "Characteristic of cervical cancer is the presence of high risk (HR) human papillomavirus (HPV) DNA in more than 99% of these tumors." | ( de Jong, S; de Vries, EG; Tan, S; van der Zee, AG, 2012) |
| "Cervical cancer is the second common type of cancer among women worldwide, with the human papillomavirus (HPV) recognized as the major causative agent." | ( Grace Nirmala, J; Narendhirakannan, RT, 2011) |
| "Cervical cancer is the most common cancer among women in many areas of India which contributes for a fifth of the global burden of disease." | ( Deodhar, K; Franceschi, S; Gheit, T; Jayant, K; Jeronimo, J; Kelkar, R; Malvi, SG; Nene, BM; Romao, CC; Sankaranarayanan, R; Shastri, S; Sylla, BS; Tenet, V; Tommasino, M; Vaccarella, S, 2012) |
| "Cervical cancer is the most common cancer among women in India and a leading cause of death in these women." | ( Bhatla, N; Pathak, S; Singh, N, 2012) |
| "Cervical cancer is one of the leading gynecological malignancies in women." | ( Jabbour, HN; Katz, AA; Sales, KJ; Sutherland, JR, 2012) |
| "Advanced cervical cancer is routinely treated with radiotherapy and cisplatin-containing chemotherapy." | ( Burger, C; Dahl, O; De Wit, R; Jones, EL; Koper, P; Mella, O; Prosnitz, LR; Schem, BC; Uitterhoeve, AL; Van Der Steen-Banasik, E; Van Der Velden, J; Van Der Wilt, C; Van Der Zee, J; Van Tinteren, H; Westermann, A, 2012) |
| "Cervical cancer is common among women worldwide." | ( Mandal, S; Raychaudhuri, S, 2012) |
| "Cervical cancer is the second most common female cancer worldwide, and it remains a challenge to manage preinvasive and invasive lesions." | ( Alshatwi, AA; Ramesh, E, 2013) |
| "Cervical cancer is the third most common cancer in women worldwide and often affects women under 40 years of age with young families." | ( Szarewski, A, 2012) |
| "Cervical cancer is the second-most common malignancy in women worldwide." | ( Ghatage, P; Sabagh, H, 2012) |
| "Cervical cancer is the second most common cancer among women up to 65 years of age and is the most frequent cause of death from gynaecological cancers worldwide." | ( Cornes, P; Flubacher, M; Forrest, JL; Scatchard, K; Williams, C, 2012) |
| "Cervical cancer is one of the most common tumors affecting women's health worldwide." | ( Cai, J; Guo, M; Hu, L; Huang, Z; Li, W; Luo, J; Shu, Z; Wang, W; Zeng, Y, 2012) |
| "Cervical cancer is the third most frequent cancer in women worldwide, mostly treated with cisplatin-based chemoradiotherapy." | ( Catarino, R; Faustino, I; Figueiredo, T; Lombo, L; Medeiros, R; Nogueira, A; Nogueira-Silva, C; Pereira, D; Silva, IH, 2013) |
| "Cervical cancer is one of the most common forms of cancer in women is the second biggest cause of female cancer mortality worldwide." | ( Khanna, P; Verma, R, 2013) |
| "Cervical cancer is the most frequent female malignancy in most developing countries." | ( Abate, E; Aseffa, A; Ashenafi, S; Bekele, L; Belayneh, M; El-Dawi, N; El-Hassan, A; El-Hassan, I; El-Tayeb, M; Engers, H; Mihret, W; Yamuah, L, 2013) |
| "Cancer of the uterine cervix is a worldwide menace taking innumerable womens' lives." | ( Mandal, S; Raychaudhuri, S, 2012) |
| "Cervical cancer is one of the most common gynecological malignancies that causes a serious health problem worldwide." | ( Batra, S; Bhambani, S; Bharadwaj, M; Hussain, S; Salhan, S; Singhal, P; Thakur, N, 2013) |
| "Cervical cancer is a major public health problem for women in sub-Saharan Africa." | ( Andreasen, A; Bousso, K; Brown, J; Changalucha, J; Descamps, D; Hayes, R; Herazeh, M; Kapiga, S; Kavishe, B; Kiviat, N; Lebacq, M; Mayaud, P; Mbaye, KD; Sow, PS; Thomas, F; Toure, M; Watson-Jones, D, 2013) |
| "Cervical cancer is both preventable and curable, yet it remains one of the leading causes of mortality in women worldwide." | ( Bradford, L; Goodman, A, 2013) |
| "Cervical cancer is the most common solid carcinoma diagnosed during pregnancy; obviously, pregnancy adds complexity to treatment recommendations." | ( Bartsch, R; Chrysikos, D; Sergentanis, TN; Zagouri, F, 2013) |
| "Cervical cancer is the most common gynecological cancer in developing countries." | ( Adepiti, AC; Ajenifuja, KO; Burk, RD; Eklund, C; Gage, JC; Hutchinson, M; Reilly, M; Schiffman, M; Wentzensen, N, 2013) |
| "Cervical cancer is the most common genital malignancy and the high-risk human papillomaviruses (HPV type 16, 18 and 31, and so on) are major agents for its cause." | ( Anderson, RA; Li, W, 2014) |
| "Cervical cancer is the most common form of cancer in Indian women, causing high morbidity and mortality." | ( Bharati, K; Ganguly, NK, 2013) |
| "Cervical cancer is one of the most common cancers in women." | ( Enokida, H; Itesako, T; Kinoshita, T; Nakagawa, M; Nohata, N; Seki, N; Shozu, M; Yamamoto, N; Yoshino, H, 2013) |
| "Cervical cancer is the second most common cause of cancer in women and has a high mortality rate." | ( Banerjee, A; Gupta, RK; Pathak, S; Sharma, C; Singh, N, 2013) |
| "Cervical cancer is the third most common cancer among Malaysian women." | ( Dahlui, M; Gan, DE, 2013) |
| "Cervical cancer is one of the leading causes of death among women with gynecological malignancies." | ( Amit, A; Keidar, Z; Lavie, O; Lowenstein, L; Netzer, I; Sobeh, S; Yosef, RB, 2013) |
| "Cervical cancer is a human papilloma virus (HPV)-related cancer, but most HPV infections are transient or intermittent and resolve spontaneously." | ( Akrami, SM; Mirsalehian, A; Modarressi, MH; Motevaseli, E; Mousavi, AS; Shirzad, M, 2013) |
| "Cancer of the uterine cervix is one of the most common cancers among women worldwide." | ( Mohan, SS; Singh, LR; Singh, NN; Thippeveeranna, C, 2013) |
| "Cervical cancer is the third most common form of cancer that strikes Malaysian women." | ( Dahlui, M; Gertig, D; Mohamed, M; Rashid, RM, 2013) |
| "Cervical cancer is one of the most frequent cancers in women worldwide." | ( Ishak, I; Rashwan, H; Sawalludin, N, 2013) |
| "In India, cervical cancer is the most common woman-related cancer, followed by breast cancer." | ( Farhath, S; Mumtaj, P; Vijaya, PP, 2013) |
| "Cervical cancer is the most common gynecological cancer and one of the major causes of female cancer-related death worldwide particularly in developing countries." | ( Armania, N; Ithnin, H; Yazan, LS; Zulfahmi, S, 2013) |
| "Cervical cancer is one of the most common malignancies in women and insensitive to chemotherapy clinically." | ( Cheng, X; Li, Y; Lu, W; Shen, Y; Wan, X; Wang, F; Wang, P; Xie, X; Ye, F, 2013) |
| "OBJECTIVE." | ( Logeswaran, P; Mercier, G; Mhlanga, JC; Mirpour, S; Russo, G; Subramaniam, RM, 2013) |
| "Cervical cancer is one of the most common cancers worldwide." | ( Charoenvilaisiri, S; Poomkokruk, A; Sakonlaya, D; Tapanadechopone, P, 2012) |
| "Cervical cancer is one of the most common cancers and cause of cancer-related deaths in women worldwide." | ( Kerdel, FA; Richmond, NA; Velazquez-Vega, J; Viera, MH, 2013) |
| "Cervical cancer is caused by human papillomavirus (HPV) in collaboration with other non-viral factors." | ( Chung, SH; Lambert, PF; Park, JW; Son, J, 2014) |
| "Cervical cancer is the second largest form of cancer to infest the leading cause of death in women worldwide." | ( Chetia, P; Choudhury, AD; Choudhury, MD; Chowdhury, A; Talukdar, AD, 2014) |
| "Cervix cancer is the second most common cancer among women worldwide, whereas paclitaxel, the first line chemotherapeutic drug used to treat cervical cancer, shows low chemosensitivity on the advanced cervical cancer cell line." | ( Huang, CH; Hung, YC; Pan, TL; Rau, KM; Wang, PW, 2013) |
| "Cervical cancer is preventable but continues to cause the deaths of more than 270,000 women worldwide each year, most of them in developing countries where programs to detect and treat precancerous lesions are not affordable or available." | ( Bartolini, RM; Huong, TT; Jeronimo, J; Kumakech, E; Mugisha, E; Nga, le T; Paul, P; Penny, ME; Winkler, JL, 2013) |
| "Cervical cancer is the leading cause of cancer mortality in India, accounting for 17% of all cancer deaths among women aged 30 to 69 years." | ( Krishnan, S; Madsen, E; Porterfield, D; Varghese, B, 2013) |
| "Cervical cancer is the second most common cancer among Malaysian women with an ASR of 17." | ( Abdul Rashid, RM; Dahlui, M, 2013) |
| "Cervical cancer is the second most common cancer of the genital tract." | ( Hasan, MM; Kamel, HH; Sanad, AS, 2014) |
| "Cervical cancer is preventable but continues to cause the deaths of more than 270,000 women worldwide each year, most of them in developing countries where programs to detect and treat precancerous lesions are not affordable or available." | ( Bartolini, RM; Huong, TT; Jeronimo, J; Kumakech, E; Mugisha, E; Nga, le T; Paul, P; Penny, ME; Winkler, JL, 2013) |
| "Cervical cancer is the leading cause of cancer mortality in India, accounting for 17% of all cancer deaths among women aged 30 to 69 years." | ( Krishnan, S; Madsen, E; Porterfield, D; Varghese, B, 2013) |
| "Oral and cervical cancers are major malignancies in men and women, respectively, in India." | ( Begum, R; Desai, A; Patel, JB; Patel, KR; Patel, PS; Shah, FD; Shukla, SN; Vajaria, BN, 2014) |
| "Cervical cancer is the second most common cancer among women worldwide, with developing countries accounting for >80% of the disease burden." | ( Deodhar, K; Kannan, S; Kumar-Sinha, C; Mahantshetty, U; Mulherkar, R; Shrivastava, SK; Thomas, A, 2013) |
| "Cervical cancer is the leading cause of cancer mortality among women in India." | ( Badwe, RA; Dikshit, R; Gupta, S; Mishra, GA; Mittra, I; Shastri, SS; Singh, S, 2014) |
| "Cervical cancer is the third commonest type of cancer among women in Malaysia." | ( Abdullah, MF; Abidin, Z; Ayub, MC; Hamzi Abdul Raub, S; Isa, NM; Kamaluddin, MA; Kassim, F; Mohd Amin, WA; Noor, RM; Omar, B; Syed Husain, SN; Tan, GC; Vicknesh, V; Zailani, HA; Zakaria, Z, 2014) |
| "Cervical cancer is the third largest cause of cancer mortality in India." | ( Dhaliwal, GS; Khaira, HK; Kumar, S; Maria, AK; Rana, ML; Saini, S; Sharma, AK; Singh, N; Verma, K, 2014) |
| "Cervical cancer is the third most common type of cancer in women worldwide and radiotherapy remains its predominant therapeutic treatment." | ( Cao, H; Cao, J; Ji, R; Lu, Z; Luo, J; Tang, Y; Yang, H; Zhang, S; Zhou, X; Zhou, Y; Zhu, W, 2014) |
| "Cervical cancer is the third most common malignant disease of women worldwide." | ( Ki, KD; Lee, JM; Seol, HJ; Ulak, R, 2014) |
| "Cervical cancer is the seventh most common malignancy in both genders combined and the third most common cancer in women." | ( Amanpour, S; Arjomandnejad, M; Haddadi, M; Muhammadnejad, A; Muhammadnejad, S; Rismanchi, S; Sherkat-Khameneh, N, 2014) |
| "• Hypoxia in cervical cancer is an independent risk factor • BOLD MRI reflect oxygenation status of tissue adjacent to perfused microvessels • Pretreatment tumour R2* reveal negative correlation with final tumour size response • Accurate oxygenation assessment in cervical cancer may help clinical decision making." | ( Huh, SJ; Kim, CK; Park, BK; Park, SY; Park, W, 2014) |
| "Cervical cancer is a leading cause of death by cancer among women worldwide." | ( Ji, J; Liu, H; Liu, J; Wang, Y, 2014) |
| "Cervical cancer is still one of the leading causes of cancer deaths in women worldwide, especially in the developing countries." | ( Guo, Y; Ma, J; Meng, X; Shang, H; Wang, Q; Wang, Y; Zheng, Y, 2014) |
| "Cervical cancer is a major cause of mortality among women in developing countries." | ( Camacho, J; de Guadalupe Chávez-López, M; Gariglio, P; Hernández-Gallegos, E; Vázquez-Sánchez, AY, 2014) |
| "Most cases of cervical cancer are associated with human papilloma virus (HPV) infection of high risk types." | ( Bajpai, D; Banerjee, A; Bhatla, N; Jain, SK; Jayaram, HN; Pathak, S; Singh, N, 2014) |
| "Cervical cancer is a clinical and pathological heterogeneity disease, which requires different types of treatments and leads to a variety of outcomes." | ( Chen, X; Hou, Y; Li, C; Li, H; Li, K; Lou, G; Ning, X; Sun, F; Yin, M; Zhang, T; Zheng, J; Zhou, X, 2014) |
| "Cervical cancer is the second-most-common cause of malignancies in women worldwide, and the oncogenic activity of the human papilloma virus types (HPV) E7 protein has a crucial role in anogenital tumors." | ( Atyabi, F; Ghaemi, A; Gorji, A; Kalhor, HR; Kelishadi, M; Moradi, A; Sajadian, A; Tabarraei, A; Tahamtan, A, 2014) |
| "Cervical cancer is characterized by an immunosuppressive microenvironment and a Th2-type cytokine profile." | ( Baena, A; Bedoya, AM; Borrero, M; Córdoba, CM; Herrero, R; Pareja, R; Patterson, JR; Rojas, F; Sanchez, GI; Tate, DJ; Zea, AH, 2014) |
| "Cervical cancer is potentially the most preventable and treatable cancer." | ( Murthy, NS; Suman, G; Suryanarayana, SP; Swapnajaswanth, M, 2014) |
| "Cervical cancer is one the most common malignancies among females." | ( Feng, ZZ; Hu, JG; Huang, YJ; Li, D; Liu, F; Liu, G; Tang, J; Wang, QY; Zhang, YY, 2014) |
| "Cervical cancer is the third most prevalent cancer in women and disproportionately affects those in low resource settings due to limited programs for screening and prevention." | ( Boyd, P; Major, I; McConville, C; Wang, W, 2014) |
| "Cervical cancer is one of the most common gynecological cancers in association with high mortality and morbidity." | ( Chou, SC; Lin, YC; Wang, IT, 2014) |
| "Cervical cancer is one of the leading causes of cancer in women worldwide." | ( D'Sa, JL; Mary, B, 2014) |
| "Cervical cancer is a neoplasia primarily caused by Human papillomavirus (HPV) infection." | ( de Freitas, LM; Fontana, CR; Soares, CP, 2014) |
| "Cervical cancer is a major health problem of Indian women." | ( Ghosh, SN; Mohanty, G, 2015) |
| "Nearly all cervical cancers are initiated by a subset of high-risk human papilloma viruses (HPVs)." | ( Bulut, G; Üren, A, 2015) |
| "Cervical cancer is the leading cause of cancer-related mortality among women in India; however, participation in prevention and screening is low and the reasons for this are not well understood." | ( Dune, T; Montgomery, MP; Shetty, AK; Shetty, PK, 2015) |
| "Cervical cancer is one of the most common cancers affecting women worldwide." | ( Barua, A; Krishnappa, P; Lin, YJ; Mohamad, IB, 2014) |
| "Cervical cancer is the most common gynecological malignancy in the developing countries like India." | ( Bharadwaj, M; Bharadwaj, S; Hussain, S; Kumar, A; Singhal, P, 2015) |
| "Cervical cancer is the third most common cancer and the third leading cause of death among women." | ( Cho, NP; Cho, SD; Choi, ES; Jung, JY; Nam, JS, 2014) |
| "Cervical cancer is the third most common cancer in women worldwide." | ( Bruce, J; Chaudary, N; Hill, RP; How, C; Kogo, R; Liu, FF; Shi, W; Yip, KW; Zahedi, P, 2015) |
| "Cervical cancer is one of the most common carcinomas in the genital system." | ( Gu, Y; Li, W; Ouyang, Z; Shen, Y; Shu, Y; Sun, Y; Wang, L; Wu, X; Xu, Q; Yu, B; Zhang, Q, 2014) |
| "Cervical cancer is the fourth most common cancer affecting women worldwide, according to the latest IARC release with 528 000 new cases every year." | ( Bicho, M; Bicho, MC; Castelão, C; da Silva, AP; Inácio, Â; Matos, A; Medeiros, R, 2015) |
| "Cervical cancer is the most common solid cancer diagnosed in pregnancy." | ( Favero, G; Köhler, C; Marnitz, S; Morgenstern, B; Mueller, M; Oppelt, P; Runnebaum, I; Schmittel, A; Schneider, A; Tsunoda, A, 2015) |
| "Breast and cervical cancers are the most common causes of cancer mortality among women in India, but actually they are largely preventable diseases." | ( Barnwal, K; Bhandari, R; Kishor, K; Malik, A; Rath, G; Roy, S; Shankar, A; Singh, R; Srivastava, V; Upadyaya, S, 2015) |
| "Cervical cancer is one of the most common gynaecological women cancer and suggested to be modulated by estrogenic signals." | ( Hao, Q; Ji, XH; Wu, YZ; Zhang, Q; Zhang, YM, 2015) |
| "Cervical cancer is considered as the second most common female malignant disease." | ( Guan, BZ; Luo, X; Ma, XF; Shuai, HL; Yan, RL; Zhang, J, 2015) |
| "Cervical cancer is the most common malignant cancer of the female reproductive organs worldwide." | ( Adon, MY; Aris, T; Bakhtiar, MF; Ibrahim Tamim, NS; Kamaluddin, MA; Mahmud, SH; Muhamad, NA; Noh, MA, 2015) |
| "Cervical cancer is the second most common cancer among women worldwide, with around 500,000 new diagnoses and 273,000 deaths per year." | ( Eke, AC; Eleje, GU; Eleje, LI; Igberase, GO; Igwegbe, AO, 2015) |
| "Cervical cancer is the second most common women carcinoma worldwide and the fourth leading cause of cancer-associated mortality in women." | ( Bai, X; Ma, Y; Zhang, G, 2015) |
| "Cervical cancer is the second leading gynecological malignancy threat to the health of women in the world." | ( Guo, J; Han, J, 2015) |
| "Cervical cancer is one of the commonest cancers among women all over the world." | ( Arunkumar, G; Aswathyraj, S; Bhat, PV; Kamath, V; Sabeena, S, 2015) |
| "Cervical cancer is the commonest cancer amongst African women, and yet preventative services are often inadequate." | ( Fallala, MS; Mash, R, 2015) |
| "Oral, breast, and cervical cancers are amenable to early detection and account for a third of India's cancer burden." | ( Basu, P; Bhadelia, A; Bhatla, N; Birur, P; Colaco, R; Dey, S; Dhillon, PK; Grover, S; Gupta, H; Gupta, R; Gupta, V; Knaul, FM; Krishnan, S; Lewis, MA; McMikel, A; Mehrotra, R; Mukherji, A; Naik, N; Nyblade, L; Pati, S; Pillai, MR; Rajaraman, P; Ramesh, C; Rath, GK; Reddy, KS; Reithinger, R; Sankaranarayanan, R; Schurmann, A; Selvam, J; Shanmugam, MS; Shridhar, K; Siddiqi, M; Squiers, L; Subramanian, S; Travasso, SM; Verma, Y; Vijayakumar, M; Weiner, BJ, 2015) |
| "Cervical cancer is one of the most common carcinomas in the female reproductive system." | ( Cheng, H; Gao, Y; Tan, W; Wang, Y; Yang, G, 2015) |
| "Cervical cancer is the second most common cause of cancer death in women worldwide." | ( Cai, H; Li, Y; Li, Z; Liu, R; Liu, X; Ma, H; Ren, J; Shi, X; Sui, Y; Tan, L; Wang, J; Wang, S; Xue, C; Yan, Y; Yang, Y; Zhang, X; Zhang, Y, 2015) |
| "Cervical cancer is known to be a preventable disease through the detection of cervical cancer precursors, historically using cytology of the cervix as the primary screening test." | ( Denny, L; Prendiville, W, 2015) |
| "Cervical cancer is the second most common gynecological malignancy worldwide." | ( Das, P; Dey, A; Kumar, R; Murti, K; Nath, A; Singh, JK; Trivedi, V, 2015) |
| "Cervical cancer is caused by infection with high risk human papillomavirus (HR-HPV)." | ( Kalpana, B; Marks, MA; Poli, UR; Rao, M; Sowjanya, AP; Sujatha, M; Vedantham, H, 2016) |
| "Cervical cancer is a leading cause of morbidity and mortality in women worldwide." | ( Chen, G; Cheng, Y; Hong, L; Hu, M; Huang, J; Li, B; Zhou, L, 2015) |
| "Cervical cancer is one of the most common gynecological cancers in the world but in India, it is the top most cancer among women." | ( Bharadwaj, M; Das, BC; Gissmann, L; Hussain, S; Kumar, A; Mehrotra, R; Sharma, G, 2015) |
| "Cervical cancer is one of the most frequent gynecological malignancies in women worldwide." | ( Lu, Y; Ma, X; Wang, N; Wei, H; Yin, D; Zhang, Q; Zhang, S; Zhang, Y, 2016) |
| "Cervical cancer is the 2nd most frequent and top killer cancer among women in Ethiopia." | ( Deksissa, ZM; Ferede, HA; Tesfamichael, FA, 2015) |
| "Cervical cancer is one of the most common gynecologic malignant tumors." | ( Qian, JH; Wu, GQ; Ying, J; Zhang, D; Zhang, J; Zhou, XH; Zhou, YX, 2015) |
| "Uterine cervix cancer is the second most common malignancy in women worldwide with human papillomavirus (HPV) as the etiologic factor." | ( Dias, S; Domingues, G; Felix, A; Ferreira, J; Goncalves, LG; Lam, EW; Maximo, V; Serpa, J; Silva, F; Silva, LS, 2016) |
| "However, cervical cancer is largely preventable when early screening and treatment are available." | ( Firnhaber, C; Lince-Deroche, N; Michelow, P; Phiri, J; Smith, JS, 2015) |
| "Cervical cancer is one of the most frequent malignant tumours in women." | ( Guo, L; Lan, J; Ma, J; Wu, H; Xie, X; Zhang, C; Zhu, J, 2015) |
| "Cervical cancer is the second commonest type and third cause of cancer death among women in low-income countries." | ( Alemayehu, M; Derbew, M; Eva, K; Gessesse, Z; Getachew, Y; Hiruye, A; Mammo, D; Mariam, DH; Michael, HG; Tadesse, Z; Yebyo, H, 2015) |
| "Cervical cancer is one of the most common female malignancies in the world, and chemotherapeutic drug resistance is a major obstacle to cancer therapy." | ( Cai, L; Liu, D; Wang, Z, 2016) |
| "Cervical cancer is the commonest cancer affecting women in Malawi, which has the highest rate of this disease in the world." | ( Bates, MJ; Mijoya, A, 2015) |
| "Cervical cancer is the most common cancer in Sub-Saharan Africa." | ( Allan, B; Faesen, M; Firnhaber, C; Goeieman, B; Levin, S; Michelow, P; Omar, T; Rameotshela, S; Schnippel, K; Smith, JS; Swarts, A; Williams, S; Williamson, AL, 2016) |
| "Cervical cancer is one of the most common cancer to affect women worldwide." | ( Acosta, O; De Crevoisier, R; Devillers, A; Le Gouestre, J; Leseur, J; Ospina, JD; Roman-Jimenez, G; Simon, A; Terve, P, 2015) |
| "Cervical cancer is a major cause of morbidity and mortality particularly in developing countries." | ( Arora, H; Biswas, S; Gandhi, G; Naseem, A; Perwez, A; Qureshi, R; Rizvi, MA; Wajid, S, 2016) |
| "Cervical cancer is the fourth most common cancer among women worldwide." | ( Ju, W; Kang, Y; Lee, H, 2016) |
| "Cervical cancer is one of the most common cancers among women worldwide." | ( Chauhan, N; Chauhan, SC; Gara, RK; Jaggi, M; Khan, S; Kumari, S; Maher, DM; Sikander, M; Yallapu, MM; Zafar, N; Zaman, MS, 2016) |
| "Cervical cancer is the fourth most common cancer among women worldwide." | ( Abdul Karim, AK; Kwang, NB; Mahayudin, T; Shan, LP; Teik, CK; Yien, HL, 2016) |
| "Cervical cancer is the most common cancer found in Indian women." | ( Canon, C; Effoe, V; Shetty, AK; Shetty, V, 2017) |
| "Cervical cancer is the second leading cause of cancer deaths in women worldwide." | ( Bai, C; Chen, J; Cheng, F; He, H; Liu, C; Qin, H; Wang, J; Yang, X; Yu, X; Zheng, J; Zou, K, 2016) |
| "Cervical cancer is one of the most prevalent malignancies in women worldwide." | ( Chi, Y; Du, R; Tang, W; You, W; Zhao, Y; Zheng, J, 2016) |
| "Cervical cancer is the third most common cancer among women worldwide, with about 500,000 new patients diagnosed and over 250,000 deaths every year." | ( Alemu, A; Bayu, H; Berhe, Y; Mulat, A, 2016) |
| "Cervical cancer is the second commonest cancer among Indian women and its association with human papilloma virus (HPV) is well established." | ( Arunkumar, G; Aswathyraj, S; Bhat, P; Chameetachal, A; Devadiga, S; Hindol, M; Kamath, V; Krishnan, A; Mathew, M; Prabhu, S; Sabeena, S, 2016) |
| "Cervical cancer is characterized as an important public health problem." | ( Bidóia, DL; Consolaro, ME; de Carvalho Scharf Santana, N; de Oliveira Silva, S; de Souza Bonfim Mendonça, P; Desoti, VC; Lima, NA; Nakamura, CV; Nakamura, TU; Ratti, BA; Ximenes, VF, 2016) |
| "Cervical cancer is a challenging pathologic entity because of its lack of response to conventional chemotherapy." | ( Loutradis, D; Patta, J; Pergialiotis, V; Stefanidi, D; Stefanidis, K, 2015) |
| "Cervical cancer is one of the most common malignancies among women in India." | ( Bharadwaj, M; Hussain, S; Nag, A; Sharma, U; Singhal, P, 2016) |
| "Cervical cancer is one of the most common gynecological cancers in Iranian women." | ( Abdi, R; Alikhasi, A; Amouzegar-Hashemi, F; Esmati, E; Kalaghchi, B, 2016) |
| "Cervical cancer is one of the most common cancers in women worldwide." | ( Cheng, X; Li, H; Wu, X, 2016) |
| "Cervical cancer is the leading cause of morbidity and mortality of women from cancer in the developing World." | ( Desire, BK; Félix, KW; Oscar, LN; Philippe, CM; Prosper, KL; Thierry, K; Wembodinga, GU, 2016) |
| "Cervical cancer is the leading cause of cancerrelated death in Sub-Saharan African women." | ( Doudéadoum, N; Gaulier, A; Kemian, M; Mortier, E; Némian, F, 2016) |
| "Cervical cancer is the fourth most frequently diagnosed tumor and the fourth leading cause of cancer death in females worldwide." | ( Bózsity, N; Mernyák, E; Minorics, R; Ocsovszki, I; Schneider, G; Szabó, J; Wang, HC; Wölfling, J; Wu, CC; Zupkó, I, 2017) |
| "Cervical cancer is among the most widely diagnosed cancer among women today." | ( Abu, N; Akthar, N; Alitheen, NB; Ho, WY; Kamarul, T; Ky, H; Tan, SW; Yeap, SK, 2017) |
| "Cervical cancer is the fourth most common cancer among women globally and the second most common cancer among Indian women." | ( Mishra, GA; Pimple, SA; Shastri, SS, 2016) |
| "Cervical cancer is a cause of cancer death, making it as the one of the most common cause for death among women globally." | ( Dai, LP; Liu, YQ; Luo, CL; Song, CH; Wang, KJ; Wang, P; Ye, H; Zhang, JY, 2016) |
| "Cervical cancer is one of the most common cancers in women worldwide and it is a prominent cause of cancer mortality." | ( Au, MK; Chang, CH; Chou, HC; Chou, HM; Chou, YR; Chu, YL; Chung, JG; Lu, HF; Shang, HS; Shih, YL; Yeh, MY, 2016) |
| "Cervical cancer is the most frequently diagnosed cancer among women in India." | ( Acharya, AS; Bachani, D; Dahiya, N; Gupta, S; Haresh, K; Rath, G; Sharma, D, 2016) |
| "Purpose Cervical cancer is the leading cause of cancer death among the 20 million women with HIV worldwide." | ( Asmelash, A; Bvochora-Nsingo, M; Chabner, B; Chiyapo, S; Clayman, R; Dryden-Peterson, S; Efstathiou, JA; Grover, S; Kayembe, MKA; Kebabonye-Pusoentsi, M; Lin, LL; Lockman, S; Mapes, AC; Medhin, H; Mmalane, M; Ramogola-Masire, D; Randall, TC; Russell, AH; Suneja, G; Tapela, N; Viswanathan, AN, 2016) |
| "Cervical cancer is the most common gynecological cancer occurring in pregnancy, creating a complex situation both for patient and physician." | ( De Vincenzo, R; Ricci, C; Scambia, G, 2016) |
| "Cervical cancer is the third most prevalent cancer among women worldwide." | ( Ji, D; Liu, J; Liu, K; Sun, Y; Tian, H; Wu, B; Wu, F; Zhang, G; Zhang, H; Zhang, Y, 2016) |
| "Cervical cancer is the second most common cause of cancer related morbidity and mortality in women with 50% mortality rate." | ( Akhter, SN; Alam, MJ; Banu, S; Bashar, A; Rahman, MF; Sarker, AS; Uddin, MJ, 2016) |
| "Cervical cancer is the second most prevalent cancer in women worldwide." | ( Gurjar, BS; Leekha, A; Rizvi, MA; Tyagi, A; Verma, AK, 2016) |
| "Cervical cancer is the fourth most common cause of cancer of women worldwide." | ( Monk, BJ; Verma, J; Wolfson, AH, 2016) |
| "Globally, cervical cancer is the most common malignancy affecting women." | ( Cheng, YM; Hsu, YC; Tsai, CC, 2016) |
| "Cervical cancer is the second most common in Thailand, but the mortality rate may be rising yearly." | ( Bhamarapravatana, K; Leaungsomnapa, Y; Lertcharernrit, J; Sananpanichkul, P; Suknikhom, W; Suwannarurk, K, 2016) |
| "Cervical cancer is one of the most common malignant diseases in working-age women." | ( Haruma, T; Hiramatsu, Y; Ida, N; Kusumoto, T; Masuyama, H; Nakamura, K; Seki, N, 2017) |
| "Cervical cancer is the second most commonly diagnosed type of cancer among women after breast cancer." | ( Chen, X; Li, A; Liu, H; Peng, H; Peng, R; Sun, Y; Wen, L; Wu, T; Yi, H; Yin, P; Zhang, Z; Zhou, Y, 2016) |
| "Cervical cancer is one of the most life threatening types of cancer among women and is generally resistant to chemotherapy." | ( Başaran, E; Büyükköroğlu, G; Şenel, B; Yazan, Y; Yenilmez, E, 2016) |
| "Cervical cancer is the fourth major cause of cancer-related deaths in women worldwide and is the most common cancer in developing countries." | ( Chopra, M; Wasim, L, 2016) |
| "Cervical cancer is the second most common cancer of woman in the world, and human papillomavirus (HPV) infection plays an important role in the development of most of the cases." | ( Li, YH; Tan, W; Tan, ZH; Tian, Y; Zhang, Y, 2016) |
| "Cervical cancer is the fourth most common malignancy in women worldwide, and resistance to chemotherapy drugs is the biggest obstacle in the treatment of cervical cancers." | ( Li, G; Mao, X; Song, X; Xia, J; Yu, X; Zhang, Y, 2017) |
| "Cervical cancer is a world-wide problem that requires transformative therapeutic strategies." | ( Bouvet, M; Delong, JC; Endo, I; Hiroshima, Y; Hoffman, RM; Hozumi, C; Hwang, HK; Igarashi, K; Kawaguchi, K; Kikuchi, T; Kiyuna, T; Komatsu, S; Lwin, TM; Miyake, K; Murakami, T; Murata, T; Tanaka, K; Zhang, Y, 2017) |
| "Cervical cancer is one of the most common female malignancies, and cisplatin-based chemotherapy is routinely utilized in locally advanced cervical cancer patients." | ( He, J; Qin, Q; Shi, W; Tao, T; Wang, Q; Yang, X; Yang, Y, 2017) |
| "Cervical cancer is a major world health problem for women." | ( Chen, Z; Han, L; Han, S; Jiang, L; Liu, B; Liu, J, 2017) |
| "Although cervical cancer is the fourth most common cancer in women worldwide, a systematic study about the prognostic value of specific changes in the chromatin structure, such as histone acetylation or histone methylation, is missing." | ( Beyer, S; Dannecker, C; Hofmann, S; Jeschke, U; Kost, BP; Kuhn, C; Mayr, D; Schulze, S; Zhu, J, 2017) |
| "Cervical cancer is the sixth most common cancer in Chinese women." | ( Chen, J; Hou, B; Huang, ZP; Li, F; Liu, X; Liu, Y; Qian, S; Song, N; Tian, YH; Wang, LG; Ye, L; Zhou, T, 2017) |
| "Human cervical cancer is the fourth most common carcinoma in women worldwide." | ( Chen, J; Chen, R; Du, L; Jiang, S; Pan, Y; Qi, Q; Xia, C; Xiao, G, 2017) |
| "Cervical cancer is a cause of cancer death, making it one of the most common causes of death among women globally." | ( Dong, Y; Meng, X; Wang, S, 2017) |
| "Cervical cancer is the third highest cause of death in developing countries and most commonly results from high‑risk human papillomavirus (HR‑HPV) infection." | ( Boonsiri, P; Daduang, J; Daduang, S; Jearanaikoon, P; Kiatpathomchai, W; Kumvongpin, R; Prasongdee, P; Sae-Ung, N; Sandee, A; Swangvaree, SS; Wilailuckana, C; Wongsena, M, 2017) |
| "Cervical cancer is a major health problem and a leading cause of death among women in India." | ( Chaudhary, S; Chawla, A; Chawla, PC, 2016) |
| "Cervical cancer is the fourth most common malignancy diagnosed in women worldwide." | ( Bacon, MA; Bajaj, A; Chuang, LT; Fisher, BJ; Gaffney, DK; Harkenrider, MM; Jhingran, A; Kitchener, HC; Mileshkin, LR; Small, W; Viswanathan, AN, 2017) |
| "Cervical cancer is one of the most common gynecological malignancies worldwide." | ( He, G; Li, C; Li, J; Qian, X; Yang, L; Yuan, Z, 2017) |
| "Cervical cancer is a common malignant tumor in women with increased incidence and younger onset age." | ( Ma, Y; Ou, SR; Wu, ZY; Zhou, X; Zuo, JH, 2017) |
| "Cervical cancer is one of the most common malignant tumors in women all over the world." | ( Chen, H; Chen, Z; Gao, L; He, J; Li, G; Li, X; Li, Z; Liao, S; Long, Y; Ma, J; Peng, S; Wu, M; Xiang, J; Xiao, S; Xiong, W; Zeng, Z; Zhang, M; Zhou, M; Zhou, Y; Zhu, G, 2017) |
| "Cervical cancer is one of the most common female malignancies worldwide." | ( He, SH; Liu, HG; Yue, QF; Zhou, YF, 2017) |
| "Cervical cancer is the leading cause of cancer-related death in women in South Africa." | ( Breytenbach, E; De Strooper, LMA; Dreyer, G; Heideman, DAM; Hesselink, AT; Kremer, WW; Meijer, CJLM; Richter, KL; Rozendaal, L; Snijders, PJF; Steenbergen, RDM; Van Aardt, MC; Van Zummeren, M; Witte, BI, 2017) |
| "Cervical cancer is the fourth cause of cancer-related mortality among females worldwide." | ( Abedini, MR; Babaei, E; Hoshyar, R; Mollaei, H; Safaralizadeh, R, 2017) |
| "Breast and cervical cancer are two of the most common cancers among women worldwide and were the two leading causes of cancer related death for women in India in 2013." | ( Krishnan, S; Nyblade, L; Stockton, M; Travasso, S, 2017) |
| "Cervical Cancer is the most common genital cancer in women in India." | ( Jindal, HA; Kaur, A; Murugan, S, 2017) |
| "Cervical cancer is one of the most common malignancies of the female reproductive system." | ( Chen, GD; Fan, GY; Li, ZG; Qian, DY; Wu, YL; You, KL, 2017) |
| "Cervical cancer is a largely preventable disease, and the strategic implementation of a cervical cancer prevention programme is partly dependent on the impact of human papillomavirus (HPV) infection interpreted within the context of the country's sociodemographic attributes." | ( Anwar Shafii, MK; Belinson, J; Bhoo-Pathy, N; Goh, PP; Gravitt, P; Hairizan Nasir, N; Khoo, SP; Subramaniam, S; Tan, HD; Woo, YL; Yap, SH; Zeng, M, 2018) |
| "Cervical cancer is the second most prevalent cancer among women in the developing countries including Ethiopia." | ( Addissie, A; Ayele, W; Gebreheat, G; Gebremariam, A; Hirpa, S; Jemal, A; Teame, H, 2018) |
| "Studies on cervical cancer are urgently required to improve clinical outcomes." | ( Guo, Z; He, L; Hu, Z; Janardhan, A; Kathera, C; Kumar, AK; Luo, L; Ma, Z; Mao, H; Pan, F; Wu, T; Yang, H; Yang, Y; Zhou, S; Zhu, H, 2018) |
| "Cervical cancer is the fourth leading cause of cancer death in females worldwide and the second leading cause of mortality among women." | ( Li, H; Li, X; Tan, W; Yang, W; Zhang, B; Zheng, J, 2018) |
| "Cervical cancer is one of the most common cancers in women living in developing countries." | ( Al Sharif, M; AlSharif, D; Chatterjee, K; Fata, JE; Mazza, C; Syar, P, 2018) |
| "Cervical cancer is the fourth most common cancer in women worldwide, and existing treatments cause severe side effects and great burdens." | ( Chen, S; Cheng, L; Liu, Q; Wang, J; Wang, M; Wang, S; Wu, X; Xia, X; Yang, L; Zhu, R, 2017) |
| "Cervical cancer is a major cause of cancer-related mortality in women in the developing world." | ( Bagga, R; Bhattacharyya, S; Dhaliwal, L; Javed, S; Rayat, CS; Sharma, BK; Sharma, S; Sood, S; Srinivasan, R, 2018) |
| "Cervical cancer is the most common malignancy of the female reproductive tract, and the poor response to prophylactic vaccines and the toxicity of high‑dose chemotherapeutic drugs have limited their clinical application." | ( Chen, X; Chen, Y; Shi, Z; Wang, X; Zhuang, H, 2018) |
| "Cervical cancer is an extremely prevalent disease worldwide." | ( Gong, JM; He, YX; Shan, WW; Shen, Y, 2018) |
| "Cervical cancer is fourth most common fatal cancer in women worldwide." | ( Prasad, N; Sabarwal, A; Singh, RP; Yadav, UCS, 2018) |
| "Cervical cancer is a common gynecological malignancy with high incidence and mortality." | ( Dai, J; Li, L; Liang, H; Ling, X; Shao, J; Tang, H; Wang, C, 2018) |
| "Cervical cancer is common in resource-poor settings with high prevalence of tuberculosis, pelvic inflammatory disease, and human immunodeficiency virus (HIV) infection." | ( Abu-Rustum, NR; Bryant, EP; de Greve, T; Lindeque, BG; Reyneke, F; Sathekge, MM; Snyman, LC; Wethmar, EI, 2018) |
| "Breast and cervical cancers are global health concerns and major cause of deaths among women." | ( Al-Balushi, MS; Al-Busaidi, JZ; Al-Jabri, AA; Aleemallah, GM; H Al-Shubi, AS; Hakkim, FL; Hasson, SS; Rashan, L, 2018) |
| "Cervical cancer is considered the fourth most common malignant disease in women." | ( Bao, Y; Li, T; Meng, X; Wang, J; Wang, N; Wang, S, 2018) |
| "Cervical cancer is the third most commonly diagnosed tumor type and the fourth cause of cancer-related death in females." | ( Alves, ALV; Cury, FP; Gomes, INF; Longato, GB; Martinho, O; Melendez, ME; Oliveira, BG; Pinto, FE; Reis, RM; Ribeiro, RIMA; Romão, W; Rosa, MN; Silva, LRV; Silva, VAO; Tansini, A, 2019) |
| "Cervical cancer is the third most common cause of cancer in women." | ( Cheung, J; Düzgüneş, N; Konopka, K, 2018) |
| "Cervical cancer is the fourth most common gynecological cancer worldwide." | ( Li, QS; Liang, YR; Lu, JL; Wang, YQ, 2018) |
| "In China, cervical cancer is the fifth most commonly diagnosed cancer, and the outcomes for patients with advanced or recurrent disease are poor." | ( Feng, YY; Zhang, Q; Zhou, H; Zhou, JG; Zhou, NJ, 2018) |
| "Cervical cancer is the second most common cancer in India." | ( Biswas, AS; Chakraborty, A; Kamal, VK; Rath, GK; Roy, S; Shankar, A, 2018) |
| "Cervical cancer is a common type in gynecologic malignant tumor that accounts for the leading morbidity only after breast cancer in female." | ( Chen, HY; Hu, YJ; Ma, LH; Wang, Y; Zhang, HP; Zhu, B, 2018) |
| "Cervical cancer is the most common cause of female cancer-related mortality worldwide." | ( Fan, L; Fang, X; Huang, C; Lin, R; Lin, Z; Lu, R; Yao, T; Zhang, J, 2019) |
| "Cervical cancer is one of the most aggressive human cancers with poor prognosis due to constant chemoresistance and repeated relapse." | ( Chen, Y; Feng, X; Fu, S; Hou, X; Lei, Y; Li, C; Li, J; Li, L; Zhou, J; Zhou, L, 2018) |
| " Cervical cancer is the fourth most common cancer worldwide among women, with the number of new cases increasing from 493 243 in 2002 to 527 000 in 2012." | ( Almonte, M; Dlamini, X; Ginindza, TG; Sartorius, B, 2018) |
| "Cervical Cancer is the second most leading cause of death among Indian women." | ( Chaudhari, HR; Chaudhari, NA; Joshi, SV, 2020) |
| "Cervical cancer is one of the main causes of cancer death worldwide." | ( Çermik, TF; Dağ, S; Ergul, N; Yilmaz, B, 2019) |
| "Cervical cancers are the most common forms of cancer that occur in women globally and are difficult to be cured in their terminal stages." | ( Sheng, X; Xie, B; Zhang, H; Zhang, S; Zhang, Z, 2019) |
| "Cervical cancer is a major cause of cancer-related death in women world-wide." | ( Das, S; Kundu, CN; Narayan, S; Nayak, A; Nayak, D; Sethy, C, 2019) |
| "Cervical cancer is the second leading cause of new cancer cases and cancer-related deaths among women in India, with an estimated 96,922 new cases and 60,078 deaths each year." | ( Agrawal, S; Dhillon, PK; Ghosh, A; Hallowell, BD; Mehrotra, R; Patel, SA; Saraf, D; Saraiya, M; Senkomago, V; Van Dyne, EA, 2019) |
| "Cervical cancer is the second most common cancer in women worldwide." | ( Clemente-Soto, AF; González-Maya, L; Milan-Pacheco, C; Peralta-Zaragoza, O; Salas-Vidal, E; Sánchez-Carranza, JN, 2019) |
| "Cervical cancer is a leading cause of death among women in low- and middle-income countries, and women living with HIV are at high risk for cervical cancer." | ( Carpenter, CL; Ekstrand, ML; Grover, S; Nyamathi, AM; Shin, SS; Sinha, S; Wang, Q; Yadav, K; Zetola, NM, 2019) |
| "Cervical cancer is among the most common cancers in women worldwide." | ( Mokhtar, N; Romli, R; Saddki, N; Shahabudin, S, 2019) |
| "Breast and cervical cancers are the two most common cancers among women worldwide." | ( Amooheidari, A; Javanmard, SH; Naderi, J; Samani, F; Vahabzadeh, G; Vaseghi, G, 2019) |
| "Cervical cancer is a leading cause of cancer-related deaths among women in developing countries." | ( Ahmad, S; Imran Siddiqi, M; Khan, S; Naseem, I; Singh, S; Zafar, A, 2019) |
| "Cervical cancer is the third most common highest mortality in women worldwide." | ( Dang, M; Qian, L; Su, W; Wang, C; Wang, Y; Zhang, W, 2019) |
| "Research on anticervical cancer is urgently required to enhance clinical outcomes." | ( Chen, YW; Huang, JQ; Jiang, LL; Xu, J; Yan, JY; Yang, Q; Zhu, J, 2019) |
| "Cervical cancer is the second cancer that threatens women' s health,and has attracted the attention of researchers at home and abroad because of its extremely high mortality rate." | ( Gong, XJ; Su, M; Zhou, X, 2019) |
| "Cervical cancer is a major cause of death in females worldwide." | ( Barton, CE; Diaz-Cruz, ES; McDonnell, AM; Pyles, HM, 2019) |
| "Background: Cervical cancer is a preventable disease caused by human papillomaviruses." | ( Hairon, SM; Ismail, MP; Md Salleh, MS; Mohd Isa, SA, 2019) |
| "Cervical cancer is one of the most commonly diagnosed lethal malignancies among gynecological malignant tumors worldwide." | ( Li, X; Liu, Z; Su, J; Zhang, F, 2019) |
| "Cervical cancer is a life-threatening complication, appearing as the uncontrolled growth of abnormal cells in the lining of the cervix." | ( Chen, Y; Gopinath, SCB; Lakshmipriya, T; Wang, H, 2019) |
| "Cervical cancer is one of the most life-threatening types of cancer among women and is generally resistant to chemotherapy." | ( Büyükköroğlu, G; Şenel, B; Yenilmez, E, 2019) |
| "Cervical cancer is the fourth most lethal human malignancy and the leading cause of death among females around the world." | ( Fan, Y; Hao, Y; Liu, Y; Tao, L; Xu, W; Yang, Y; Zhang, Y, 2019) |
| "Cervical cancer is a major public health problem especially in developing countries." | ( Bajracharya, N; Bhattachan, K; Dangal, G; Karki, A; Parajuli, S; Poudel, R; Pradhan, HK; Shrestha, R; Tiwari, K, 2019) |
| "Cervical cancer is one of the most common cancers between women and is known as the third leading cause of female cancer related deaths annually." | ( Asemi, Z; Mirzaei, H; Reiter, RJ; Shafabakhsh, R; Teymoordash, SN, 2019) |
| "Cervical cancer is the third most common gynecological malignancy." | ( Baik, M; Choi, YJ; Ho, JY; Hur, SY; Ko, M; Lee, H; Lee, S; Lee, SU; Liu, JJ; Park, JY, 2019) |
| "Cervical cancer is the second most frequent cancer in women in Mexico, and its development depends on the presence of human papillomaviruses in the uterine cervix." | ( Gutiérrez-Hoya, A; López-Santiago, R; Moreno-Lafont, M; Soto-Cruz, I; Valle-Mendiola, A; Weiss-Steider, B; Zerecero-Carreón, O, 2019) |
| "Cervical cancer is considered poorly chemo-sensitive in women and its treatment remains unsatisfactory." | ( Cheng, ZY; Chueh, FS; Chung, JG; Kuo, CL; Lin, CH; Peng, SF, 2019) |
| "Cervical cancer is one of the most common gynecological tumors in females." | ( Ding, Y; Su, Y; Tian, Y; Wang, J; Wang, X, 2019) |
| "Cervical cancer is the second most prevalent cancer worldwide." | ( Hou, J; Huang, Y; Jia, G; Liu, Z; Shao, X; Song, B; Zhao, R, 2019) |
| "Cervical cancer is the tenth most frequent cancer in Egyptian women." | ( Abd El-Fattah, NH; Gad, MM; Galal, SB; Helmy, W, 2019) |
| "Cervical cancer is caused by a persistent infection of the mucosal epithelia with high-risk human papilloma viruses (HPVs)." | ( Gettemans, J; Steels, A; Vannevel, L; Zwaenepoel, O, 2019) |
| "Introduction: Cancer of the cervix is the second most common cancer in women in India." | ( Giridhar, P; Gupta, S; K P, H; P K, J; Rath, GK; Sharma, D, 2019) |
| "Cervical cancer is the third most common cancer affecting women around the world in which the Human Papillomavirus (HPV) is the one of the recognized causative agent affecting women health." | ( Minhat, HS; Razak, NZSA; Rejali, Z; Tusimin, M; Yee, CL; Zainol, MI, 2019) |
| "Cervical cancer is one of the most common causes of cancer death in females." | ( Chen, F; Deng, J; Guo, H; Han, Q; Li, S; Xi, H; Zhang, W; Zhang, Z, 2020) |
| "In India, cervical cancer is one of leading causes of cancer mortality among women 30 to 69 years of age, accounting for 17% of all cancer deaths." | ( Joshi, N; Mishra, N; Negi, D; Singh, A, 2020) |
| "Cervical cancer is associated with the human papilloma virus (HPV) and nowadays is the fourth most frequent cancer among women." | ( Beck, RCR; Buffon, A; Chaves, P; Frank, LA; Gazzi, RP; Guterres, SS; Mello, PA; Peña, F; Pohlmann, AR, 2020) |
| "BACKGROUND Cervical cancer is a major threat to female health worldwide." | ( Hongjuan, M; Li, W; Minglian, L; Ping, Z; Xuemei, G; Yi, H; Zhongxiang, Z, 2020) |
| "Cervical cancer is the fourth common cancer in women worldwide." | ( Barra, F; Bifulco, G; Della Corte, L; Evangelisti, G; Ferrero, S; Foreste, V; Giampaolino, P, 2020) |
| "Cervical cancer is the fourth-ranked cancer in the world and is associated with a large number of deaths annually." | ( Asemi, Z; Chaichian, S; Haddad Kashani, H; Moazzami, B; Sadoughi, F; Zaroudi, M, 2020) |
| "Cervical cancer is one of the most common causes of death among women globally." | ( Wang, J, 2020) |
| "Cervical cancer is the fourth most common cancer in women globally." | ( Guo, J; Tong, W; Yang, C, 2020) |
| "Cervical cancer is an aggressive human cancer with poor prognosis among women, and urgently requires effective treatments." | ( Bai, H; Yin, H, 2020) |
| "Cervical cancer is still one of the most common female cancers in Asia and the leading cause of cancer-related deaths in low- and middle-income countries." | ( Aoki, ES; Bhatla, N; Kim, M; Li, K; Ocviyanti, D; Saika, K; Singhal, S; Suh, M; Termrungruanglert, W; Yin, R, 2020) |
| "Cervical cancer is the second most common cancer diagnosed among women in India and current estimates indicate low screening rates." | ( Adsul, P; Gowda, S; Jaykrishna, P; Madhivanan, P; Nayaka, S; Pramathesh, R; Srinivas, V, 2020) |
| "Cervical cancer is the fourth most common gynecological malignancy affecting the health of women worldwide and the second most common cause of cancer‑related mortality among women in developing regions." | ( Chan, C; Chen, J; Deng, L; Gan, H; Lei, Y; Leung, P; Liu, A; Liu, D; Qi, M; Xue, F; Ye, G; Ye, W; Zhang, D, 2020) |
| "At present, cervical cancer is the fourth leading cause of cancer among women worldwide with no effective treatment options." | ( Caetano, W; César, GB; Consolaro, MEL; da Silva, VRS; Damke, E; Damke, GMZF; de Freitas Meirelles, LE; de Oliveira Silva, S; de Souza Bonfim-Mendonça, P; Gonçalves, RS; Hioka, N; Ratti, BA; Souza, RP, 2020) |
| "Cervical cancer is a prevalent malignancy among women of developing countries including India." | ( Chakrabarti, G; Das Mukherjee, D; Datta, S; Ghosh Dastidar, D; Kumar, D; Kumar, NM; Tantak, MP, 2020) |
| "Cervical cancer is the fourth most common cause of mortality in women worldwide." | ( Arega, S; Ganguly, N; Ghosal, S; Hazra, R; Mohanty, R; Sahu, B; Sen, P, 2020) |
| "Cervical cancer is the second most common cancer in Ethiopia next to breast cancer." | ( Fentie, AM; Gebretekle, GB; Tadesse, TB, 2020) |
| "Cervical cancer is the fourth leading killer of female cancer patients worldwide." | ( He, ZL; Jiang, LH; Lu, L; Pei, XD; Shen, LQ; Wang, XY; Xiao, JS; Yang, Y; Yao, HL, 2020) |
| "Cervical cancer is preventable." | ( Ariffin, F; Baharum, NN; Isa, MR; Tin, ST, 2020) |
| "Cervical cancer is one of the most common cancers among females worldwide and advanced patients have extremely poor prognosis." | ( Chen, X; Lou, L; Lu, G; Tian, J; Tian, M; Tian, S, 2020) |
| "Cervical cancer is the second leading type of female cancer in Ethiopia." | ( Abdissa, A; Ahmed, Y; Dube, L; Eshetu, K; Gedefaw, L; Goba, G; Godu, S; Hailekiros, H; Joloba, M; Nigussie, M; Tesfaw, G, 2020) |
| "Cervical cancer is the leading cause of cancer-related death among women worldwide." | ( Ji, J; Jiang, F; Liu, ZX; Qian, TY; Xiao, MB; Xu, MX; Xu, WS; Zhou, J; Zhu, SZ, 2020) |
| "Cervical cancer is the fourth most common female cancer worldwide, and drug targeted therapy plays a crucial role in delaying the progression of cervical carcinoma." | ( Dai, B; Liu, F; Su, Q; Wang, B; Wang, H; Xu, R; Yang, T; Zhang, Y, 2020) |
| "Worldwide cervical cancer is the third most common malignancy in women." | ( Gebrecherkos, K; Gebregyorgis, T; Gebreyesus, H; Hailemariam, G; Kifle, M; Teweldemedhin, M; Wubayehu, T, 2020) |
| "Although cervical cancer is the second most common women's cancer in the world, there are still few information about the role of checkpoint inhibitors in this neoplasm, especially in the neoadjuvant setting." | ( Benedetti Panici, P; D'Alessandris, N; Della Rocca, C; Di Maio, V; Di Pinto, A; Leopizzi, M; Musacchio, L; Palaia, I; Pecorella, I; Pernazza, A; Tomao, F, 2021) |
| "Cervical cancer is a major public health problem in India leading to high economic burden, which is disproportionately borne by the patients as out-of-pocket expenditure (OOPE)." | ( Chauhan, AS; Ghoshal, S; Prinja, S; Rai, B; Singh, MP, 2020) |
| "Cervical cancer is a serious worldwide health problem." | ( Calmon, MF; Lopes, TZ; Oliveira, PM; Rahal, P; Tedesco, AC, 2020) |
| "Cervical cancer is the most prevalent cancer among women in India." | ( Arora, P; Khurana, N; Kumar, R; Mala, YM; Mandal, S, 2021) |
| "Cervical cancer is the fourth most common female cancer worldwide." | ( Cheng, G; Du, P; Li, H; Li, X; Li, Y; Wang, R; Zhang, X; Zhi, Y, 2021) |
| "Around the world, cervical cancer is one of the most common neoplastic diseases among women, and the prognosis of patients in an advanced stage remains poor." | ( Asanoma, K; Cui, L; Hori, E; Itakura, A; Kato, K; Kato, M; Kawakami, M; Kawamura, K; Kodama, K; Matsumura, Y; Onoyama, I; Takeda, S; Yagi, H; Yahata, H; Yoshida, S, 2020) |
| "Cervical cancer is the second largest tumor disease threatening female reproductive tract health." | ( He, Z; Huang, J; Li, D; Li, H; Pan, D; Yang, H; Zhang, Y, 2020) |
| "Cervical cancer is the fourth most frequent cancer in women worldwide." | ( Han, F; Kong, B; Li, R; Li, Y; Ma, H; Qi, G; Song, K; Yan, S; Yan, X; Yuan, C, 2021) |
| "Cervical cancer is the second most common cancer among women in developing countries." | ( Joshi, R; Malla Vaidya, K; Shrestha, B, 2020) |
| "Human cervical cancer is the fourth most common malignancy among women worldwide, and it is expected to result in 460,000 deaths per year by 2040." | ( Chen, TH; Chen, YH; Chou, MC; Hsiao, YH; Tsai, HD; Yang, CK; Yang, SF, 2021) |
| "Cervical cancer is the leading cause of cancer mortality in India." | ( Chaluvarayaswamy, R; Malila, N; Murthy, SN; Somanna, SN, 2020) |
| "Cervical cancer is caused by human papillomavirus (HPV), an infectious agent with no non-human reservoir." | ( Benard, E; Brisson, M; Jit, M; Prem, K, 2021) |
| "Cervical cancer is a major contributor to mortality and morbidity in women." | ( Oka, G; Rahatgaonkar, V; Uchale, P, 2020) |
| "Human cervical cancer is the most common gynecological malignancy." | ( Hu, J; Li, Y; Shao, L; Sun, G; Sun, H; Sun, Y; Wang, P; Wang, R; Wang, X; Xie, S; Yue, Z, 2020) |
| "Cervical cancer is an important public health problem in Thailand." | ( Jamsri, P; Pangmuang, P; Ploysawang, P; Prapakorn, S; Rojanamatin, J; Sangrajrang, S; Seeda, K, 2021) |
| "Cervical cancer is an important health issue worldwide." | ( García-González, I; García-Mena, J; Gariglio, P; Hernández-Quiroz, F; Lambert, PF; Maya-Lucas, O; Murugesan, S; Ocadiz-Delgado, R; Piña-Escobedo, A; Velazquez-Martínez, C; Villalobos-Flores, LE, 2021) |
| "Cervical cancer is one of the most diagnosed malignancies among females." | ( Liu, G; Liu, Y; Ma, D; Shao, X; Zheng, X, 2021) |
| "Cervical cancer is one of the leading causes of mortality amongst women in developing countries, and resistance to therapy is the main reason for treatment failure." | ( Bhattacharyya, S; De, R; Kaur, H; Pal, A; Sharma, A; Srinivasan, R, 2021) |
| "Cervical cancer is one of the most common and important gynecological cancers, which has a global concern with an increasing number of patients and mortality rates." | ( Asemi, Z; Hallajzadeh, J; Maleki Dana, P; Nikkhah, E; Zivarpour, P, 2021) |
| "Globally, cervical cancer is the fourth most common cancer in women, with about 85% occurring in low-middle income countries (LMIC) and an age-standardised incidence rate of more than 15 per 100,000." | ( Eng, JCL; Er, JBT; Ismail-Pratt, I; Lim, YK; Ng, JSY; Wan, CSY, 2021) |
| "Cervical cancer is a global health problem." | ( Chaudary, N; Hill, RP; Milosevic, M; Stulik, L, 2021) |
| "Cervical cancer is the fourth most common cancer in women." | ( Ahmed, SF; Basalathullah, MAR; Elizabeth, NB; Malik, M; Valiyaveettil, D, 2021) |
| "In Southeast Asia, cervical cancer is the second most common cancer in women." | ( Asjes, C; Chua, B; Lim, A; Ma, V; Mohseni, M; Wee, HL, 2021) |
| "Cervical cancer is the second most common cancer in women." | ( Dai, T; Hao, X; Jiang, N; Sang, M; Sun, X; Sun, Y; Wang, X; Xie, L; Xu, H; Zhao, Q, 2021) |
| "Cervical cancer is the third most common cancer among Malaysian women." | ( Hamzah, ND; Ismail, ZHF; Jerip, AR; Kipli, M; Tan, CS, 2021) |
| "Cervical cancer is considered one of the diseases with the highest mortality among women and with limited treatment options." | ( Chen, G; Chu, J; Dang, J; Gao, J; Jin, Z; Li, L; Liu, X; Wang, J; Wang, Z, 2021) |
| "Cervical cancer is a worldwide public health problem, and improved selective therapies and anticancer drugs are urgently needed." | ( Calmon, MF; Carvalho, T; Galiardi-Campoy, AEB; Machado, FC; Rahal, P; Tedesco, AC, 2021) |
| "Cervical cancer is the fourth most common cancer and the second cause of cancer-related death among women." | ( Ahmadizadeh, C; Khojaste, E, 2022) |
| "Cervical cancer is the most common cancer and has the highest morbidity rate of gynaecological malignancies in women worldwide." | ( Im, K; Jose, SP; M, R; S, S; Saji, S, 2021) |
| "Cervical cancer is recognized as a serious worldwide health problem." | ( Abbasinia, H; Abdollahi, V; Asnaashari, M; Javani Jouni, F; Zadehmodarres, S; Zafari, J, 2022) |
| "Breast and cervical cancers are the two most common cancers among Indian women which contributed 39." | ( Badwe, RA; Chaturvedi, M; Deo, SVS; Malik, R; Manoharan, N; Mathur, P; N, V; Narasimhan, S; Panse, NS; Ramesh, C; Sathishkumar, K; Shrivastava, A; Swaminathan, R; Vijay, CR, 2021) |
| "Cervical cancer is one such type that can be monitored for a sufficiently long period toward invasive cancer phenotype." | ( Karunakaran, V; Maiti, KK; Murali, VP; Raghu, KG; Ramya, AN; Saritha, VN; Sujathan, K, 2021) |
| "Cervical cancer is a leading cause of cancer-associated mortality among women in India, with 96,922 new cases and 60,078 deaths each year, almost one-fifth of the global burden." | ( Ahmed, D; Bhatnagar, P; Denzongpa, P; Haldar, P; Harvey, P; Kaur, N; Loharikar, A; Roy, S; Singh, N; VanderEnde, K, 2022) |
| "Cervical cancer is a human papilloma virus-related disease, whereas endometrial cancer and atypical endometrial hyperplasia (AEH) are hormone-related diseases, so co-occurrence of the two is possible." | ( Ikeda, Y; Kajiyama, H; Moriyama, Y; Suzuki, S; Tamauchi, S; Yoshikawa, N, 2021) |
| "Cervical cancer is one of the leading female malignancy tumors worldwide." | ( He, H; Tang, Y; Zheng, C, 2021) |
| "Cervical cancer is one of the leading causes of mortality among women population worldwide." | ( Tiwari, M; Varma, DA, 2021) |
| "Recurrent cervical cancer is hard to treat when occurring in a previous radiated area and unresectable or distant metastasis." | ( Lai, CH; Liu, FY; Tung, HJ; Wang, CC, 2021) |
| "Although cervical cancer is a preventable disease, screening coverage in Ethiopia is far below the target." | ( Addissie, A; Destaw, A; Gizaw, M; Kantelhardt, EJ; Midaksa, M, 2021) |
| "Human cervical cancer is the fourth most common carcinoma in women in the world." | ( Jang, X; Ma, Y; Shang, H; Shi, L, 2021) |
| "Cervical cancer is the tenth diagnosed cancer in the world." | ( Bonnet, I; Brachet, PE; Castera, M; Clarisse, B; Coquan, E; Joly, F; Leconte, A; Lelaidier, A; Lequesne, J; Licaj, I; Meriaux, E, 2021) |
| "Cervical cancer is a public health problem and has devastating effects in low-to-middle-income countries (LTMICs) such as the sub-Saharan African (SSA) countries." | ( Dlamini, Z; Hull, R; Kaufmann, AM; Kgoebane-Maseko, M; Lolas, G; Marima, R; Syrigos, KN, 2021) |
| "Cancer of the uterine cervix is one of the leading causes of mortality and morbidity among women in poor countries." | ( Akhter, R; Begum, KN; Hira, HM; Shahnaz, S; Sharmin, S, 2021) |
| "Cervical cancer is a life-threatening disease and the fourth most common cancer among women worldwide." | ( Nile, A; Nile, SH; Oh, JW; Park, G; Shin, J, 2021) |
| "Cervical cancer is the most common malignant tumor in females worldwide." | ( Abbasifarid, E; Bolhassani, A; Irani, S; Sotoodehnejadnematalahi, F, 2021) |
| "Cervical cancers are usually treatable if detected in early stages by a combination of therapies." | ( Chandrashekar, S; Devegowda, D; Nataraj, SM; Raja, S; Ramesh, PS; Udayakumar, SH, 2022) |
| "Background: Cervical cancer is the fourth most common cancer among women in the world." | ( Akhter, R; Billah, MM; Flora, MS; Qayum, MO, 2021) |
| "Cervical cancer is the leading cause of cancer-related deaths in women, and treatment for cervical cancer is very limited." | ( He, SL; Li, LJ; Wang, C; Xue, M; Zeng, J, 2021) |
| "Cervical cancer is the most prevalent malignancy worldwide and propofol reportedly has anti-cancer efficiencies." | ( Du, XT; Liu, DP; Wang, XY; Zheng, YH, 2021) |
| "Cervical cancer is common in women in less developed regions of the world." | ( Bagla, VP; Makgatho, ME; Matsebatlela, TM; Mokgotho, MP; Ndlovu, MJ, 2021) |
| "Cervical cancer is the fourth most common cancer in the world, affecting mainly women residing in low- and middle-income countries." | ( Anderson, J; Antartani, R; Bellad, MB; Bidri, S; Biradar, A; Chavan, RY; Chikaraddi, S; Dalal, A; Derman, R; Donimath, K; Goudar, SS; Gudadinni, MR; Hipparagi, S; Kabadi, YM; Kangle, R; Kenyi, E; Lokare, L; Lu, E; Mensa, M; Nagmoti, MB; Patil, B; Patil, H; Patil, V; Reddy, P; Revankar, A; Thaler, K; Vernekar, S; Wani, R; Yenokyan, G; Yogeshkumar, S, 2021) |
| "Cervical cancer is the fourth most prevalent gynecological cancer worldwide, which threatens women's health and causes cancer-related mortality." | ( Chan, M; Chen, J; Chen, L; Chen, S; Chung, C; Deng, L; Huang, Y; Lei, Y; Zhang, E; Zhong, Y, 2022) |
| "Cervical cancer is characterized by the cellular transformation caused by Human Papillomavirus (HPV), favoring cell proliferation, migration, invasion, and metastasis." | ( de la Cruz-Concepción, B; Dircio-Maldonado, R; Gutiérrez-Escobar, A; Jiménez-Wences, H; Lorenzo-Moran, HY; Martínez-Carrillo, DN; Mendoza-Catalán, MA; Navarro-Tito, N; Ortuño-Pineda, C; Sotelo Leyva, C; Torres-Rojas, FI; Zacapala-Gómez, AE, 2021) |
| "Globally, cervical cancer is the second most common cancer and the third main cause of death related to cancer in women." | ( Aschner, M; Asemi, Z; Mirzaei, H; Reiter, RJ; Shafabakhsh, R, 2023) |
| "Cervical cancer is the leading cause of cancer death in women." | ( Fahriani, M; Murzalina, C; Yusuf, H, 2022) |
| "Cervical cancer is the fourth most common cancer that occurs to women worldwide." | ( Bhattacharyya, K; Dhamnetiya, D; Jha, RP; Patel, P; Shri, N; Singh, M, 2022) |
| "cervical cancer is more prevalent in the developing world affecting mainly women in the reproductive age group and is the commonest cancer among Zambian women." | ( Hamooya, BM; Hangoma, J; Hayumbu, V; Malumani, M; Masenga, SK, 2021) |
| "Cervical cancer is the fourth leading cause of cancer death among women worldwide." | ( Islam, N; Shoaib, S; Yusuf, N, 2022) |
| "Cervical cancer is the most prevalent cancer in females." | ( Awasthee, N; Das, M; Gupta, SC; Haldar, C; Minocha, T; Rai, V; Verma, SS; Yadav, SK, 2022) |
| "Cervical cancer is one of the most common cancers affecting women worldwide." | ( Biffi, S; Bortot, B; Buzzá, HH; Calixto, G; Chorilli, M; Handschin, S; Lutz-Bueno, V; Mezzenga, R; Murgia, S; Salvati Manni, L; Victorelli, FD, 2022) |
| "Cervical cancer is one of the most common malignant tumors in women, and it is essential to explore potential biomarkers such as glycopeptides closely related to cancer in physiological samples of cervical cancer patients." | ( Ding, CF; Rao, D; Wang, B; Yan, Y; Zhong, H, 2022) |
| "Cervical cancer is an aggressive type of cancer affecting women worldwide." | ( Ghate, V; Lewis, S; Sravani, AB, 2023) |
| "Cervical cancer is a major cause of gynecological related mortalities in developing countries." | ( Capalash, N; Gautam, LK; Sidhu, H, 2023) |
| "Cervical cancer is a major public health problem, representing the fourth most common cancer affecting women worldwide." | ( Beck, RCR; Buffon, A; Chaves, PS; Kliemann, LM; Loda, M; Mariot, C; Nascimento, J; Pilger, DA; Vianna, DRB, 2022) |
| "Cervical cancer is the fourth most common cancer in women, and its precise detection plays a critical role in disease treatment and prognosis prediction." | ( Chen, Z; Dong, X; Ming, Y; Wang, H; Wu, N; Zhao, J, 2022) |
| "Cervical cancer is one of the most common gynecological malignancies with poor prognosis due to constant chemoresistance and repeated relapse." | ( Bu, Y; Cui, L; Du, K; Fan, H; He, Y; Lei, Y; Li, Y; Wan, X; Wang, Y; Xiang, J; You, J; Zhang, C; Zhou, J, 2022) |
| "Cervical cancer is a severe malignant tumor that endangers the health of women worldwide." | ( He, Y; Li, L; Lv, X; Ma, J; Shen, X, 2022) |
| "Early-stage cervical cancer is mainly treated by surgery." | ( Deng, HT; Gu, YB; Huang, SM; Jiang, QQ; Li, SB; Ying, X, 2022) |
| "Cervical cancer is one of the most common and serious tumors in women." | ( Li, Q; Peng, X; Qiao, C; Tang, Y; Zhao, R; Zhu, X, 2023) |
| "Cervical cancer is the fourth most common malignancy in women, which is threatening female reproductive tract health." | ( He, ZY; Li, DC; Li, HY; Li, SJ; Liang, ZZ; Yan, J, 2022) |
| "Cervical cancer is a common malignant gynecological tumor for females all over the world." | ( Jiang, Y; Tao, J; Xu, W, 2022) |
| "Cervical cancer is the second most common cancer in women, causing >250,000 deaths worldwide." | ( Ke, XP; Li, JW; Li, L; Liu, P; Pei, JJ, 2023) |
| "Cervical Cancer is the leading cause of morbidity and mortality in India." | ( Chaluvarayaswamy, R; Malila, N; Sastry, NB; Somanna, SN, 2022) |
| "Cervical cancer is the fourth most common cancer in women." | ( Li, R; Lu, X; Wang, W; Ying, Y; Zhang, W, 2022) |
| "Cervical cancer is a crucial clinical problem with high mortality." | ( Liu, X; Wan, J; Wei, M; Xiao, D; Zhang, W, 2023) |
| "Cervical cancer is one of the most common cancers in women worldwide." | ( Dong, C; Li, Y; Liu, C; Qu, L; Zuo, Y, 2022) |
| "Cervical cancer is the most common female cancer in Eastern Africa, and the World Health Organization (WHO) recommends human papillomavirus (HPV)-based screening as a key element to eliminate the disease." | ( Iftner, T; Kahesa, C; Katanga, J; Kjaer, SK; Kjaerem, M; Linde, DS; Manongi, R; Mchome, B; Mwaiselage, J; Rasch, V; Swai, P; Thomsen, LT; Waldstrøm, M, 2023) |
| "Cervical cancer is one of the most aggressive female cancers." | ( Huang, W; Qu, Y; Yan, X; Zhang, H; Zhang, L; Zhu, L, 2022) |
| "Cervical cancer is a major gynecological tumor worldwide." | ( Chen, J; Gao, F; Liu, N; Zhang, T, 2022) |
| "Cervical cancer is associated with profound socioeconomic and racial disparities in incidence, mortality, morbidity, and years of life lost." | ( Cohen, AC; Grover, S; Kuroki, LM; Markovina, S; Rendle, KA; Schwarz, JK, 2022) |
| "Cervical cancer is the fourth most frequently diagnosed and fatal gynecological cancer." | ( Becker, S; Gasimli, K; Häupl, B; Kostova, I; Krämer, A; Mandal, R; Oellerich, T; Peña-Llopis, S; Raab, M; Rödel, F; Sanhaji, M; Strebhardt, K, 2022) |
| "Cervical cancer is the fourth most frequently diagnosed and fatal gynecological cancer." | ( Becker, S; Gasimli, K; Häupl, B; Kostova, I; Krämer, A; Mandal, R; Oellerich, T; Peña-Llopis, S; Raab, M; Rödel, F; Sanhaji, M; Strebhardt, K, 2022) |
| "Cervical cancer is the fourth most frequently diagnosed and fatal gynecological cancer." | ( Becker, S; Gasimli, K; Häupl, B; Kostova, I; Krämer, A; Mandal, R; Oellerich, T; Peña-Llopis, S; Raab, M; Rödel, F; Sanhaji, M; Strebhardt, K, 2022) |
| "Cervical cancer is a common gynecological malignancy afflicting women all over the world." | ( Fan, M; Jiang, L; Liu, M; Liu, Y; Qiao, J; Wang, C; Wang, J; Wang, X; Yu, S; Zhang, P; Zhao, D, 2022) |
| "Cervical cancer is a common gynecological malignancy afflicting women all over the world." | ( Fan, M; Jiang, L; Liu, M; Liu, Y; Qiao, J; Wang, C; Wang, J; Wang, X; Yu, S; Zhang, P; Zhao, D, 2022) |
| "Cervical cancer is a common gynecological malignancy afflicting women all over the world." | ( Fan, M; Jiang, L; Liu, M; Liu, Y; Qiao, J; Wang, C; Wang, J; Wang, X; Yu, S; Zhang, P; Zhao, D, 2022) |
| "Cervical cancer is one of the most common malignancies in women with high morbidity and mortality." | ( Bai, W; Hou, C; Kong, D; Li, D; Li, Y; Liu, Y; Lu, X; Ma, J; Papukashvili, D; Rcheulishvili, N; Zhao, H, 2022) |
| "Cervical cancer is one of the most common malignancies in women with high morbidity and mortality." | ( Bai, W; Hou, C; Kong, D; Li, D; Li, Y; Liu, Y; Lu, X; Ma, J; Papukashvili, D; Rcheulishvili, N; Zhao, H, 2022) |
| "Cervical cancer is one of the leading causes of women's mortality in developing countries." | ( Chandel, R; Chauhan, S; Goel, H; Jha, AK; Jha, M; Jha, NK; Jha, SK; Mathur, R; Pamidimarri, S; Sharan, M; Shrivastava, A; Syeda, S, 2023) |
| "Cervical cancer is one of the leading causes of women's mortality in developing countries." | ( Chandel, R; Chauhan, S; Goel, H; Jha, AK; Jha, M; Jha, NK; Jha, SK; Mathur, R; Pamidimarri, S; Sharan, M; Shrivastava, A; Syeda, S, 2023) |
| "Cervical cancer is the most common cancer among Nepalese women." | ( Dawadi, T; Mulmi, R; Pathak, A; Pradhananga, KK; Sharma, M; Shrestha, G; Siwakoti, B, 2022) |
| "Cervical cancer is rare in adolescent and pediatric populations, with adenocarcinoma being the most commonly reported." | ( Bujor, IE; Cristofor, A; Găină, MA; Gireada, R; Lozneanu, L; Mandici, CE; Matasariu, DR; Plamadeala, P; Scurtu, AM; Ursache, A, 2022) |
| "Cervical cancer is a prevalent malignancy that is a major health problem for women worldwide." | ( Kang, MJ; Kim, HM; Song, SO, 2022) |
| "Cervical cancer is linked with the constitutive activation of growth factors and gene mutations-induced pro-survival signaling pathways." | ( Chen, L; Dong, H; He, X; Li, H; Wang, T; Yuan, Y; Zhang, D; Zhou, L, 2023) |
| "Cervical cancer is a public health problem of extensive clinical importance." | ( Du, P; Huang, M; Li, G; Wu, L, 2022) |
| "Cervical cancer is the fourth most common cancer among women worldwide." | ( Avila, E; Bernadez-Vallejo, SV; Camacho, J; Díaz, L; García-Becerra, R; García-Quiroz, J; Gómez-Ceja, KA; Lara-Sotelo, G; Larrea, F; Prado-Garcia, H; Segovia-Mendoza, M; Vargas-Castro, R, 2023) |
| "Cervical cancer is known globally as one of the most common health problems in women." | ( Almotairy, A; Almutairi, M; Althobaiti, A; Alyahya, M; Ashour, EA; Bandari, S; Repka, MA, 2023) |
| "Cervical cancer is one of the most common female malignant tumors, with typical cancer metabolism characteristics of increased glycolysis flux and lactate accumulation." | ( Cai, H; Dai, M; Gao, Y; He, C; Liang, Z; Shan, S; Su, M; Wan, S; Wang, H; Yang, J; Zhao, M, 2023) |
| "Cervical cancer is the fourth most common female malignancy." | ( Bjurberg, M; Markus, M; Sartor, H; Trägårdh, E, 2023) |
| "Cervical cancer is one of the leading causes of death among women." | ( Al-Najjar, MAA; Alam, MS; Zeyaullah, M, 2022) |
| "Cervical cancer is one of the most common malignant tumors in women." | ( Wang, L; Wang, X; Xia, L; Zhang, H; Zhang, X; Zhu, L, 2023) |
| "Although cervical cancer is clinically considered an estrogen-independent tumor, the role of estrogen in cervical cancer, particularly cervical adenocarcinoma, remains controversial." | ( Hashimoto, K; Kimura, T; Kinose, Y; Kitano, S; Kodama, M; Nakamura, K; Ogawa, M; Sawada, K; Toda, A; Yamashita, S, 2023) |
| "Cervical cancer is the fourth most prevalent malignant tumor among women globally." | ( Goreal, AA; Othman, AA; Pity, IS, 2023) |
| "However, not all cervical cancer is caused by HPV infection, which may also be related to other factors, such as nutritional status and lifestyle." | ( Cui, W; Fang, F; Han, X; Liu, Y, 2023) |
| "Globally, cervical cancer is a major public health problem, with about 604,000 new cases and over 340,000 deaths in 2020." | ( Arbyn, M; Bor, JP; Mwenda, V; Njeru, J; Njiri, P; Nyangasi, M; Olwande, S; Temmerman, M; Tummers, P; Weyers, S, 2023) |
| "Cervical cancer is the fourth leading cause of cancer death in women, and is one of the most common malignant tumors of the reproductive system." | ( Guo, W; Jing, W, 2023) |
| "Cervical cancer is the fourth most common cancer among women, and cytopathological images are often used to screen for this cancer." | ( Chen, H; Chen, J; Fan, Z; Grzegorzek, M; Jiang, T; Li, C; Li, X; Liu, W; Sun, H; Wu, X; Zheng, Y, 2023) |
| "Cervical cancer is the second leading cause of deaths due to cancer among women in India." | ( Muraleedharan, VR; Muthuramalingam, MR, 2023) |
| "Cervical cancer is a significant cause of morbidity and mortality in women worldwide." | ( Alasmari, S; Alghamdi, YS; Alhazmi, AY; Almasoudi, HH; Hakami, MA; Makkawi, M; Mashraqi, MM, 2023) |
| "Cervical cancer is the fourth most common malignancy in women globally." | ( Song, Y; Wang, S, 2023) |
| "Cervical cancer is one of the most common cancers and a major cause of morbidity among women globally." | ( Kibudde, S; Lwanira, CN; Mulamira, P; Najjemba, JI; Ndagire, R, 2023) |
| "Cervical cancer is the fourth most common malignant tumors in female worldwide." | ( Diao, G; Guo, J; Han, J; Huang, J; Li, L; Ma, T; Ren, Y; Zheng, X; Zheng, Y, 2023) |
| "Cervical cancer is the fourth most common cancer." | ( Wang, J; Xing, X; Xu, L; Zhou, H; Zhou, J, 2023) |
| "Cervical cancer is one of the most common cancers that affects middle-aged women and the discovery of new drugs to aid clinical management is needed." | ( Dong, L; Hong, W; Huang, H; Pang, Z; Ren, Y; Wang, H; Wu, H; Yang, X; Zhang, J; Zhao, Z, 2023) |
| "Cervical cancer is a serious threat to women's health globally." | ( Cui, H; Qin, S; Yin, S; Yu, S, 2023) |
| "cervical cancer is a major public health problem among women in sub-Saharan Africa." | ( Meda, N; Ouattara, A; Sawadogo, M; Tassembedo, S; Traore, IT; Winter, CH, 2023) |
| "Cervical cancer is the fourth most common cancer in women worldwide." | ( Paramitha, PP; Winata, IGS; Yusrika, MU, 2023) |
| "Cervical cancer is the third most common malignancy in women globally." | ( Paramitha, PP; Winata, IGS; Yusrika, MU, 2023) |
| "Cervical cancer is a huge worldwide health burden, impacting women in impoverished nations in particular." | ( Das, PP; Kumar, D; Sagar, R; Sengupta, S; Sharma, S; Yadav, R, 2023) |
| "Cervical cancer is the second-most prevalent gynecologic cancer in India." | ( Ghorai, S; Ghosal, S; Kumar Jana, S; Mondal, R; Patra, S; Rath, A; Shand, H, 2023) |
| Excerpt | Reference |
|---|
| "Nine patients with advanced cancer of the uterine cervix, having failed radiotherapy, were treated with a combination regimen of parenteral methotrexate, bleomycin, and cis-dichlorodiammineplatinum(II)." | ( Kaplan, BH; Moukhtar, M; Vogl, SE, 1979) |
| "Twenty cases of advanced (Stage III) cancer of the cervix were treated with intratumour injection of 40% urea solution and local application of 50% urea ointment." | ( Anasuya, SR; Gandhi, GM; Kawathekar, P; Krishnamurthy, KR, 1977) |
| "74 patients with untreated cervical cancer (FIGO II and III) were skintested with a battery of recall antigens, and also sensitised and challenged with DNCB." | ( Luger, T; Michalica, W; Micksche, M; Tatra, G, 1978) |
| "Modes of treatment for cervical cancer will vary according to geographic location, the expertise of those providing treatment, and current clinical trials." | ( Fraser, RC, 1976) |
| "Twenty four patients with advanced cancer of cervix were submitted to sequential chemotherapy 5FU and MTX." | ( Mathur, RK; Mathur, V; Sharma, K; Tripathi, N, 1992) |
| "In the treatment of cervical cancer, it is used as part of combined-modality regimens prior to radiotherapy." | ( Gill, I; Muggia, FM, 1992) |
| "A 36-year-old woman with disseminated cervical cancer and multiple metastatic lesions in both kidneys was being treated with five courses of bleomycin, vindesine, mitomycin C, and cisplatin." | ( Beijnen, JH; Rodenhuis, S; ten Bokkel Huinink, WW; Vlasveld, LT; Wanders, J, 1992) |
| "In 11 cases of advanced cancer of the uterine cervix, serum and urinary levels of alpha 1-microglobulin (alpha 1-m) and beta 2-microglobulin (beta 2-m), and urinary albumin (Alb) and lysozyme (LZM) were determined before the chemotherapy and 1,2 and 3 weeks after the therapy." | ( Date, Y; Iwanari, O; Kitao, M; Miyako, J; Moriyama, M; Nakayama, S; Ryuhkoh, K; Yoshino, N, 1990) |
| "Seventeen patients with recurrent cervical cancer were prospectively treated with a combination of bleomycin, vincristine, and mitomycin C (BOM)." | ( Goplerud, DR; Krebs, HB; Wheelock, JB, 1990) |
| "Twenty evaluable patients with advanced cervical cancer refractory to one prior chemotherapy regimen were treated with a 5-day schedule of fludarabine phosphate." | ( Alberts, DS; Green, S; Hannigan, EV; Surwit, EA; Von Hoff, DD, 1990) |
| "Twenty-five patients with cervical cancer (4 post-operative cases with FIGO stage Ib or IIb, 2 with stage IV, and 19 recurrence) were treated with a new BOMP consisting of bleomycin (5 mg/body, drip, i." | ( Chen, JT; Fujimoto, I; Koi, S; Nakayama, K; Seimiya, Y; Shimizu, Y; Teshima, H; Yamakawa, Y; Yamauchi, K; Yokosuka, K, 1991) |
| "In uterine cervical cancer, each group of 9 cases administered single dose of 400 mg of 5'-DFUR and 7 cases administered 400 mg of 5'-DFUR 3 times a day continuously for 7 days was investigated." | ( Hasegawa, K; Ikeda, M; Kinugasa, M; Kobashi, Y; Noda, K; Odagiri, H; Ohiwa, T; Sekiba, K; Takeuchi, K; Watanabe, Y, 1991) |
| "However, cervical cancer is a relatively drug-resistant disease and prolonged cisplatin treatment appears to induce multiple mechanisms of tumor resistance." | ( Alberts, DS; Garcia, D; Mason-Liddil, N, 1991) |
| "Microinvasive cervical cancer presented in a woman with retroperitoneal fibrosis in remission following steroid therapy." | ( Bower, JD; McGehee, RP; Rivlin, ME, 1991) |
| "A total of 10 uterine cervical cancer patients (stage IIb 2, stage IIIb 6, stage IVb 2) were treated two times with selective intra-arterial injection of combined drugs of CDDP, ADR, 5-FU, MMC before operation or radiation therapy." | ( Abe, M; Honda, T; Kinashi, Y; Mori, T; Nagata, Y; Tai, S; Takai, I, 1990) |
| "A total of 25 patients with inoperable cervical cancer were treated by daily radiotherapy (2 Gy); sensitisation was obtained by administration of 5 mg cisplatin 30 min before each irradiation session." | ( Chauvel, P; Courdi, A; Fontana, X; Lagrange, JL; Milano, G; Troger, V, 1990) |
| "Survival in patients with advanced cervical cancer (stage III B) treated by radical radiotherapy is low." | ( Garcia-Puche, JL; Lara, PC; Pedraza, V, 1990) |
| "Regeneration of clonogens in human cervical cancer was assessed by the pathological evaluation of the hysterectomy specimen after intracavitary 252Cf neutron brachytherapy implants separated by varying time intervals followed by extrafascial hysterectomy." | ( Feola, J; Maruyama, Y; Urano, M; Wierzbicki, J, 1990) |
| "Seventeen patients with recurrent uterine cervical cancer were treated with combination chemotherapy consisting of consecutive intravenous drip infusion of PEP 5 mg for 6 days and intravenous infusion of MMC 10 mg on the 6th day." | ( Chiba, T; Hiura, M; Kaneko, H; Tanaka, M; Yokoyama, T; Yorishima, M, 1988) |
| "We have been treating advanced cancer of the cervix uteri with intra-arterial cisplatin (CDDP) and peplomycin (PEP) (injected into the bilateral internal iliac artery), combined with radiotherapy and hysterectomy." | ( Date, Y; Iida, K; Iwanari, O; Kijima, S; Kitao, M; Miyako, J; Moriyama, M; Nakayama, S; Takahashi, K; Yamamoto, K, 1988) |
| "Patients with advanced, recurrent cervical cancer who have failed radiation therapy often have underlying renal compromise." | ( Chambers, JT; Chambers, SK; Del Prete, SA; Flynn, SD; Schwartz, PE, 1989) |
| "We have been treating advanced cancer of the uterine cervix with intra-arterial cisplatin (CDDP) and pepleomycin (PEP) (injected into the bilateral internal iliac artery), combined with radiotherapy and hysterectomy." | ( Date, Y; Fujita, Y; Iwanari, O; Kitao, M; Miyako, J; Moriyama, M; Nakayama, S; Ryukou, K; Yasui, K; Yoshino, N, 1989) |
| "The results of radiation treatment for cervical cancer obtained at the Institute Clinic are discussed." | ( Kholin, VV; Zharinov, GM, 1989) |
| "Seven patients with advanced cancer of the uterine cervix were treated by anal submucosal injection of methotrexate." | ( Shafik, A, 1989) |
| "A 69 year-old woman with recurrent uterine cervical cancer was treated by etoposide because of ascites retention and elevated serum SCC level." | ( Kawashima, Y; Kobayashi, H, 1989) |
| "4 cases of uterine cervical cancer with radiotherapy, including 2 cases of primary and 2 cases of postoperative radiotherapy, were managed by Maalox treatment with intervals of one to nine years between radiotherapy and Maalox instillation." | ( Kawagoe, K; Kawana, T, 1989) |
| "In patients with laryngeal and cervical cancer platelet capacity to adhesion was considerably reduced during radiotherapy with the use of metronidazole." | ( Andreev, VG; Berdov, BA; Chekalina, SI; Pavlov, VV, 1989) |
| "Fifty patients with cervical cancer were treated with radical hysterectomy and lymphadenectomy followed by postoperative radiation therapy for high risk factors (nodal metastases, lymphvascular space invasion, close or involved margins) at the University of Alabama at Birmingham Medical Center from 1969 to 1984." | ( Barter, JF; Hatch, KD; Orr, JW; Shingleton, HM; Soong, SJ, 1989) |
| "Following intracavitary radium for cervical cancer some typical nosocomial pathogens like Streptococcus faecalis, Enterobacter, Klebsiella, Proteus and Pseudomonas were isolated significantly more frequently than before treatment." | ( Gerstner, G; Kucera, H; Rotter, M; Weghaupt, K, 1986) |
| "Eleven patients who had advanced cancer of the cervix were treated with combination chemotherapy containing Cisplatin as a primary treatment." | ( Barrier, J; Bercau, G; Ciraru-Vigneron, N; Espie, M; Marty, M; Mignot, L; Muray, JM; Payraudeau-Daoud, P, 1987) |
| "Radiotherapy for invasive cervical cancer involves a high risk of local complications." | ( Tana, S; Trenti, N; Volterrani, F, 1987) |
| "Combined radiotherapy of cervical cancer was shown to result in disorder of absorptive-excretory function of the liver, disturbed fat assimilation in the small intestine and a decrease in gastrin production." | ( Modnikov, OP, 1985) |
| "Chemotherapy of cervical cancer is a difficult problem." | ( Guthrie, D, 1985) |
| "Nine patients with advanced cervical cancer were treated with a combination chemotherapy (MVP) consisting of mitomycin C 8 mg/m2 i." | ( Adachi, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Nakada, H; Ogawa, M; Tada, A; Usui, N; Yamazaki, H, 1985) |
| "One-hundred-fifteen patients with cervical cancer were treated by placing bleomycin, carbazilquinone (Carboquone), and 5-fluorouracil suppositories in contact with cancer lesions located in the vaginal portion of the uterus or by inserting them into the cervical canal, twice a week, one to 14 times." | ( Fujiyama, N; Iwata, M; Kikyo, T; Machida, Y; Masuda, H; Nagai, K; Shiojima, Y; Suda, T; Sumiyoshi, Y, 1981) |
| "Thirty-three patients with advanced cervical cancer (31 squamous cancer, two adenosquamous cancer) previously untreated with cytotoxic drugs, were treated with bleomycin, 5 mg daily, for seven days and mitomycin C, 10 mg, on day 8." | ( Gullberg, B; Johnsson, JE; Mattsson, W; Sigurdsson, K; Simonsen, E; Stendahl, U; Tropé, C, 1983) |
| "The principle treatment of cervical cancer now consists of surgery and radiotherapy, which have produced excellent treatment results." | ( Kohno, I; Sekiba, K, 1983) |
| "Thirty-five patients with advanced cervical cancer were treated with a combination chemotherapy regimen comprising cisplatin, vinblastine, and bleomycin (PVB)." | ( Atkinson, K; Coppleson, M; Elliott, P; Friedlander, M; Green, D; Houghton, R; Kaye, SB; Russell, P; Solomon, J; Sullivan, A, 1983) |
| "Twelve patients with uterocervical cancer had panhysterectomy and were administered piperacillin (PIPC) at a dose of 2 g by one shot injection 2 times a day for a period of 5--6 days." | ( Koike, K; Ohshima, T, 1983) |
| "Three groups of uterine cervix cancer patients (before treatment, 6 weeks after radiation and 2 and more years after treatment) are all characterized by different M." | ( Schreiner, P; Siracký, J, 1982) |
| "Chemotherapy for cervical cancer patients with recurrent and/or advanced disease has been complicated by excessive toxicity and short duration of responses, leading to little or no improvement in survival." | ( Chambers, JT; Chambers, SK; Kohorn, EI; Lamb, L; Schwartz, PE, 1994) |
| "Twenty seven patients with cervical cancer were treated with PVP therapy including cisplatin 50mg/m2, vinblastine 4mg/m2 and peplomycin 15mg/body during the period from 1984 to 1989." | ( Hatae, M; Hokanishi, H; Onishi, Y, 1993) |
| "Four patients with cervical cancer (squamous cell carcinoma: two cases of stage Ib, one of stage IIa, adenocarcinoma: one of stage Ib), were treated preoperatively by intravaginal administration of CDDP (20 mg) suppositories with pessary 7 times every other day." | ( Fujii, T; Furui, J; Kioka, H; Murakami, J; Naito, H; Nakagawa, H; Sanada, M; Tanaka, T; Tanimoto, H; Tanioka, Y, 1995) |
| "Total 21 cases of cervical cancer were alloted randomly into 5'-DFUR group (daily dose 800 mg for 3 days) consisting of 11 patients and UFT group (daily dose 600 mg for 3 days) consisting of 10 patients, the unchanged substances (5'-DFUR in the 5'-DFUR group and tegafur concentrations in the UFT group) and 5-FU concentrations in serum and tissues were measured 6 hours after administration of the drugs." | ( Aida, I; Kasuga, Y; Ohwada, M; Sato, I; Suzuki, M; Tamura, T, 1995) |
| "A patient with recurrent cervical cancer was treated with multiple biological therapies including TIL and TNF therapy, and irradiation." | ( Goto, S; Kera, J; Sakai, S; Soma, GI; Suma, Y; Takeuchi, S, 1994) |
| "In patients with locally advanced cervical cancer, most of the treatment failures occur within the pelvis." | ( Boubli, L; Cowen, D; Delpero, JR; Gamerre, M; Gouvernet, J; Houvenaeghel, G; Noirclerc, M; Perez, T; Resbeut, M; Viens, P, 1994) |
| "Since cervical cancer may have a more fulminant course in HIV-infected women and has become an AIDS-defining illness, the surveillance and treatment of cervical neoplasia may need to be more aggressive." | ( Ciacco, KH; Stratton, P, 1994) |
| "Drug therapy for cervical cancer is slowly undergoing evaluation in early disease stages, in which it is more likely to make an impact." | ( Muderspach, L; Muggia, FM, 1994) |
| "A total of 203 patients with cancer of cervix stage IIIB, treated by radiation alone were analysed retrospectively for the incidence of late rectal and recto-sigmoid complications." | ( Deore, SM; Dinshaw, KA; Shrivastava, SK; Supe, SJ; Viswanathan, PS, 1993) |
| "The purpose of screening for cervical cancer is to prevent the appearance of invasive disease by the detection and treatment of precancerous lesions." | ( Agarwal, SS; Das, DK; Murthy, NS; Prabhakar, AK; Sharma, S, 1993) |
| "Twenty women with cervical cancer were enrolled in a clinical trial to determine the maximal safe dose of WR2721 plus radiation therapy and cisplatin on a novel daily x 5 schedule." | ( Beitler, JJ; Bruckner, H; Goldberg, G; Haynes, H; Hochster, H; Holland, JF; Mandeli, J; Runowicz, C; Smith, H; Wadler, S, 1993) |
| "Seven patients had had cancer of the uterine cervix, and one patient had had cancer of the prostate treated with radiotherapy at a median time of 30 months (range, 9-46 months) previously." | ( Eu, KW; Goh, HS; Ho, YH; Seow-Choen, F; Tay, SK, 1993) |
| "Sixty women with advanced cervical cancer (30 patients with unfavorable Stage IIB and 30 patients with Stages III and IVA) were treated with CR comprising of a combination of external and intracavitary RT delivering between 7000 to 7500 cGy total to point A and 5890 to 6015 cGy to point B along with one cycle of 5-FU and mitomycin C and a second cycle of 5-FU and cis-platinum." | ( Caplan, R; Flam, M; John, M; Quivey, J; Rotman, M; Russell, A; Steinfeld, A, 1996) |
| "Eighteen patients with squamous cell cancer of the cervix were treated with i." | ( Edwards, CL; Ende, K; Fishman, A; Freedman, RS; Kaplan, A; Kavanagh, JJ; Kieback, DG; Kudelka, AP; Levy, T; Mante, R; Steger, M; Verschraegen, CF, 1996) |
| "Locally advanced cervical cancer could be treated with Interferon-alpha plus retinoic acid concomitant with standard radiotherapy." | ( Senapad, S; Sritongchai, C; Tepmongkol, P; Veerasarn, V, 1996) |
| "A grade IV Papanicolaou cervical cancer was treated with endocervical cone biopsy (electrocoagulation) in a 28 year-old lady." | ( Korsh, OB; Kroiss, T; Melnyk, A, 1996) |
| "We evaluated 3 patients with advanced cervical cancer treated with cisplatin intra-arterially and intravenously." | ( Cheng, X; Irie, T; Itamochi, H; Kanamori, Y; Kigawa, J; Minagawa, Y; Okada, M; Terakawa, N, 1997) |
| "A survival analysis of treated cases of cervix cancer that were registered in the Bangalore (India) Population Based Cancer Registry between 1 January 1987 and 31 December 1989 was performed." | ( Nandakumar, A; Venugopal, T; Viswanathan, N, 1998) |
| "36 women with locally advanced cervical cancer were treated with concomitant brachytherapy and chemotherapy before surgery and/or definitive external radiotherapy." | ( Froudarakis, G; Haldeopoulos, D; Haralambakis, Z; Koukourakis, M; Koumantakis, E; Livas, V; Mazonakis, M; Papageorgiou, N; Varveris, H, 1998) |
| "Eight patients with uterine cervical cancer received two or three courses of neoadjuvant chemotherapy, including 254-S i." | ( Adachi, S; Ando, K; Inoue, J; Kohyama, K; Nakao, N; Narasaki, K; Takayasu, Y; Takemura, T; Yamano, T, 1998) |
| "Eligibility included squamous cell cancer of the cervix, measurable disease, allowed no more than one prior chemotherapy regimen which did not include etoposide, WBC >/=3000/microliter, platelet count >/=100, 000/microliter, serum creatinine | ( Blessing, JA; Rose, PG; Van Le, L; Waggoner, S, 1998) |
| "Patients with advanced-stage cervical cancer are treated with radiation." | ( Yamamoto, K, 1998) |
| "Prognostic factors in cancer of the cervix for patients treated with external beam irradiation (EBR) and low-dose-rate (LDR) brachytherapy have been characterized." | ( Hackl, A; Kapp, DS; Kapp, KS; Lahousen, M; Pickel, H; Poschauko, J; Stuecklschweiger, GF, 1998) |
| "Twenty-six patients with squamous cell cancer of the cervix were treated with i." | ( Dakhil, SR; Downey, G; Edwards, CL; Freedman, RS; Fueger, R; Gacrama, P; Greenberg, H; Kavanagh, JJ; Kudelka, AP; Loyer, E; Rusinkiewicz, J; Winn, R, 1996) |
| "Twenty-five patients with advanced cervical cancer (IIb-IVa) were treated with neoadjuvant chemotherapy followed by radical hysterectomy or radiotherapy." | ( Hongo, A; Ikuhashi, H; Kobashi, Y; Kodama, J; Kudo, T; Miyagi, Y; Mizutani, Y; Okuda, H; Yoshinouchi, M, 1999) |
| "Women with bulky stage IB cervical cancers (tumor, > or =4 cm in diameter) were randomly assigned to receive radiotherapy alone or in combination with cisplatin (40 mg per square meter of body-surface area once a week for up to six doses; maximal weekly dose, 70 mg), followed in all patients by adjuvant hysterectomy." | ( Bundy, BN; Chafe, WE; Gersell, D; Keys, HM; Muderspach, LI; Stehman, FB; Suggs, CL; Walker, JL, 1999) |
| "Treatment decisions for cervical cancer, a common disease worldwide, depend on demonstrating whether or not tumor invasion of the surrounding tissue has occurred." | ( Aspenblad, U; Auer, G; Eriksson, E; Moberger, B; Salo, S; Skyldberg, B; Tryggvason, K, 1999) |
| "As a result, the number of cervical cancer patients who visit radiotherapy departments has decreased significantly." | ( Ito, H, 1999) |
| "In human cervix cancer treated with radiotherapy, we have previously shown from separate groups of patients that tumor hypoxia and proliferation rate as measured by bromodeoxyuridine (BrdU) labeling index (LI) are important determinants of clinical outcome." | ( Fyles, AW; Levin, W; Manchul, LA; Milosevic, M; Pintilie, M; Syed, A; Tsang, RW, 2000) |
| "Cisplatin and paclitaxel are active in cervical cancer and both are able to potentiate the effects of radiotherapy." | ( Casella, G; De Vivo, R; Ferrari, E; Frezza, P; Iodice, F; Perrone, F; Pignata, S; Ricchi, P; Silvestro, G; Tambaro, R; Tramontana, F; Tramontana, S, 2000) |
| "For both the cervical cancer cell line CaSki containing integrated HPV-16 DNA and the laryngeal carcinoma cell line HEp-2 transfected with HPV-16 DNA, prolonged progesterone treatment enhances their colony formation efficiency both on plastic surface and in soft agar." | ( Auborn, K; James, C; Yuan, F, 1999) |
| "In patients with locally advanced cancer of the uterine cervix, oral enzyme therapy was found to be effective in significantly reducing radiation therapy-related side effects such as genitourinary symptoms, subcutaneous changes and reactions of the vaginal mucosa." | ( Daftary, GV; Dale, PS; George, D; Tamhankar, CP, 2001) |
| "As PKC activity changes in TPA-treated cervical cancer cells, telomerase activities were increased at low dose of TPA and decreased at high dose." | ( Hur, SY; Ki, IK; Kim, JW; Kim, TE; Kim, YW; Lee, JM; Namkoong, SE, 2001) |
| "Human cervical cancer cell lines, ME-180 and HeLa, were treated with cRA and IFNalpha followed by radiation." | ( Chung, CT; Kim, JH; Lee, YJ; Ryu, S; Stein, JP, 2001) |
| "We presented a case of locally advanced cervical cancer treated by intraarterial infusion chemotherapy, and evaluated the blood flow of uterine arteries before and after chemotherapy by using a transvaginal ultrasonic color Doppler device." | ( Minagawa, Y; Onohara, Y; Takahashi, H; Tsudo, T, 2001) |
| "In C33A cervical cancer cells, DIM was more potent than I3C [dose at which the number of viable cells was 50% of that in untreated cultures (LD(50)) = 50-60 micromol/L for DIM and 200 micromol/L for I3C in a mitochondrial function assay] and faster acting." | ( Auborn, KJ; Carter, TH; Chen, DZ; Qi, M, 2001) |
| "Twenty-three patients with advanced uterine cervical cancer who were treated with RT were prospectively evaluated." | ( Magnotta, VA; Mayr, NA; Otake, S; Ueda, T; Yuh, WT, 2002) |
| "Of 114 patients with cervical cancer Stage IB-IV, the first 39 patients received radiotherapy, the following 75 patients received identical radiotherapy plus concomitant chemotherapy (3 cycles of carboplatin and 5-fluorouracil)." | ( Aalders, JG; Canrinus, AA; de Bruijn, HW; de Vries, EG; Pras, E; Sluiter, WJ; Szabo, BG; ten Hoor, KA; Willemse, PH, 2002) |
| "The aim of this study was to determine cervical cancer cell sensitivity to chemotherapy-induced apoptosis based on human papillomavirus (HPV) status." | ( Carson, LF; Leung, BS; Padilla, LA, 2002) |
| "HPV-positive cervical cancer cells have an inherent resistance to chemotherapy-induced apoptosis." | ( Carson, LF; Leung, BS; Padilla, LA, 2002) |
| "A 76-year-old woman with stage IIb cervical cancer with a bulky tumor experienced aortitis during continuous intraarterial cisplatin-based chemotherapy." | ( Kawato, H; Kikukawa, T; Kondo, E; Tanaka, H; Toyoda, N, 2002) |
| "To improve the prognosis of cervical cancer, we studied combination chemotherapy of intravenous nedaplatin and intraarticular cisplatin with transcatheter arterial embolization (TAE)." | ( Adachi, S; Hori, Y; Koyama, K; Ogasawara, T; Oku, H; Takemura, T; Tsubamoto, H; Tsuji, Y, 2001) |
| "Eleven cervical cancer patients were included in this prospective study that evaluated one tandem and ovoid brachytherapy procedure for each patient." | ( Bosch, WR; Grigsby, PW; Laforest, R; Low, DA; Malyapa, RS; Miller, TR; Mutic, S; Zoberi, I, 2002) |
| "In human papillomavirus (HPV)-positive cervical cancer cells, the endothelin A receptor (ET(A)R) mediates an endothelin-1-induced mitogenic effect, thus representing a relevant target for antitumor therapy." | ( Bagnato, A; Cirilli, A; Muller, A; Natali, PG; Nicotra, MR; Salani, D; Simeone, P; Venuti, A, 2002) |
| "A total of 49 patients with cervical cancer were treated with a combination of EBRT (median 45 Gy, range 41." | ( Avadhani, J; Deore, S; Garg, M; Gorla, G; Guha, C; Malhotra, H; Sood, B; Vikram, B, 2002) |
| "Patients with cervical cancer who develop pelvic recurrence after primary surgery are usually treated with radiation-based therapy." | ( Ikeda, H; Ishiko, O; Manabe, T; Negoro, S; Tanaka, M; Tsuda, H; Yamamoto, K, 2003) |
| "Forty-seven patients with cervical cancer who were to be treated by combined radiation therapy and chemotherapy were imaged before beginning treatment." | ( Dehdashti, F; Grigsby, PW; Miller, TR; Pinkus, E, 2003) |
| "A total of 136 patients with cervix cancer who were treated with external beam radiotherapy (EBRT) and HDR ICR from 1995 to 1999 were retrospectively analyzed." | ( Ahn, YC; Han, Y; Huh, SJ; Kang, MK; Kim, B; Lee, JE; Lim, DH; Park, W; Shin, KH; Shin, SS, 2003) |
| "Fourteen patients with biopsy-proved cervical cancer were studied by PET with (60)Cu-ATSM before initiation of radiotherapy and chemotherapy." | ( Dehdashti, F; Grigsby, PW; Lewis, JS; Mintun, MA; Siegel, BA; Welch, MJ, 2003) |
| "(60)Cu-ATSM-PET in patients with cervical cancer revealed clinically relevant information about tumor oxygenation that was predictive of tumor behavior and response to therapy in this small study." | ( Dehdashti, F; Grigsby, PW; Lewis, JS; Mintun, MA; Siegel, BA; Welch, MJ, 2003) |
| "Twenty-five cases of advanced cervical cancer (15 cases of stage II with high risks, 10 of stage III, referred to as the 254-S group) treated by NAC using nedaplatin, mitomycin C and peplomycin were compared with 30 cases (22 cases of stage II with high risks, 8 of stage III, referred to as the CDDP group) treated using cisplatin and mitomycin C which is the conventional regimen, in terms of measurable response, pathological response, rate of lymph node metastasis, cumulative survival rate, side effects and relapse style." | ( Aso, T; Ichimura, M; Ohara, M; Otsuka, I; Shimabukuro, K; Somekawa, Y; Terauchi, T; Tsugata, M; Umeki, H; Wakana, K; Yamaguchi, Y, 2003) |
| "the responsiveness of cervical cancer to neoadjuvant chemotherapy allows surgical treatment in a larger number of patients and results in longer overall and disease-free survival." | ( Framarino, ML; Imperato, F; Marzetti, L; Marziani, R; Mossa, B; Napolitano, U, 2003) |
| "Eligibility included nonsquamous cell cancer of the cervix, measurable disease, no more than one prior chemotherapy regimen no prior etoposide, WBC > or = 3000/microl, platelets > or = 100,000/microl, serum creatinine < or = 2 mg%, and adequate hepatic function." | ( Blessing, JA; Buller, RE; Mannel, RS; Rose, PG; Webster, KD, 2003) |
| "Advanced cervical cancer has been predominantly treated with a combination of external beam and brachytherapy in Japan." | ( Chishima, F; Himi, K; Hiraiwa, Y; Idei, T; Kawamori, J; Nagaishi, M; Nakajima, Y; Ohtani, K; Sakamoto, H; Takami, N; Tanaka, Y; Yamamoto, T, 2003) |
| "These results suggest that HPV-positive cervical cancer cells are capable of responding efficiently to DNA damage provoked by NCS treatment through a p53-dependent pathway in spite of the presence of E6 protein." | ( Alvarez, E; Bañuelos, A; Gariglio, P; Monroy, A; Moreno, M; Ocadiz, R; Reyes, E, 2003) |
| "Patients with cervix cancer can be treated on schedule with concurrent carboplatin and pelvic radiation therapy." | ( Haake, M; Hall, JB; Higgins, RV; Naumann, WR, 2003) |
| "Ten patients with advanced or recurrent cancer of the cervix with no prior chemotherapy were entered in a phase II trial from October 2000 to November 2001." | ( Behtash, N; Ghaemmaghami, F; Khanafshar, N; Modares, M; Moosavi, A; Toogeh, G; Yarandi, F, 2003) |
| "Recurrent and advanced cervical cancers are associated with high mortality and a lack of effective treatment options, especially for women who are poor candidates for surgery or radiation therapy." | ( Bloss, JD; Mutch, DG, 2003) |
| "In the management of cervical cancer, chemotherapy has received increasing attention in the last two decades and is currently used in neoadjuvant regimens, as salvage treatment in patients with disseminated or recurrent disease, or as a radiosensitizer." | ( Buda, A; Dell'Anna, T; Mangioni, C; Signorelli, M, 2003) |
| "Treatment of cervical cancer SiHa cells with streptomycin and its analogues (gentamicin and netilmicin) did not affect the basal cytosolic Ca(2+) ([Ca(2+)](i)) level." | ( Chiu, WT; Chou, CY; Shen, MR, 2003) |
| "Treating uremic patients with cervical cancer by cisplatin-based chemotherapy combined with radiation is hampered by the reduced renal excretion of cisplatin." | ( Huang, JY; Lai, PC; Shih, IH; Wu, CH, 2004) |
| "Japanese women with low-stage cervical cancer receiving radical hysterectomy and radiotherapy have a good 5-year survival rate." | ( Hasegawa, K; Izumi, R; Kudo, R; Nakajima, H; Ohashi, K; Okuda, H; Origasa, H; Sugimori, H; Takahashi, T; Yamamoto, K, 2004) |
| "Patients with advanced stage invasive cervical cancer (CC) exhibit highly complex genomic alterations and respond poorly to conventional treatment protocols." | ( Arias-Pulido, H; Basso, K; Dürst, M; Gissmann, L; Mansukhani, M; Meyer, L; Murty, VV; Nandula, SV; Narayan, G; Pothuri, B; Schneider, A; Sugirtharaj, DD; Vargas, H; Villella, J, 2004) |
| "Reactivation of p73 expression in two cervical cancer cell lines by demethylation treatment supported the role of methylation in the regulation of p73 expression." | ( Chan, KY; Cheung, AN; Chiu, PM; Leung, RC; Liu, SS; Ng, TY; Ngan, HY; Tam, KF; Wong, LC, 2004) |
| "There were 14 patients with stage IVB cervical cancer who were previously untreated." | ( Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Sukthomya, V; Tonusin, A, 2004) |
| "The survival of cervix cancer patients is associated with their hemoglobin (Hgb) level during radiotherapy." | ( Alberts, DS; Chang, PC; Conrad, ME; Greer, BE; Jiang, C; Lavey, RS; Liu, PY; Markman, M; Robinson, WR; Wynn, RB, 2004) |
| "Recurrent and/or metastatic cervical cancer patients were treated with 41." | ( Richel, O; Rietbroek, R; Schilthuis, MS; Van der Velden, J; Van Dijk, JD; Westermann, AM; Zum Vörde Sive Vörding, PJ, 2004) |
| "The treatment of human cervical cancer cells with As(2)O(3) induces dissipation of mitochondrial membrane potential (Deltapsi(m)), translocation of AIF from mitochondria to the nucleus, and subsequent cell death." | ( Bae, S; Cho, CK; Chung, HY; Hong, SI; Kang, CM; Kang, YH; Kim, MJ; Lee, SJ; Lee, YS; Park, IC; Park, MJ; Park, MT; Rhee, CH; Yi, MJ, 2004) |
| "To compare the outcome of patients with cervical cancer and negative lymph nodes by fluorodeoxyglucose-positron emission tomography (FDG-PET) treated with irradiation (RT) and concurrent chemotherapy or RT alone." | ( Dehdashti, F; Grigsby, PW; Herzog, TJ; Mutch, DG; Rader, J; Siegel, BA; Zoberi, I, 2005) |
| "Importantly, cervical cancers that arose in the mice treated the first 6 of 9 months with estrogen must have regressed, based upon the reduced incidence of cancers in these mice compared with those treated for 6 months with estrogen, then immediately analyzed." | ( Brake, T; Lambert, PF, 2005) |
| "HeLa cells were used as a model for cervical cancer in this study, and the effect of electrochemical treatment on these cells was examined in four different dosage groups (5 V + 5 C, 10 V + 5 C, 5 V + 10 C and 10 V + 10 C)." | ( Jiang, Z; Li, D; Li, L; Li, QQ; Luan, Y; Reed, E; Tang, B; Zhang, W, 2005) |
| "Current therapy for cervical cancer includes radiation therapy." | ( Benbrook, DM; Gould, NS; Guruswamy, S; Kamelle, SA; Rutledge, TL; Tillmanns, TD, 2005) |
| "The modern approach to cervical cancer prevention, characterized by use of cytology and multiple visits for diagnosis and treatment, has frequently proven challenging and unworkable in low-resource settings." | ( Blumenthal, PD; Lauterbach, M; Sankaranarayanan, R; Sellors, JW, 2005) |
| "Untreated cervical cancer patients with a hemoglobin <12 g/dL were randomized to intramuscular iron or to transfusion." | ( Candelaria, M; Cetina, L; Dueñas-González, A, 2005) |
| "Twelve newly diagnosed patients with cervical cancer were treated with magnesium valproate after a baseline tumor biopsy and blood sampling at the following dose levels (four patients each): 20 mg/kg; 30 mg/kg, or 40 mg/kg for 5 days via oral route." | ( Angeles, E; Cabrera, G; Candelaria, M; Cantu, D; Cetina, L; Chavez-Blanco, A; Duenas-Gonzalez, A; Garcia-Lopez, P; Gonzalez-Fierro, A; Perez-Cardenas, E; Perez-Plasencia, C; Segura-Pacheco, B; Taja-Chayeb, L; Trejo-Becerril, C; Zambrano, P, 2005) |
| "Early stage cervical cancer is treated with surgery or radiation with equivalent results." | ( Gercel-Taylor, C; Spanos, WJ; Taylor, DD; Yashar, CM, 2005) |
| "Most cervical cancer patients with pelvic recurrent or persistent disease are not candidates for exenteration, therefore, they only receive palliative chemotherapy." | ( Brom, R; Candelaria, M; Cantu, D; Cetina, L; Chanona, J; de la Garza, J; Dolores, R; Duenas-Gonzalez, A; Gonzalez, A; Lopez-Graniel, C; Uribe, J, 2005) |
| "The standard therapy for invasive uterine cervical cancer causes loss of the woman's fertility." | ( Akiyama, F; Hasumi, K; Kobayashi, Y, 2006) |
| "FDG uptake within primary cervical cancer, as measured by SUV, is predictive of disease-free survival in patients undergoing radiotherapy for cervical cancer." | ( Dehdashti, F; Grigsby, PW; Lin, LL; Miller, TR; Siegel, BA; Xue, F, 2006) |
| "Biopsy-confirmed high-grade cervical cancer precursor lesions and cancer at 6 and 12 months in the HPV DNA and VIA groups compared with the delayed evaluation (control) group; complications after cryotherapy." | ( De Souza, M; Denny, L; Dupree, W; Kuhn, L; Pollack, AE; Wright, TC, 2005) |
| "Forty-six patients with cervical cancer, 43 with squamous cell carcinoma, 2 adenocarcinoma, and 1 small cell carcinoma, 41 being treated initially and 5 being recurrent cases of which 2 had undergone radiotherapy plus chemotherapy, 2 radical hysterectomy plus pelvic radiotherapy after operation, and 1 radical hysterectomy plus chemotherapy, aged 38 (22-61), were treated with irinotecan hydrochloride, 60 mg/m(2) in 250 ml normal saline administered on days 1, 8, and 15 by intravenous infusion over 60 min, plus cisplatin, 60 mg/m(2) in 500 ml 5% glucose given on day 1." | ( Chen, SY; Chen, TH; Gu, MJ; Ma, D; Song, XJ; Wang, CY; Zhang, QH; Zhu, T, 2005) |
| "Effective neoadjuvant chemotherapy on cervical cancer, combination therapy of irinotecan hydrochloride and cisplatin win opportunity for treatment and improves their life quality with tolerable side effects." | ( Chen, SY; Chen, TH; Gu, MJ; Ma, D; Song, XJ; Wang, CY; Zhang, QH; Zhu, T, 2005) |
| "Nearly all cervical cancers are etiologically attributable to human papillomavirus (HPV) infection and pharmaceutical treatments targeting HPV-infected cells would be of great medical benefit." | ( Baege, AC; Centeno, JA; Disbrow, GL; Hartmann, D; Kierpiec, KA; Schlegel, R; Thibodeaux, CA; Yuan, H, 2005) |
| "Radiation therapy for cervical cancer involves a team of specialists, including diagnostic radiologists (DRs), radiation oncologists (ROs), and medical physicists (MPs), to optimize imaging-based radiation therapy planning." | ( Adli, M; Edwards, SM; Karatas, R; Karatas, Y; Mayr, NA; Montebello, JF; Movahed, A; Wolff, JD; Wu, DH; Yuh, WT, 2005) |
| "A total of 48 patients with advanced cervical cancer, treated with CT-based EBRT plus simultaneous cisplatin chemotherapy (40mg/m(2) of body surface per week for 5 weeks) and MRI-based HDR-BT, were included for analysis." | ( Bachtiary, B; Dimopoulos, J; Kirisits, C; Klos, B; Knocke-Abulesz, TH; Pötter, R; Rheinthaller, A; Sissolak, G, 2006) |
| "Four human cervical cancer cell lines were treated for 24 h with various concentration of paclitaxel, and the sensitivity was analysed by an MTT assay." | ( Faried, A; Faried, LS; Kanuma, T; Kuwano, H; Minegishi, T; Nakazato, T; Tamura, T, 2006) |
| "Eleven cervical cancer patients who received Ir-192 intracavitary brachytherapy with tandem and transverse ovoids were included in this study." | ( Khorprasert, C; Lertsanguansinchai, P; Shotelersuk, K; Sukhaboon, J, 2005) |
| "We analyzed 37 cervical cancer patients receiving concurrent cisplatin (40 mg/m(2)/wk) and intensity-modulated pelvic radiotherapy." | ( Collins, YC; Haslam, JJ; Hurteau, JA; Kochanski, JD; Lengyel, E; Mehta, N; Mell, LK; Mundt, AJ; Roeske, JC; Yamada, SD, 2006) |
| "The proliferation of all four cervical cancer cells was inhibited evidently when treated with 5-aza-dC and the inhibiting rate of cell growth along with the increasing concentration of 5-aza-dC." | ( Lu, Y; Ma, D; Meng, L; Wang, H; Wang, S; Wu, S; Wu, Y; Xi, L; Xu, G; Xu, Q; Zhao, Y; Zhou, J, 2006) |
| "Biopsies of 44 patients with cervical cancers (Stage IIB: n=9; Stage IIIB: n=31; Stage IVA: n=4) treated with radiotherapy were assessed by immunochemistry for expression of Survivin." | ( Bache, M; Dunst, J; Hänsgen, G; Holzapfel, D; Holzhausen, HJ; Kappler, M; Taubert, H, 2007) |
| "We reviewed all patients with cervical cancer stage IB-IIA who were treated with two treatment modalities, i." | ( Ayatollahi, H; Behtash, N; Ghaemmaghami, F; Modarres, M; Mousavi, A; Nazari, Z, 2006) |
| "The stage IIB-IIIB cervical cancer patients were randomized to have Tegafur-Uracil 225 mg/m(2)/day orally, 5 days a week and carboplatin 100 mg/m(2) IV over 30-60 min, weekly on day 1 concurrent with standard radiotherapy (Group A) or carboplatin alone concurrent with standard radiotherapy (Group B)." | ( Kamnerdsupaphon, P; Khorprasert, C; Lertsanguansinchai, P; Lorvidhaya, V; Sangruchi, S; Sookpreedee, L; Suntornpong, N; Udompunturak, S; Veerasarn, V, 2007) |
| "About 50% of cervical cancers are associated with human papillomavirus type 16 (HPV-16), and since the HPV-16 E6 and E7 oncoproteins are constitutively expressed in the tumor cells, they are attractive targets for cytotoxic T lymphocyte (CTL)-mediated immunotherapy." | ( Akatsuka, Y; Ito, K; Ito, Y; Iwata, K; Kiyono, T; Kodera, Y; Kondo, E; Kuzushima, K; Morishima, S; Morishima, Y; Nakanishi, T; Nawa, A; Takahashi, T; Torikai, H; Tsujimura, K, 2007) |
| "The incidence of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy is estimated to be more than 50%." | ( Cho, HJ; Kim, JH; Kim, JW; Kim, SH; Kim, SW; Kim, YT; Nahm, EJ; Yoon, BS, 2007) |
| "We report on a patient with a high-risk cervical cancer during pregnancy treated with neoadjuvant chemotherapy (NACT) followed by radical surgery." | ( Bader, AA; Petru, E; Winter, R, 2007) |
| "Thirty-six patients with Stage IB2-IVA cervical cancer treated with EF-IMRT were evaluated." | ( Beriwal, S; Edwards, RP; Gan, GN; Heron, DE; Kelley, JL; Kim, H; Lalonde, R; Selvaraj, RN, 2007) |
| "For the treatment of advanced cervical cancer, external beam pelvic doses and total doses to point A were 47 + 3." | ( Blake, P; Colombo, A; Du Bois, A; Gaffney, DK; Mirza, MR; Narayan, K; Pignata, S; Portelance, L; Pötter, R; Randall, M; Reed, N; Sadoyze, A; Toita, T; Trimble, EL, 2007) |
| "A small proportion of our patients with cervical cancer would benefit from chemoradiotherapy with concomitant cisplatin, illustrating the difficulties of applying "standard" treatment to the developing world." | ( Kigula-Mugambe, JB; McArdle, O, 2007) |
| "In locally advanced extensive cervix cancer, local control of > or = 85% can be achieved with low treatment related morbidity (G3/G4), when exploiting the potential of MRI based 3D treatment planning including dose volume adaptation and dose escalation and a combined intracavitary/interstitial brachytherapy, if appropriate." | ( Dimopoulos, J; Georg, P; Kirisits, C; Knocke, TH; Lang, S; Pötter, R; Reinthaller, A; Wachter, S; Wachter-Gerstner, N; Waldhäusl, C; Weitmann, H, 2007) |
| "Treatment of cervical cancer in developing countries is highly dependent on the resources and skills available." | ( Ansink, AC, 2007) |
| "Sentinel node mapping method for cervical cancer patients undergoing primary surgical therapy is a feasible option." | ( Emerich, J; Sawicki, S; Wydra, D, 2007) |
| "Patients with untreated squamous cell cervical cancer and PLN or PALN metastasis detected by CT/MRI were enrolled." | ( Chang, TC; Chao, A; Hong, JH; Hsueh, S; Lai, CH; Ng, KK; See, LC; Tsai, CS; Yen, TC, 2008) |
| "Human cervical cancer SiHa cells were cultured in vitro under hypoxic conditions (37 degrees C, 5% CO(2), 1% O(2)) and treated with different concentrations of HCPT for 24 h." | ( Shi, W; Yu, S, 2007) |
| "The medical records of 100 women with cervical cancer stage IB2 to IVA who were treated with weekly cisplatin 40 mg/m(2) concurrent with pelvic radiotherapy at Srinagarind Hospital between January 2003 and June 2006 were reviewed and analyzed." | ( Chumworathayi, B; Luanratanakorn, S; Pattamadilok, J; Tangsiriwatthana, T; Yuenyao, P, 2007) |
| "Thirty-eight women with biopsy-proved cervical cancer underwent (60)Cu-ATSM PET before the initiation of radiotherapy and chemotherapy." | ( Dehdashti, F; Grigsby, PW; Laforest, R; Lewis, JS; Siegel, BA; Welch, MJ, 2008) |
| "Two of the 20 (10%) cervical cancer patients responded to treatment, with one complete response of 25 weeks and one partial response of 14 weeks." | ( Elbendary, AA; Homesley, HD; Lowendowski, GS; Meltzer, NP; Nieves, L; Vaccarello, L, 2008) |
| "A 46-year-old woman who had recurrent cervical cancer in the right pelvic sidewall underwent concurrent salvage chemoradiotherapy." | ( Bae, DS; Huh, SJ; Lee, JA; Oh, D, 2008) |
| "Patients with cervical cancer who had negative para-aortic lymph nodes (PALNs) identified by pretreatment surgical staging were compared with patients who had only radiographic exclusion of PALN metastases before they received treatment with pelvic radiation and brachytherapy (RT) plus cisplatin (C)-based chemotherapy." | ( Gold, MA; Lanciano, R; Rose, PG; Tian, C; Whitney, CW, 2008) |
| "A total of 9 patients with cervical cancer (5 patients treated in neoadjuvant setting and 4 patients for recurrent disease) were administered 80 mg/m(2) of 254-Sintravenously on day 1 and 50 mg/m(2) of CPT-11 intravenously on day 1, 8 and 15." | ( Anzai, N; Hiruma, R; Kamide, T; Kamiya, N; Kotake, Y; Matsumoto, R; Sasaki, H; Shinozaki, H; Tada, A; Wachi, T, 2008) |
| "Patients with previously untreated cervical cancer, with Stage III/IVA disease, or Stage IB/II with high-risk factor (primary tumor diameter >/=50 mm or positive lymph node) were entered into this study." | ( Fuwa, N; Inokuchi, H; Kodaira, T; Nakahara, R; Nakamura, T; Nakanishi, T; Tachibana, H; Tomita, N, 2009) |
| "During radiation therapy for cervical cancer, FDG-PET can be used to monitor treatment response." | ( Grigsby, PW; Lin, LL; Miller, TR; Schwarz, JK; Siegel, BA, 2008) |
| "In the past, women with early-stage cervical cancer have been treated with radical radiotherapy or radical surgery, and women with locally advanced disease with radical radiotherapy, each offering a good chance of cure." | ( Symonds, P; Tierney, JF; Vale, C, 2008) |
| "A case of cervical cancer associated with irreducible procidentia successfully treated with external beam radiation and extracorporeal HDR-AL with concomitant chemotherapy followed by obliterative vaginal surgery is reported for the first time." | ( Abfalter, E; Lunzer, H; Marth, C; Reimer, D; Steppan, I; Sztankay, A; Zeimet, AG, 2008) |
| "ALA-PDT is effective in treatment of cervical cancer." | ( Bian, ML; He, GF; Li, HY; Xiang, Q; Xiao, C; Zhao, YW, 2008) |
| "The applications of PET/CT in cervical cancer patients include: assessing local tumor extension (information on metabolic tumor activity and possible endometrial involvement), evaluating pelvic nodal involvement (even in cases with negative CT or MRI studies), detection of distant metastases (PET/CT should be the first imaging technique used to evaluate extrapelvic disease before pelvic exenteration), radiation therapy planning (in patiens with PET scans positive for lymph nodes), identification of persistent/recurrent disease (especially in assessing response to neoadjuvant therapy and prognosis (with an inverse response-survival relationship." | ( Alfonso, JM; Gonzalez, C; Gorospe, L; Jover, R; Lourido, D; Rojo, A, 2008) |
| "The risk of failure in advanced cervical cancer patients treated in the CCRT era can be predicted." | ( Chang, WC; Chen, SW; Hung, YC; Liang, JA; Lin, FJ; Yang, SN; Yeh, LS, 2008) |
| "Approximately one-third of cervical cancer patients develop disease recurrence and the majority of these recurrences occur within the first 2 years after completion of therapy." | ( Grigsby, PW, 2008) |
| "2004, 285 patients with stage IIB-IIIB cervical cancer treated in Maternal and Child Health Hospital of Jiangxi Province were randomly assigned to receive radiotherapy alone or concurrent chemoradiotherapy." | ( Li, HP; Li, LY; Luo, B; Pan, M; Shu, KY; Zeng, SY, 2008) |
| "Although one-third of the world cervical cancer burden is endured in India, Bangladesh, Nepal and Sri Lanka, there are important gaps in our knowledge of the distribution and determinants of the disease in addition to inadequate investments in screening, diagnosis and treatment in these countries." | ( Ariyaratne, Y; Ashrafunnessa, KS; Basu, P; Bhatla, N; Esmy, PO; Gravitt, PE; Nene, BM; Sankaranarayanan, R; Shah, A, 2008) |
| "Studies in cervical cancer have utilized topotecan administered on days 1-5 of each 21- or 28-day cycle." | ( Arias, D; Candelaria, M; Cantu, D; Cetina, L; Coronel, J; Dueñas-González, A; González-Fierro, A, 2009) |
| "Patients with cervix cancer treated radically with chemoradiotherapy had DCE-MRI at three time points: before starting treatment, after 2 weeks of radiotherapy, and in the 5th week of radiotherapy." | ( Arends, M; Brenton, JD; Crawford, RA; Graves, MJ; Lomas, DJ; Priest, AN; Sala, E; Tan, LT; Zahra, MA, 2009) |
| "Patients with advanced cervical cancer and highly hypoxic primary tumors show increased frequency of locoregional treatment failure and poor disease-free and overall survival rates." | ( Egeland, TA; Ellingsen, C; Gaustad, JV; Gulliksrud, K; Mathiesen, B; Rofstad, EK, 2009) |
| "A current paradigm in the treatment of cervical cancer with radiation therapy is that intracavitary brachytherapy is an essential component of radical treatment." | ( Bazan-Perkins, B; Candelaria, M; Cantú, D; Cetina, L; Coronel, J; Dueñas-González, A; Flores, V; Garcia-Arias, A; Gonzalez, A; Rivera, L, 2009) |
| "The purpose of this pilot study on cervical cancer patients treated at selected sites in Malaysia is to examine the achievability of collecting information on patients." | ( Devi Beena, CR; Gerard, LC; Tang, TS, 2008) |
| "NACT is an effective treatment for cervical cancer." | ( Chai, D; Chu, YX; Zhang, J; Zheng, A, 2008) |
| "Drug-treated or untreated cervical cancer HeLa, breast cancer MCF-7 and melanoma MeWo cell lines were irradiated at 6." | ( Allshire, A; Anoopkumar-Dukie, S; Conere, T; Sisk, GD, 2009) |
| "For locally advanced cervical cancer, the current literature supports the use of (18)F-FDG PET for assessing treatment response 3 mo after the completion of concurrent chemoradiation." | ( Dehdashti, F; Delbeke, D; Grigsby, PW; Schwarz, JK, 2009) |
| "Using cervical cancer cell models, we found that HeLa (LKB1-deficient cell) responded less to the anti-proliferative effect exerted by AICAR treatment (p < 0." | ( Chan, DW; Liu, VW; Ngan, HY; Yu, SY, 2009) |
| "From 1998 to 2008, we identified 65 cervical cancer patients with FIGO (International Federation of Gynecology and Obstetrics) Stage IB1-IVA disease who received definitive external beam radiation therapy and high-dose rate brachytherapy with tandem and ovoid applicators." | ( Anker, CJ; Boucher, KM; Cachoeira, CV; Gaffney, DK; Rankin, J, 2010) |
| "Patients with early-stage cervical cancer referred for surgical treatment were enrolled in the study." | ( Cibula, D; Drazdakova, M; Dundr, P; Fischerova, D; Freitag, P; Pavlista, D; Pinkavova, I; Slama, J; Zikan, M; Zima, T, 2009) |
| "SS in cervical cancer is a feasible and safe pretreatment procedure, and when associated with CT, it improves OS and DFS." | ( Clagnan, WS; de Andrade, JM; Dos Reis, FJ; Garieri, AP; Marana, HR; Tiezzi, DG; Zola, FE, 2009) |
| "Twenty women with squamous cell cervical cancer were randomly assigned to receive ether standard whole pelvic radiotherapy with concurrent cisplatin and fluorouracil infusion every 4 weeks or the same radiotherapy with concurrent cisplatin every 1 week." | ( Penpattanagul, S; Porapakkhan, P; Sukhaboon, J, 2009) |
| "The treatment strategy for elderly cervical cancer patients should be individually planned according to the disease stage and performance status of the patients." | ( Cheng, M; Huang, MN; Wu, LY; Zhang, R; Zhang, WH, 2009) |
| "Patients with stages II to IVa cervical cancer aged 55 years or older were compared with patients younger than 55 years who received weekly cisplatin during pelvic radiation for differences in chemoradiation administration, toxicity, and outcome." | ( Kunos, C; Lanciano, R; Rose, PG; Tian, C; Waggoner, S, 2009) |
| "Meanwhile, 18 cases with early cervical cancer at stage of I b were treated by total hysterectomy and bilateral salpingo-oophorectomy, their anterior vaginal tissues were selected as controls." | ( Chen, LL; Li, B; Lin, XY; Ouyang, L; Zhang, QF; Zhang, SL, 2009) |
| "Five cervix cancer patients undergoing PDR brachytherapy (Varian GammaMed Plus with 192Ir) were monitored." | ( Andersen, CE; Lindegaard, JC; Nielsen, SK; Tanderup, K, 2009) |
| "Forty patients with early-stage cervical cancer underwent pretreatment FDG-PET/computed tomography before radical hysterectomy and lymph node dissection." | ( Grigsby, PW; Huettner, P; Miller, TR; Rader, J; Showalter, TN, 2009) |
| "Biopsy specimens of invasive cervical cancer before neoadjuvant chemotherapy were obtained from 46 patients who subsequently underwent radical hysterectomy at Hokkaido University Hospital and Gunma University Hospital from 1994 to 2007." | ( Hassan, MK; Hosaka, M; Kanuma, T; Minegishi, T; Mitamura, T; Ohta, Y; Sakuragi, N; Watari, H, 2010) |
| "The authors studied cervical cancer patients with pelvic lymph node metastasis, as evidenced on FDG-PET, who were treated between November 2003 and October 2008." | ( Dehdashti, F; Grigsby, PW; Kidd, EA; Siegel, BA, 2010) |
| "Treatment of cervical cancer cell lines (HeLa and DoTc2-4510) with PMA had no effect on MMP-2 expression and a moderate stimulatory effect in ovarian cancer cell line SK-OV-3." | ( Kalinovsky, T; Monterrey, JC; Niedzwiecki, A; Rath, M; Roomi, MW, 2010) |
| "A single-visit approach to cervical cancer prevention in Roi Et province using visual inspection with acetic acid and cryotherapy appeared to have an effect in revealing an increased cervical cancer incidence rate by achieving higher coverage, resulting in increased case finding." | ( Blumenthal, PD; Chumworathayi, B; Kamsa-Ard, S; Limpaphayom, KK; Supaatakorn, P; Wongsena, M, 2010) |
| "Stage IB2-IV cervix cancer patients were treated with escalating doses of Iri starting from 30 mg/m(2) and a fixed dose of CP at 20 mg/m(2), both weekly concomitantly with a 45-Gy pelvic irradiation." | ( Dalenc, F; Delannes, M; El Demery, M; Fabbro, M; Gladieff, L; Guichard, F; Kerr, C; Kurtz, JE; Paraiso, D; Pujade-Lauraine, E, 2010) |
| "All 560 patients with cervical cancer underwent pretreatment FDG-PET lymph node staging." | ( Dehdashti, F; Grigsby, PW; Kidd, EA; Mutch, DG; Powell, MA; Rader, JS; Siegel, BA, 2010) |
| "The validation cohort consisted of 44 cervical cancer patients treated with concurrent cisplatin and pelvic radiotherapy." | ( Aydogan, B; Bafana, R; Dandekar, V; Hasselle, MD; Liang, Y; Mell, LK; Mundt, AJ; Roeske, JC; Rose, BS; Yashar, CM; Yeginer, M, 2011) |
| "The study included 37 cervical cancer patients treated with concurrent weekly cisplatin and pelvic radiation therapy." | ( Jiang, SB; Lewis, JH; Liang, Y; Mell, LK; Messer, K; Mundt, AJ; Rose, BS; Yashar, CM, 2010) |
| "HeLa (HPV 18+), SiHa (HPV 16+) cervix cancer cells and non-tumorigenic immortalized HaCaT cells (control) were treated with PTX, ADR or PTX + ADR." | ( Aguilar-Lemarroy, A; Bravo-Cuellar, A; de Alba-Garcia, JE; de Celis-Carrillo, R; del Toro-Arreola, S; Dominguez-Rodriguez, JR; Hernandez-Flores, G; Jave-Suarez, LF; Lerma-Diaz, JM; Ortiz-Lazareno, PC; Sahagun-Flores, JE, 2010) |
| "Using a mouse model of human cervical cancer, we demonstrate that combined treatment with a copper chelator and cisplatin increases cisplatin-DNA adduct levels in cancerous but not in normal tissues, impairs angiogenesis, and improves therapeutic efficacy." | ( Hanahan, D; Ishida, S; McCormick, F; Smith-McCune, K, 2010) |
| "Patients with stage IB, IIA, or IIB cervical cancer who were initially treated with radical hysterectomy and pelvic lymphadenectomy, and were proven to have pelvic lymph node metastasis (pN1) or microscopic involvement of the parametrium (pT2b), participated in this study." | ( Hirashiki, K; Ito, H; Kato, K; Kato, S; Kiyohara, H; Mitsuhashi, A; Shozu, M; Tate, S; Uno, T; Usui, H, 2010) |
| "A retrospective review of all cervical cancer patients treated with curative intent using radical radiotherapy +/- chemotherapy from 1992 to 2005 was performed." | ( Balaraj, K; E, C; Fung-Kee-Fung, M; Kobeleva, S; Le, T; Samant, R, 2010) |
| "Thirty patients with stage IB2 to IIIB uterine cervical cancer were treated with paclitaxel (60 mg/m) and carboplatin (area under the curve, 2-an area under the time-concentration curve of 2 mg x min/mL based on creatinine clearance) every week for 6 cycles." | ( Hosokawa, K; Kitawaki, J; Koshiba, H; Kuroboshi, H; Mori, T; Okubo, T; Sawada, M; Tatsumi, H, 2010) |
| "Six patients with locally advanced cervical cancer (IIB-IIIB) treated with definitive chemoradiotherapy and magnetic resonance imaging (MRI)-guided brachytherapy were analyzed." | ( Assenholt, M; Fenkell, L; Haie-Meder, C; Lindegaard, J; Nielsen, SK; Pötter, R; Tanderup, K, 2011) |
| "As the single-visit approach for cervical cancer screening gains popularity, more women will have been treated with cryotherapy." | ( Alonzo, TA; Bullard, K; Cremer, M; Felix, J; Garcia, L; Lerner, V; Masch, R; Maza, M; Moore, E; Peralta, E, 2010) |
| "When treating advanced cervical cancer, HDRICB consisting of four 6 Gy insertions and weekly cisplatin shows a trend of increasing late bladder complications." | ( Chang, WC; Chen, SW; Hung, YC; Liang, JA; Lin, FJ; Lin, WC; Yang, SN; Yeh, LS, 2010) |
| "Seven patients with cervical cancer in the second trimester decided to delay delivery together with neoadjuvant chemotherapy." | ( Favero, G; Hasenbein, K; Köhler, C; Markman, M; Marnitz, S; Oppelt, P; Schmittel, A; Schneider, A, 2010) |
| "From Nov 2002 to Nov 2007, 110 cervical cancer patients were treated by combination of (252)Cf neutron intracavitary brachytherapy and external beam radiotherapy." | ( Bu, J; Cao, JX; Li, R; Song, W; Wang, YX, 2010) |
| "The treatment of a squamous cervical cancer cell line, SiHa, with 20 μM curcumin and genistein resulted in demethylation of promoter of the RARβ2 gene and led to the reactivation of the gene." | ( Capalash, N; Jha, AK; Kaur, J; Nikbakht, M; Parashar, G; Shrivastava, A, 2010) |
| "An educational fact sheet about cervical cancer and the HPV vaccine was administered in between the two parts." | ( Basu, P; Mittal, S, 2011) |
| "Patients with locally advanced cervical cancer (LACC) are usually treated with concurrent chemoradiotherapy." | ( Bannier, M; Bats, AS; Brenot-Rossi, I; Ferron, G; Gauthier, H; Ghazzar, N; Houvenaeghel, G; Leblanc, E; Lecuru, F; Lumbroso, S; Morice, P; Narducci, F; Querleu, D; Uzan, C; Zerdoud, S, 2011) |
| "Eighty patients with cervical cancer who had been planned to undergo brachytherapy at Dr." | ( Cepni, I; Cepni, K; Gul, S; Güralp, O; Mayadagli, A; Sal, V, 2011) |
| "To evaluate the outcome of stage IVA cervical cancer treated with radiation and concurrent cisplatin-based chemotherapy." | ( Ali, S; Lanciano, R; Rose, PG; Stehman, FB; Whitney, CW, 2011) |
| "The diameter and volume of cervical cancers decreased after therapy in 14/17 lesions (responders) and increased in 3/17 lesions (nonresponders)." | ( Bellomi, M; Belmonte, M; Colombo, N; Landoni, F; Maniglio, M; Raimondi, S; Rizzo, S; Summers, P, 2011) |
| "ADC values of cervical cancer after therapy showed significant differences compared with pretherapy values, particularly for responders." | ( Bellomi, M; Belmonte, M; Colombo, N; Landoni, F; Maniglio, M; Raimondi, S; Rizzo, S; Summers, P, 2011) |
| "Epo is widely used to treat cervical cancer-related anaemia." | ( Aguilar, C; Lappin, TR; Lopez, TV; Lopez-Marure, R; Maxwell, P; Rocha-Zavaleta, L; Shi, Z, 2011) |
| "Twenty-two patients with cervical cancer that had positive LNs underwent preradiotherapy (pre-RT) and inter-RT PET/CT." | ( Ahn, SJ; Chung, WK; Jeong, JU; Jeong, SY; Nah, BS; Nam, TK; Song, JY; Yoon, MS, 2011) |
| "She was diagnosed with uterine cervix cancer and underwent total abdominal hysterectomy, bilateral salpingo-oophorectomy, and pelvic node dissection and received adjuvant chemotherapy and radiation therapy 9 years ago." | ( Hong, IK; Kim, DY, 2011) |
| "To evaluate outcomes of cervical cancer screening within HIV care and treatment clinics in Kenya." | ( Bukusi, EA; Cohen, CR; Huchko, MJ, 2011) |
| "The data set of 24 patients with cervical cancer treated with high dose-rate brachytherapy applications was analyzed." | ( Deshpande, DD; Engineer, R; Khanna, N; Mahantshetty, U; Merchant, NH; Shrivastava, S; Swamidas, J, 2011) |
| "A total of 120 cases with cervical cancer were divided into 2 groups and retrospectively reviewed: Sixty FIGO IB2-IIB patients in NACT group were treated with 2 cycles of irinotecan 60 mg/m(2) on days 1 and 8 plus cisplatin 60 mg/m(2) on day 1 followed by surgery." | ( Cao, LP; Liang, LZ; Liu, JH; Min, Z; Xiong, Y, 2011) |
| "In patients with cervical cancer, the 3-month posttherapy F-FDG PET/CT value is an indicator of therapeutic response to chemoradiation and needs further validation in clinical trials." | ( Abdul-Karim, FW; Faulhaber, P; Kunos, C; Radivoyevitch, T, 2011) |
| "Twenty patients with biopsy proven cervical cancer undergoing definitive radiotherapy with/without concomitant Cisplatin chemotherapy and suitable for brachytherapy were invited to participate in this study." | ( Deshpande, DD; Engineer, R; Khanna, N; Mahantshetty, U; Merchant, NH; Shrivastava, S; Swamidas, J; Thakur, MH, 2012) |
| "Sixteen patients with cervical cancer metastatic to the PALs treated with EFRT were evaluated." | ( Hasumi, Y; Horie, K; Kato, S; Kazumoto, T; Kino, N; Mizukami, T; Saito, Y; Yokota, H; Yoshida, D, 2011) |
| "Forty-four patients with cervical cancer were treated with three-dimensional high dose rate IGBT." | ( Beriwal, S; Edwards, RP; Houser, C; Kannan, N; Kelley, JL; Kim, H; Krivak, TC; Mogus, R; Olawaiye, A; Richard, S; Sukumvanich, P, 2011) |
| "Treatment of cervical cancer cells with RAMB1 triggers unfolded protein responses, including aggresome formation and Hsp90 stabilization, and increases p53 steady state levels." | ( Anchoori, RK; Bazzaro, M; Destro, F; Felthauser, A; Gavioli, R; Iizuka, Y; Isaksson Vogel, R; Khan, SR; Peng, S; Roden, RB; Sueblinvong, T, 2011) |
| "Patients with locally advanced cervical cancer who had primary radiation treatment in concurrent with weekly carboplatin (100mg/m(2) or AUC 2) from 1997 to 2008 were identified." | ( Cholpaisal, A; Chongthanakorn, M; Katanyoo, K; Manusirivithaya, S; Rongsriyam, K; Tangjitgamol, S; Tantivatana, T, 2011) |
| "HeLa (HPV 18+), SiHa (HPV 16+) cervix cancer cells and non-tumorigenic immortalized HaCaT cells (control) were treated with PTX, CIS or both." | ( Aguilar-Lemarroy, Adel C; Bravo-Cuellar, A; Castellanos-Esparza, YC; de Celis-Carrillo, R; del Toro-Arreola, S; Dominguez-Rodriguez, JR; Hernandez-Flores, G; Jave-Suarez, LF; Lerma-Diaz, JM; Ortiz-Lazareno, PC, 2011) |
| "Our "see and treat" cervical cancer prevention program using the VIA/EDI approach is a feasible, high-output and high-efficiency program, worthy of considering as an additional cervical cancer screening method in Botswana, especially for women with limited access to the current cytology-based screening services." | ( de Klerk, R; Friedman, HM; Monare, B; Ramogola-Masire, D; Ratshaa, B; Zetola, NM, 2012) |
| "The records of 96 patients treated for cervical cancer from 2006 to 2010 were retrospectively reviewed." | ( Lin, S; Liu, JR; Pan, SD; Xu, HD; Yue, JH; Zhang, M, 2012) |
| "Standard treatment of locally advanced cervical cancer currently consists of concurrent chemoradiation, leading to a 5-year disease-free survival of 66-79%, indicating that there is still ample room for improvement." | ( de Jong, S; de Vries, EG; Tan, S; van der Zee, AG, 2012) |
| "The conditions of 26 women with cervical cancer who underwent (18)F-FDG-PET before treatment with concurrent cisplatin and intensity-modulated radiation therapy were analyzed." | ( Hoh, CK; Jensen, LG; Lau, SK; Liang, Y; Mell, LK; Rose, BS; Yashar, CM, 2012) |
| "MiR-145 expression in cervical cancer cells was wild-type p53-dependent, and cortisol-induced down-regulation of miR-145 expression prevented chemotherapy-induced apoptosis, whereas over-expression of miR-145 enhanced sensitivity to mitomycin and reversed the chemoresistance induced by glucocorticoids." | ( Chen, C; Du, L; Guo, L; Guo, N; Hu, M; Liu, D; Ma, Y; Qian, L; Shi, M; Song, L; Wang, L; Yang, Z; Yu, M; Zhao, M, 2012) |
| "ACA in locally advanced cervical cancer had poorer response rate from treatment and also used longer time to achieve CR than SCC." | ( Katanyoo, K; Manusirivithaya, S; Sanguanrungsirikul, S, 2012) |
| "Treatment of advanced-stage cervical cancers with (chemo)radiation causes cytotoxicity through induction of high levels of DNA damage." | ( de Bock, GH; de Jong, S; de Vries, EG; Hollema, H; Kok, M; Noordhuis, MG; Pras, E; Roossink, F; Schuuring, E; Slagter-Menkema, L; ten Hoor, KA; van der Zee, AG; van Vugt, MA; Wieringa, HW; Wisman, GB, 2012) |
| "Forty-two cases of cervical cancer (FIGO IIb to IVa) were divided randomly into two groups: radiotherapy alone (21 cases) and radiation plus chemotherapy (Nedaplatin) group." | ( Ke, QH; Liu, Z; Su, XY; Yang, JY; Zhang, WT; Zhou, SQ, 2011) |
| "Treatment of the cervical cancer patients, especially young women, is a very important clinical problem." | ( Gmyrek, L; Jońska-Gmyrek, J; Kubik, P, 2011) |
| "26 women, affected by locally advanced cervical cancer and triaged for surgery after NACT, were submitted to three cycles of neoadjuvant chemotherapy." | ( Cittadini, G; Costantini, S; Mammoliti, S; Marchiolè, P; Moioli, M; Sala, P; Valenzano Menada, M, 2012) |
| "The records of 256 Stage IB and II cervical cancer patients treated with postoperative RT/RCT from 1992-2007 were retrospectively reviewed." | ( Aras, AB; Demirci, S; Demircioglu, B; Dikmen, Y; Hanhan, M; Ozsaran, A; Ozsaran, Z; Yavas, F, 2012) |
| "Human cervical cancer HeLa cells were treated with FRAP and apoptosis was detected by cell morphologic observation, annexin-V-PI staning and western blot analysis on the expression of protein associated with cell death." | ( Baek, NI; Cho, JG; Choi, JH; Chung, HG; Chung, KS; Ju, HK; Lee, HW; Lee, KT, 2012) |
| "A total of 62 patients of stage Ib2-IIb cervical cancer received neoadjuvant chemotherapy of paclitaxel plus cisplatin for 2 - 3 courses." | ( Chen, ML; He, CM; Jin, S; Liang, FB; Wu, XM, 2012) |
| "Fifty-six cases with cervical cancer (FIGO II b to IVa) were divided randomly into two groups: radiotherapy alone (28 cases) and radiation plus chemotherapy (TP) group." | ( Du, W; Huang, M; Ke, QH; Lei, Y; Luo, F; Yang, JY; Zhou, SQ, 2012) |
| "After the cervical cancer cells were treated with a correspondent agent for 24 hours, the number of surviving cells were measured utilizing cell counting kits-8 (CCK-8), and the hypoxia inducible factor-1alpha (HIF-1alpha) levels were detected by Western blotting." | ( Chen, L; Cheng, YX; Hong, L; Hu, M; Huang, JL; Li, BS; Xia, LB; Zhou, LM, 2012) |
| "Thirty-five patients with cervical cancer underwent DCE-MRI before CCRT, 4 weeks after starting therapy and at 1 month after the end of therapy." | ( Huh, SJ; Kim, B; Kim, CK; Kim, JH; Park, BK; Park, SY, 2012) |
| "• DCE-MRI of cervical cancer may be useful in monitoring changes with therapy." | ( Huh, SJ; Kim, B; Kim, CK; Kim, JH; Park, BK; Park, SY, 2012) |
| "Most women with early cervical cancer (stages I to IIA) are cured with surgery or radiotherapy, or both." | ( Edelweiss, MI; Medeiros, LR; Pohlmann, PR; Rosa, DD; Stein, AT, 2012) |
| "We nested cervical cancer screening into family planning clinics at select sites also receiving PEPFAR support for antiretroviral therapy (ART) rollout." | ( Baptista, AJ; Cordoso, A; Moon, TD; Sidat, M; Silva-Matos, C; Vermund, SH, 2012) |
| "The study included 234 cervical cancer patients, FIGO stage Ib1-IVa, treated with definitive radiation or chemoradiation therapy." | ( Dehdashti, F; El Naqa, I; Grigsby, PW; Kidd, EA; Siegel, BA, 2012) |
| "Advanced cervical cancer is routinely treated with radiotherapy and cisplatin-containing chemotherapy." | ( Burger, C; Dahl, O; De Wit, R; Jones, EL; Koper, P; Mella, O; Prosnitz, LR; Schem, BC; Uitterhoeve, AL; Van Der Steen-Banasik, E; Van Der Velden, J; Van Der Wilt, C; Van Der Zee, J; Van Tinteren, H; Westermann, A, 2012) |
| "Sixty-eight patients with advanced cervical cancer were prospectively registered in the USA, Norway and the Netherlands, and treated with a combination of radiotherapy (external beam radiotherapy and brachytherapy for a biologically effective dose of at least 86." | ( Burger, C; Dahl, O; De Wit, R; Jones, EL; Koper, P; Mella, O; Prosnitz, LR; Schem, BC; Uitterhoeve, AL; Van Der Steen-Banasik, E; Van Der Velden, J; Van Der Wilt, C; Van Der Zee, J; Van Tinteren, H; Westermann, A, 2012) |
| "Results of cervical cancer treatment with external beam radiation and HDR intracavitary brachytherapy in our hospital are encouraging." | ( Geli, E; Gkeli, MG; Koukourakis, GV; Miliadou, A; Sotiropoulou-Lontou, A; Tsalafoutas, I, 2013) |
| "Patients with cervical cancer were treated at a single institution with radiotherapy alone or concomitant chemoradiotherapy for curative intent." | ( Bentzen, SM; Bradley, KA; Dunn, EF; Gondi, V; Petereit, DG; Sklenar, KL; Straub, M; Tannehill, SP, 2012) |
| "Twenty women with cervical cancer underwent pretreatment FDG-PET/CT and pelvic MRI." | ( Dehdashti, F; DeWees, T; Esthappan, J; Grigsby, PW; Narra, VR; Olsen, JR; Schwarz, JK; Siegel, BA, 2013) |
| "After establishment of human cervical cancer xenograft model, the comparisons between 5-ALA-PDT with radiotherapy were performed with respect to treatment efficacies (survival rate, body weight, and tumor volume) and side effects (appearance and behavior, ovarian endocrine functions, and skin lesion around the tumor)." | ( Cao, D; Gui, T; Liu, J; Mao, Y; Shen, K; Sun, S; Wang, Y; Yang, J, 2013) |
| "Although the prognosis of uterine cervical cancer has improved due to the advances of treatment modalities, survival of recurrent or metastatic cervical cancer remains poor." | ( Fujii, T; Hiraike, H; Kawana, K; Kozuma, S; Miyamoto, Y; Nagasaka, K; Nakagawa, K; Nakagawa, S; Oda, K; Seiki, T; Sone, K; Taketani, Y; Tanikawa, M; Wada-Hiraike, O; Yano, T, 2013) |
| "Patients with locally advanced cervical cancer (LACC) are usually treated with concurrent chemoradiotherapy." | ( Calles, L; García-Espantaleón, M; Iglesias, E; Jiménez, JS; Mucientes, J; Pereira, A; Perez-Medina, T; Rodríguez, B, 2013) |
| "Approximately 88% of cervical cancer cases are diagnosed in low-resource countries, yet very few resources are allocated to prevention and treatment programs." | ( Bradford, L; Goodman, A, 2013) |
| "Meanwhile, cervical cancer cell lines Caski and C33A were treated with different concentration of folate." | ( Ding, L; Hao, JX; Hao, M; Wang, JT; Zhao, WM; Zhou, Q, 2012) |
| "All patients with locally advanced cervix cancer treated with definitive radiation were entered into a prospective database." | ( Au-Yeung, G; Bernshaw, DM; Kondalsamy-Chennakesavan, S; Mileshkin, L; Narayan, K; Rischin, D, 2013) |
| "In our study, 2 human cervical cancer cell lines, HeLa and SiHa, were treated with different concentrations (20, 10, 5, and 2." | ( Huang, ML; Lin, ZQ; Liu, LY; Lu, HW; Mo, SM; Yao, TT, 2013) |
| "Serum from 68 cervical cancer patients treated within a phase-III-trial with either simultaneous cisplatin radiochemotherapy or sequential systemic carboplatin and paclitaxel followed by percutaneous irradiation was analyzed by ELISA." | ( Blohmer, J; Braicu, EI; Chekerov, R; Fotopoulou, C; Kümmel, S; Lichtenegger, W; Mentze, M; Richter, R; Sehouli, J; Stamatian, F; Yalcinkaya, I, 2013) |
| "We report two cases of G-CSF-producing uterine cervical cancer who were successfully treated with carbon-ion radiotherapy (C-ion RT)." | ( Kamada, T; Kato, S; Kiyohara, H; Nakano, T; Ohkubo, Y; Suzuki, Y, 2013) |
| "A total of 480 consecutive cervical cancer patients treated with radiation therapy (RT) alone or concomitant CRT for curative intent were retrospectively analyzed." | ( Bradley, KA; Dunn, EF; Gondi, V; Petereit, DG; Shaverdian, N; Sklenar, KL; Straub, MR, 2013) |
| "Patients with cervical cancer treated with weekly cisplatin and pelvic IMRT had grades 1-5 HT (23%, 33%, 25%, 0%, and 0% of patients, respectively)." | ( D'Souza, D; Gaur, R; Hildebrandt, E; Jhingran, A; Klopp, AH; Miller, BE; Moughan, J; Nuanjing, J; Portelance, L; Salehpour, MR; Small, W; Souhami, L, 2013) |
| "Patients after radical hysterectomy for cervical cancer, with at least 1 high-risk characteristic, were administered paclitaxel 135 mg/m(2), carboplatin area under the curve = 5 every 3 weeks for 3 cycles concomitant with radiation therapy as adjuvant treatment." | ( Kang, SB; Kim, JH; Kim, KT; Kim, SM; Kim, YM; Kim, YT; Lee, JM; Lee, TS; Park, BJ, 2013) |
| "Late side effects after cervical cancer radiotherapy are partially reversible, but their time course is organ-dependent." | ( Boni, A; Dörr, W; Georg, D; Georg, P; Ghabuous, A; Goldner, G; Pötter, R; Schmid, MP, 2013) |
| "For 10,000 women with locally advanced cervical cancer, the cost of therapy and AEs was $173." | ( Clements, A; Cohn, DE; Smith, B; Straughn, JM; Tierney, BJ, 2013) |
| "We treated cervical cancer cells with 5-aza-2'-deoxycytidine and get a microarray analysis." | ( Liang, J; Lin, Z; Liu, L; Rao, Q; Xie, Q; Yao, T; Zheng, C, 2013) |
| "Human cervical cancer cell lines, including C33A cell with HPV negative and Caski cell with HPV16 positive, were treated with different concentration of folate." | ( Bai, L; Ding, L; Hao, M; Wang, JT; Wang, Y; Wu, TT, 2013) |
| "Among 104 cervical cancer patients selected for the present study, 54 and 50 patients were treated with chemo- and radiotherapy respectively." | ( Lokanatha, V; Rajendra, W; Subbaiah, KV; Subramanyam, D, 2013) |
| "Women with uterine cervical cancer who were treated with radical hysterectomy and pelvic lymphadenectomy and displayed positive pelvic lymph nodes were eligible for this study." | ( Isohashi, F; Ito, K; Kimura, T; Mabuchi, S; Ogata, T; Ogawa, K; Takahashi, R; Tsutui, T; Yokoi, T; Yoshioka, Y, 2013) |
| "All patients diagnosed with cervical cancer from 2000 to 2009 who were referred for radical treatment and who received 6 fractions of brachytherapy were retrospectively reviewed." | ( Choo, BA; Koh, WY; Lee, KM; Lim, GH; Lim, K; Tey, J, 2013) |
| "Both HeLa and SiHa cervical cancer cell lines were treated with 10% Noni, 10 mg/dl cisplatin, or a combination of both 10% Noni and 10 mg/dl cisplatin for 24 hours." | ( Gupta, RK; Singh, N, 2013) |
| "In preoperative cervical cancer biopsy samples from poor prognoses patients after cisplatin chemoradiotherapy, FGF13-positive cells were detected more abundantly than in the biopsy samples from patients with good prognoses." | ( Hirose, R; Ikekita, M; Imai, T; Imamura, T; Kato, S; Komatsu, T; Matsuda, C; Murata, K; Nakawatari, M; Nakayama, F; Ohno, T; Okada, T; Wakatsuki, M, 2013) |
| "Patients with recurrent cervical cancer after cisplatin-based chemoradiation or neoadjuvant chemotherapy followed by surgery and radiotherapy who were treated with concurrent platinum-based chemotherapy and hyperthermia were eligible for this retrospective analysis." | ( Boere, IA; Franckena, M; Heijkoop, ST; Stalpers, LJ; van der Velden, J; van Doorn, HC; Westermann, AM, 2014) |
| "In recurrent cervical cancer, FDG-PET provides clinically valuable information with a high impact on treatment decisions." | ( Bjurberg, M; Brun, E, 2013) |
| "However, the poor uptake of cervical cancer screening is a major problem in detecting early pre-cancerous lesions and thus, delay in initiating treatment for cervical cancer." | ( Abdul Rashid, RM; Dahlui, M, 2013) |
| "Treatment plans for five cervical cancer patients were generated for D-RSBT, single-shield RSBT (S-RSBT), and (192)Ir-based intracavitary brachytherapy with supplementary interstitial brachytherapy (IS + ICBT) assuming five treatment fractions." | ( Flynn, RT; Kim, Y; Liu, Y; Wu, X; Yang, W, 2013) |
| "A total of 46 stage Ib1-IVa cervical cancer patients with positive para-aortic lymph nodes treated at Fudan University Shanghai Cancer Center between 2009 and 2011 were reviewed." | ( Huang, X; Huang, XW; Ke, GH; Liu, SP; Wu, XH, 2013) |
| "Treatment of recurrent and metastatic cervical cancer remains a challenge, especially in developing countries, which lack efficient screening programs." | ( Cai, Y; Hu, CJ; Zhou, L, 2014) |
| "To select suitable chemotherapy for cervical cancer patients by ATP-tumor chemosensitivity assay." | ( Jiang, Y; Yang, L; Yuan, Z; Zhang, Y; Zhao, Q, 2013) |
| "Patients with locally advanced cervix cancer were randomly assigned to CIS chemoradiotherapy versus CIS/TPZ chemoradiotherapy." | ( Ali, S; Cohn, DE; Craighead, PS; DiSilvestro, PA; Gajewski, WH; Lee, YC; Lucci, JA; Monk, BJ; Muller, C; Spirtos, NM; Steinhoff, MM; Tewari, KS, 2014) |
| "Herein, we evaluated the recurrence of cervical cancer after raloxifene therapy in our preclinical model of human papillomavirus-associated cervical carcinogenesis." | ( Chung, SH; Lambert, PF; Spurgeon, ME, 2014) |
| "Seventy-five cervical cancer patients treated with radiochemotherapy received conventional MRI and DWI prior to therapy, after 2 weeks of therapy, after four weeks of therapy and after therapy completion." | ( Kuang, F; Rao, Z; Wang, J; Yan, Z, 2014) |
| "All patients with cervical cancer treated in curative intent with external beam radiotherapy +/- chemotherapy and image-guided adaptive brachytherapy between January 1998 and June 2009 at the Medical University of Vienna were included in this retrospective analysis." | ( Dörr, W; Franckena, M; Georg, P; Kirchheiner, K; Pötter, R; Schmid, MP; Sturdza, A, 2014) |
| "Conversely, C33A cervical cancer cells containing mutant p53 co-treated with VOR and DOX did not exhibit Bad upregulation, acetylated p53 induction or consequent synergistic growth inhibition." | ( Hoe, KL; Hwang, SO; Kim, DU; Kim, JH; Lee, SJ; Nam, JH; Nam, M; Noh, EJ, 2014) |
| "Most patients in whom recurrent cervical cancer develops have previously received cisplatin with radiation therapy, which reduces the effectiveness of cisplatin at the time of recurrence." | ( Huang, H; Landrum, LM; Leitao, MM; Long, HJ; Michael, HE; Monk, BJ; Oaknin, A; Penson, RT; Ramondetta, LM; Reid, TJ; Sill, MW; Tewari, KS, 2014) |
| "Twenty-seven patients with cervical cancer underwent PET/MR pelvic examination before radiotherapy." | ( Guo, Q; Ma, J; Ma, Q; Sun, H; Xin, J; Zhang, S, 2014) |
| "In see-and-treat VIA-based cervical cancer prevention programs in low-resource countries, visual LEEP can be used to treat women who do not meet the criteria for ablative treatment." | ( Chigbu, CO; Onyebuchi, AK, 2014) |
| "The mean score of global health of cervical cancer patients post treatment was 77." | ( Dhaliwal, GS; Khaira, HK; Kumar, S; Maria, AK; Rana, ML; Saini, S; Sharma, AK; Singh, N; Verma, K, 2014) |
| "For the 83 patients with HPV 16-cancer of the cervix (cervical cancer) I-III stages it was performed a comparative analysis of primary tumor response to therapy, the clinical outcome of the disease for 3-5 years after radical treatment and an evaluation of the possible contribution in these rates of the physical status of the virus." | ( Beziaeva, GP; Kiseleva, VI; Krikunova, LI; Liubina, LV; Mkrtchian, LS; Panarina, LV; Saenko, AS; Zamulaeva, IA, 2013) |
| "Three cervical cancer cell lines (HeLa, SiHa, and Me180) were treated with a PPARγ inhibitor, T0070907, and/or radiation." | ( An, Z; Muthusami, S; Park, WY; Yu, JR, 2014) |
| "A total of 127 patients with cervical cancer receiving concomitant pelvic radiotherapy (RT) and cisplatin were evaluated." | ( Akmansu, M; Alco, G; Aslay, I; Bayman, E; Caglar, HB; Dagoglu, N; Demirci, S; Erpolat, OP; Etiz, D; Guney, Y; Igdem, S; Keven, E; Kilic, D; Mandel, NM; Ozsaran, Z; Saran, A, 2014) |
| "• Hypoxia in cervical cancer is an independent risk factor • BOLD MRI reflect oxygenation status of tissue adjacent to perfused microvessels • Pretreatment tumour R2* reveal negative correlation with final tumour size response • Accurate oxygenation assessment in cervical cancer may help clinical decision making." | ( Huh, SJ; Kim, CK; Park, BK; Park, SY; Park, W, 2014) |
| "Treatment of cervical cancer cells with 5-aza-2'-deoxycytidine restored the expression of GPX3 and methylation-specific PCR (MSP) confirmed the CpG methylation of the GPX3 gene." | ( Jin, R; Kim, H; Lee, DY; Renshu, L; Roh, MR; Yang, S; Yingji, S; Zhang, X; Zheng, Z, 2014) |
| "CUR may have a role in treating human cervical cancer and should be explored further." | ( Bhattarakosol, P; Patumraj, S; Yoysungnoen-Chintana, P, 2014) |
| "To evaluate a cervical cancer prevention project in Guyana utilizing visual inspection with acetic acid (VIA) and immediate cryotherapy in a single-visit approach; and to identify lessons learned to inform the improvement of cervical cancer prevention programs in Guyana and other low-resource settings." | ( Estep, D; Martin, CE; Reinsel, M; Tergas, AI; Varallo, J; Wysong, M, 2014) |
| "These results suggest that cervical cancer patients treated with radiotherapy and concurrent cisplatin do not benefit from elective PART." | ( Cuartero, J; Fyles, A; Levin, W; Manchul, L; Milosevic, M; Pintilie, M; Yan, J; Yap, ML, 2014) |
| "A total of 37 patients diagnosed with cervical cancer by biopsy were selected and treated with concurrent chemoradiotherapy." | ( Du, K; Gong, HY; Gong, ZM, 2014) |
| "Fewer than half of cervical cancer survivors with therapy-induced early menopause used HT at or close to the recommended dose, and the use decreased during follow-up." | ( Bergmark, K; Citarella, A; Everhov, ÅH; Hirschberg, AL; Nyberg, T; Rådestad, AF; Smedby, KE, 2015) |
| "However, the standard treatment for cervical cancer includes cisplatin, which can cause side effects such as hematological damage or renal toxicity." | ( Cho, NP; Cho, SD; Choi, ES; Jung, JY; Nam, JS, 2014) |
| "Treatment of advanced and relapsed cervical cancer is frequently ineffective, due in large part to chemoresistance." | ( Bashkirova, S; Duerksen-Hughes, P; Filippov, V; Filippova, M; Kokoza, A; Williams, VM; Zhang, K, 2014) |
| "Sixty-five patients with stage IIB-IVA cervical cancer enrolled in this study, received raltitrexed/cisplatin with concurrent radiotherapy." | ( Li, XY; Liu, L; Xie, XM; Zhou, C, 2014) |
| "EGFR is frequently overexpressed in cervical cancer, suggesting EGFR blockade as a promising treatment approach." | ( Armanet, S; Asselain, B; Aumont, M; Bernard, V; Berton-Rigaud, D; Beuzeboc, P; Bieche, I; Brunaud, C; Curé, H; de la Rochefordiere, A; Diallo, A; Fabbro, M; Floquet, A; Fourchotte, V; Gladieff, L; Gonzague, L; Joly, F; Kamal, M; Kerr, C; Leroy, Q; Maillard, S; Margogne, A; Minsat, M; Nadan, A; Peignaux, K; Petit, T; Petrow, P; Plancher, C; Pop, M; Scholl, SM; Sevin, E; Thomas, L; Weber, B, 2015) |
| "In metastatic or recurrent cervical cancer, cisplatin-based chemotherapy is standard." | ( Kamura, T; Kasamatsu, T; Katsumata, N; Kitagawa, R; Nakanishi, T; Nishimura, S; Satoh, T; Shibata, T; Takano, M; Ushijima, K; Yoshikawa, H, 2015) |
| "Despite recent advances in treatment, cervical cancer still remains one of the leading causes of cancer related mortality among women worldwide including India." | ( Sood, S; Srinivasan, R, 2015) |
| "Patients with cervical cancer in FIGO Stages IB1 to IVB were imaged with PET/CT prior to treatment during one of the staging work-ups." | ( Cho, SH; Chung, HW; Hong, S; Kim, SN; Kim, WY; Lee, SJ; Lim, JY; So, Y, 2015) |
| "In a public sector cervical cancer prevention program in Zambia, nurses provided visual-inspection with acetic acid (VIA) and cryotherapy in clinics co-housed with HIV/AIDS programs, and referred women with complex lesions for histopathologic evaluation." | ( Bateman, AC; Blevins, M; Chi, BH; Chibwesha, CJ; Chisele, S; Hicks, ML; Kapambwe, S; Mkumba, G; Mudenda, V; Muwonge, R; Mwanahamuntu, MH; Parham, GP; Pfaendler, KS; Sahasrabuddhe, VV; Sankaranarayanan, R; Shibemba, AL; Stringer, JS; Vermund, SH; Vwalika, B, 2015) |
| "Cisplatin treatment of a cervical cancer cell line resulted in ROS production with mitochondrial membrane depolarization and phosphorylation of JNK and p38." | ( Chen, J; Parekh, H; Simpkins, F; Simpkins, H; Solomides, C, 2015) |
| "In vitro, cervical cancer cell lines CaSki (HPV16-positive) was treated with different concentrations of folate." | ( Bai, L; Chen, X; Ding, L; Sun, X; Wang, J; Wu, T; Xu, J, 2015) |
| "After human cervical cancer SiHa cells were treated with SAHA and cisplatin (DDP) of different concentrations, inhibition and apoptosis rates, and cell cycle were detected." | ( Han, P; Wang, H; Xin, M; Xing, J; Xu, S; Zhou, JL, 2015) |
| "Standard treatment of cervical cancer FIGO stage IB1 is a radical hysterectomy with pelvic lymphadenectomy." | ( Leunen, K; Moerman, P; Neven, P; Salihi, R; Van Limbergen, E; Vergote, I, 2015) |
| "Secondary prevention of cervical cancer is the identification and treatment of preinvasive forms of the disease, which include dysplasia or cervical intraepithelial neoplasia." | ( Arkhangelskaya, PA; Bakhidze, EV; Berlev, IV, 2015) |
| "The main methods of treatment for cervical cancer are surgery, radiotherapy or their combination." | ( Kuznetsov, VV; Morkhov, KY; Nechushkina, VM, 2015) |
| "Among 5 patients with advanced cervical cancer, just 1 patient adopted pemetrexed based regimens as first-line treatment, whose curative effect was PR." | ( Huang, XE; Qian, T, 2015) |
| "The expressions of γH2AX in cervical cancer tissues of post-neoadjuvant chemotherapy decreased to 22." | ( Guo, Z; Jiang, C; Li, J; Pei, SY; Si, TB; Wang, Q; Zhao, J, 2015) |
| "Future efforts to improve cervical cancer outcomes should address preventable reasons for treatment delays among underinsured or uninsured individuals." | ( Anderson, ML; Bonnen, M; Hsieh, GL; Linesch, S; Ludwig, MS; Macdonald, A; Sajjad, A, 2015) |
| "Treatment of cervical cancer involves surgical removal and chemotherapy." | ( Cheng, H; Gao, Y; Tan, W; Wang, Y; Yang, G, 2015) |
| "All cause and cervical cancer specific survival were compared in patients who were and were not treated as recommended in the guidelines, using Cox proportional hazards models." | ( Canfell, K; Demers, AA; Goldsbury, DE; Kang, YJ; Kliewer, EV; Lotocki, R; O'Connell, DL, 2015) |
| "The management of cervical cancer patients in Manitoba, Canada was in good agreement with treatment guidelines although reasons for departure from the guideline recommendations could not be examined further due to lack of data." | ( Canfell, K; Demers, AA; Goldsbury, DE; Kang, YJ; Kliewer, EV; Lotocki, R; O'Connell, DL, 2015) |
| "Different treatments for cervical cancer, including radiotherapy (HR 1." | ( Chao, Y; Chen, TJ; Hu, YW; Hung, YP; Huon, LK; Liu, CJ; Teng, CJ; Yang, MH; Yeh, CM, 2015) |
| "In this period, 76 patients of cervical cancer satisfying our inclusion criteria were treated with concurrent chemo-radiation following ICBT with 9 Gy per fraction in two fractions, five to seven days apart." | ( Ghosh, S; Kotne, S; Rao, PB, 2015) |
| "Xenograft experiments with three cervical cancer cell lines showed Alisertib inhibited growth of HPV and non-HPV xenografts during treatment." | ( Bokhari, F; Christensen, M; Clarke, D; Fallaha, S; Gabrielli, B; Gonda, TJ; Kelly, M; Leggatt, G; Leo, P; McKee, S; McMillan, NA; Murrell, M; Oo, ZY; Ranall, MV; Sedelies, K; Shaikh, M; Skalamera, D; Soyer, HP; Stevenson, AJ; Wang, W, 2015) |
| "In patients with cervical cancer we found significant inverse correlations for SUV and ADC which could play a major role for further tumor characterization and therapy decisions." | ( Barthel, H; Brandmaier, P; Bremicker, K; Höckel, M; Kahn, T; Kluge, R; Purz, S; Sabri, O; Stumpp, P, 2015) |
| "However, cervical cancer is largely preventable when early screening and treatment are available." | ( Firnhaber, C; Lince-Deroche, N; Michelow, P; Phiri, J; Smith, JS, 2015) |
| "A total of 227 cervical cancer patients with stages IIB-IIIB treated with the same chemoradiotherapy regimen were enrolled and genotyped for GSTM1, T1 and P1 gene polymorphisms by multiplex polymerase chain reaction (mPCR) and PCR-restriction fragment length polymorphism (PCR-RFLP)." | ( Abbas, M; Banerjee, M; Kushwaha, VS; Srivastava, K, 2015) |
| "A total of 273 patients with cervical cancer, who were confirmed by histopathology and hybrid capture 2 (HC-2) assay and treated by radiotherapy, were enrolled for this study." | ( Chen, L; Huang, R; Jiang, J; Li, S; Liang, S; Lu, Z; Zhang, N, 2015) |
| "In patients with a diagnosis of occult cervical cancer made on a hysterectomy specimen after surgery for a benign indication, lymph node assessment is crucial to determine treatment." | ( Bolla, D; Fink, A; Gasparri, ML; Imboden, S; Mueller, MD; Papadia, A, 2016) |
| "Patients with locally advanced cervical cancer (stage Ib2-IIb) were treated with NAC followed by surgery, primary surgery or primary radiotherapy." | ( Abiko, K; Abou-Taleb, HA; Baba, T; Hamanishi, J; Horikawa, N; Kitamura, S; Konishi, I; Koshiyama, M; Matsumura, N; Murakami, R; Taha, AA; Yamaguchi, K; Yamanoi, K, 2016) |
| "Current standards of care for cervical cancer includes surgery, radiation, and chemotherapy." | ( Chauhan, N; Chauhan, SC; Gara, RK; Jaggi, M; Khan, S; Kumari, S; Maher, DM; Sikander, M; Yallapu, MM; Zafar, N; Zaman, MS, 2016) |
| "Patients with cervical cancer (N = 60) were prospectively examined through blood sampling and questionnaires before and 1 year after treatments." | ( Bergmark, K; Everhov, ÅH; Flöter Rådestad, A; Lindén Hirschberg, A; Nyberg, T; Smedby, KE, 2016) |
| "Patients with cervical cancer (N = 100) who received concurrent cisplatin and whole-pelvic radiotherapy were enrolled in this study." | ( Chang, Y; Fan, JQ; Li, GL; Li, Q; Song, YQ; Wu, G; Yang, Q; Yang, ZY; Zhao, YC, 2016) |
| "A total of 67 locally advanced cervical cancer patients who received CCRT underwent both DWI and PET/CT before and during (at 1month) treatment." | ( Kim, CK; Park, BK; Park, JJ, 2016) |
| "The clinical management of cervical cancer remains a challenge and the development of new treatment strategies merits attention." | ( Li, C; Li, L; Wang, X; Zhao, Y, 2016) |
| "Unfortunately, some cervical cancers show resistance to the principal chemotherapeutic agents in the treatment, decreasing the effectiveness of this therapy." | ( Guo, L; Lan, J; Su, G; Xie, X; Yang, Y; Zhang, C; Zhu, J, 2016) |
| "Patients with large, locally advanced cervical cancers (LACC) are challenging to treat." | ( Arnesen, MR; Bruheim, K; Hellebust, TP; Løndalen, AM; Malinen, E; Rekstad, BL; Stokke, C, 2016) |
| "Treatment of recurrent or advanced cervical cancer is still limited, and new therapeutic choices are needed for improving prognosis and quality of life of patients." | ( Cabral, H; Fujii, T; Kataoka, K; Kawana, K; Maeda, D; Matsumoto, Y; Miyamoto, Y; Nagasaka, K; Nakagawa, S; Nishiyama, N; Oda, K; Yano, T, 2016) |
| "Patients with advanced cervical cancer who are treated with carbo-RT have similar 3-years overall survival, progression free survival, overall response rate, and toxic effects when compared to cis-RT-treated patients." | ( da Costa Miranda, V; da Silva Rocha, LS; da Silva, SC; de Barros, LA; de Freitas, D; de Souza Caires, IQ; Diz, Mdel P; Filho, EA; Fukushima, JT; Gimenez, RD; Sebastião, AM, 2016) |
| "Previous studies in the field of cervical cancer have showed that its application may play a significant role in the treatment of cervical HPV infection with or without cervical intraepithelial neoplasia (CIN)." | ( Loutradis, D; Patta, J; Pergialiotis, V; Stefanidi, D; Stefanidis, K, 2015) |
| "Treatment of recurrent and metastatic cervical cancer remains a challenge, especially in developing countries, which lack efficient screening programs." | ( Chen, Y; Gao, Y; Li, F; Li, W; Liu, J; Pei, Z; Wu, R; Yang, Y; Zeng, J; Zhou, H, 2016) |
| "In patients with advanced cervical cancer, NLR is a potential biomarker, serving to guide systemic therapy and predict treatment outcomes." | ( Guler, OC; Onal, C; Yildirim, BA, 2016) |
| "Cases of locally advanced cervical cancer (International Federation of Gynecology and Obstetrics stages IB1 to IVA) treated with a nonsurgical curative modality (172 cases including chemoradiation or radiation therapy) were reviewed." | ( Kang, WJ; Kim, S; Kim, SW; Kim, YT; Nam, EJ; Yoon, JW, 2016) |
| "Similarly, KLK7 is highly expressed in cervical cancer cells, but its expression in the human cervical cancer cell line HeLa is only detected following TSA treatment." | ( Haun, RS; Kaushal, GP; Raju, I, 2016) |
| "Patients with cervical cancer, who were treated with daily low-dose cisplatin (8 mg/m(2)/day) and concurrent radiation (2 Gy/day, 25 fractions, five times a week), were enrolled in this study." | ( Hanawa, S; Matsuoka, A; Mitsuhashi, A; Nishikimi, K; Shozu, M; Tate, S; Uno, T; Usui, H, 2016) |
| "The standard treatment for cervical cancer in developed countries includes surgery and chemoradiation, with standard of care lagging in developing countries." | ( Davis, MA; Delaney, JR; Patel, CB; Storgard, R; Stupack, DG, 2016) |
| "Our results suggests that cervical cancer patients whose tumours are positive for the PIK3CA-E545K mutation may benefit from PI3K inhibitor therapy in concert with standard cisplatin and radiation therapy." | ( Arjumand, W; Doll, CM; Fang, S; Ghatage, P; Kornaga, E; Lees-Miller, SP; McIntyre, JB; Merry, CD; Saba, E; Wang, C, 2016) |
| "The mean global health score of cervical cancer patients after six months of treatment was 59." | ( Acharya, AS; Bachani, D; Dahiya, N; Gupta, S; Haresh, K; Rath, G; Sharma, D, 2016) |
| "QOL of newly diagnosed cervical cancer patients improved significantly following chemoradio therapy." | ( Acharya, AS; Bachani, D; Dahiya, N; Gupta, S; Haresh, K; Rath, G; Sharma, D, 2016) |
| "All the cases were locally advanced cervical cancers that received chemotherapy with platinum and/or taxanes." | ( De Vincenzo, R; Ricci, C; Scambia, G, 2016) |
| "In women with advanced or recurrent cervical cancer previously treated with platinum-based chemotherapy, S-1 plus irinotecan in a triweekly setting is a reasonable treatment regimen with an acceptable toxicity profile." | ( Kimura, T; Kobayashi, E; Kozasa, K; Mabuchi, S; Owa, T; Tomimatsu, T; Tsutui, T; Yamashita, M; Yoki, T; Yokoi, E, 2016) |
| "Fifty-one cases of cervical cancer treated with radical surgery were included in the present study and divided into oxycodone group (n = 26) and dezocine group (n = 25)." | ( He, R; Hu, X; Li, Z; Liu, S; Wu, H, 2016) |
| "Cucurbitacin D treatment of cervical cancer cells arrested the cell cycle in G1/S phase, inhibited constitutive expression of E6, Cyclin D1, CDK4, pRb, and Rb and induced the protein levels of p21 and p27." | ( Alsayari, A; Chauhan, SC; Hafeez, BB; Halaweish, FT; Jaggi, M; Malik, S; Sikander, M; Yallapu, MM, 2016) |
| "Most women with early cervical cancer (stages I to IIA) are cured with surgery or radiotherapy, or both." | ( Edelweiss, MI; Falcetta, FS; Medeiros, LR; Pohlmann, PR; Rosa, DD; Stein, AT, 2016) |
| "Patients with local advanced cervical cancer with/without NAC treatment might be unsuited for SLN mapping." | ( Akagi, H; Ashihara, K; Ohmichi, M; Tanaka, T; Terai, Y; Tsunetoh, S; Yamada, T, 2017) |
| "Unlike primary cervical cancer, the cancer recurred even in the absence of exogenous E2 when MPA treatment was ceased." | ( Baik, S; Chung, SH; Mehta, FF, 2017) |
| "When human cervical cancer cells were treated with 10 µg/ml of cisplatin for 24 and 48 h, high mobility group box 1 (HMGB1) protein expression levels significantly increased in a time‑dependent manner." | ( Li, G; Mao, X; Song, X; Xia, J; Yu, X; Zhang, Y, 2017) |
| "Analysis based on a cervical cancer dataset from The Cancer Genome Atlas (TCGA) showed association of NHERF1 expression with disease-free survival of patients received cisplatin treatment." | ( He, J; Qin, Q; Shi, W; Tao, T; Wang, Q; Yang, X; Yang, Y, 2017) |
| "Population cervical cancer prevention using VIA plus immediate cryotherapy leads to significant reduction in the population prevalence of cervical SIL." | ( Chigbu, CO; Egbuji, CC; Nnakenyi, EF; Onyebuchi, AK, 2017) |
| "The management of locally advanced cervical cancer has improved significantly with the advent of cisplatin-based chemoradiotherapy (CRT) as the primary treatment regimen." | ( Bebb, GD; Dean, M; Doll, CM; Enwere, EK; Ghatage, P; Ho, CK; Klimowicz, AC; Kornaga, EN; Lees-Miller, SP; Magliocco, AM; Phan, T, 2017) |
| "We analyzed 105 stage IIB cervical cancer patients treated with concurrent chemoradiotherapy, using log-rank tests and multivariate analyses." | ( Chang, SJ; Cho, O; Chun, M; Lee, EJ; Noh, OK; Oh, YT; Ryu, HS, 2017) |
| "A standard treatment modality for cervical cancer is the combination of surgery, chemotherapy, external-beam radiotherapy and intracavitary brachytherapy." | ( Chen, J; Hou, B; Huang, ZP; Li, F; Liu, X; Liu, Y; Qian, S; Song, N; Tian, YH; Wang, LG; Ye, L; Zhou, T, 2017) |
| "For patients with cervical cancer, neutron brachytherapy combined with external-beam radiotherapy plus concurrent chemotherapy produces a rapid response and greatly improves local control and long-term survival rates with tolerable adverse effects." | ( Chen, J; Hou, B; Huang, ZP; Li, F; Liu, X; Liu, Y; Qian, S; Song, N; Tian, YH; Wang, LG; Ye, L; Zhou, T, 2017) |
| "We propose that PKC β would sensitize cervical cancer cells to chemotherapy via reducing the chemotherapy induced autophagy in cancer cells." | ( Li, N; Zhang, W, 2017) |
| "One hundred forty-five patients with cervical cancer who underwent staging FDG PET/computed tomography and subsequent surgical resection or chemoradiotherapy were retrospectively enrolled in the study." | ( Jeon, S; Lee, JW; Lee, SM; Mun, ST, 2017) |
| "In this limited analysis, median OS of cervical cancer patients with PET/CT-positive SCLN metastases was the longest when treated with high-dose chemo-RT." | ( Grigsby, PW; Hagemann, AR; Ioffe, YJ; Massad, LS; Mutch, DG; Powell, MA; Schwarz, JK; Thaker, PH, 2018) |
| "In order to improve the sensitivity of cervical cancer cells to irradiation therapy, we targeted hexokinase 2 (HK2), the first rate-limiting enzyme of glycolysis, and explore its role in cervical cancer cells." | ( Casero, RA; Che, Q; Jiang, F; Jin, L; Kagiampakis, I; Ke, J; Liu, Y; Murray-Stewart, T; Tong, H; Wan, X; Wang, F; Wang, H; Zhang, J, 2017) |
| "Therefore, new strategies to treat cervical cancer are urgently needed." | ( Chou, CJ; Hung, CF; Tseng, SH; Yang, PM, 2017) |
| "We sampled 62 cervical cancer patients with pre-treatment FDG-PET/CT in training (n=32) or test (n=30) sets." | ( Hoh, CK; Li, N; Mahantshetty, U; Mell, LK; Moore, KL; Noticewala, SS; Shen, H; Sirak, I; Tarnawski, R; Williamson, CW, 2017) |
| "Human Cervical Cancer Cell Line, C33A and HeLa were selected for study and treated with epifriedelinol at a concentration of (50-1000 µg/ml)." | ( Fa, J; Li, B; Yang, J, 2017) |
| "After human cervical cancer cells were treated with different doses of TMPyP4, cell viability was determined by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) method, the apoptosis was observed by flow cytometry (FCM), and the expression of p38 mitogen-activated protein kinase (MAPK), phosphated p38 MAPK (p-p38 MAPK), capase-3, MAPKAPK2 (MK-2) and poly ADP-ribose polymerase (PARP) was measured by Western blot analysis." | ( Cao, YG; Cheng, MJ, 2017) |
| "The current standard of care for cervical cancer patients is radiation therapy and concurrent cisplatin (CDDP) chemotherapy." | ( Allen, C; Chang, MC; Chaudary, N; Dou, YN; Dunne, M; Huang, H; Jaffray, DA; Milosevic, M, 2017) |
| "We retrospectively analyzed the elderly cervical cancer patients (≥70 years old) treated with radical RT or CCRT between January 2006 and December 2014." | ( Hou, X; Hu, K; Lian, X; Liu, Z; Meng, Q; Qiu, J; Shen, J; Sun, S; Wang, D; Wang, W; Yan, J; Zhang, F; Zhao, M, 2017) |
| "HeLa DH cervical cancer cells on treatment with various concentrations of benzithiazole for 48 h showed a significant (p < 0." | ( Cui, Z; Li, J; Liu, W; Mao, X; Zhang, X; Zhao, J, 2017) |
| "Patients with cervical cancer recurrence after concurrent chemoradiotherapy (CCRT) who are not candidates for surgical resection or salvage radiotherapy have a dismal prognosis." | ( Aoki, Y; Arakaki, Y; Kinjyo, Y; Kozaki, M; Kudaka, W; Nakamoto, T; Nakasone, T; Ooyama, T; Sakuma, S; Shimoji, Y; Taira, Y; Wakayama, A, 2017) |
| "To identify a subset of cervical cancer (CC) patients administered chemoradiation (CT/RT) plus radical surgery (RS), who can be spared lymphadenectomy, and complications." | ( Chiantera, V; Cosentino, F; Costantini, B; Distefano, M; Ercoli, A; Fanfani, F; Ferrandina, G; Gallotta, V; Margariti, AP; Mascilini, F; Pedone Anchora, L; Scambia, G; Valentini, V, 2017) |
| "Stage IIIB cervical cancer patients with LTI have poorer treatment outcomes including response to treatment and survival outcomes than patients in the same stage without LTI." | ( Katanyoo, K, 2017) |
| "In patients with cervical cancer, both proton therapy and MRI-based target tailoring lead to a significant reduction in the dose to surrounding organs at risk and small bowel toxicity." | ( Bel, A; Buist, MR; de Boer, P; Rasch, CRN; Smit, M; Stalpers, LJA; van de Schoot, AJAJ; Westerveld, H, 2018) |
| "Women who have been treated for cervical cancer have persistent changes in their sexual function, which result in considerable distress." | ( Bergmark, K; Blomgren, B; Bohm-Starke, N; Hofsjö, A; Jahren, H, 2018) |
| "We included 34 patients treated for cervical cancer with radiotherapy and 37 healthy age-matched control women scheduled for benign gynecological surgery." | ( Bergmark, K; Blomgren, B; Bohm-Starke, N; Hofsjö, A; Jahren, H, 2018) |
| "In the cervical cancer survivors treated with radiotherapy, the vaginal epithelium volume was reduced compared to control women." | ( Bergmark, K; Blomgren, B; Bohm-Starke, N; Hofsjö, A; Jahren, H, 2018) |
| "We found that cervical cancer treatment including radiotherapy is associated with vaginal epithelial atrophy and sexual dysfunction." | ( Bergmark, K; Blomgren, B; Bohm-Starke, N; Hofsjö, A; Jahren, H, 2018) |
| "In this study, we stimulated cervical cancer cells with 5-aza-2'-deoxycytidine (5-Aza-dC) and found that this treatment inhibited cell proliferation and induced apoptosis; additionally, methylation of p16 and O-6-methylguanine-DNA methyltransferase (MGMT) was reversed, although their expression was suppressed." | ( Chen, GD; Fan, GY; Li, ZG; Qian, DY; Wu, YL; You, KL, 2017) |
| "We observed TRAIL-resistant cervical cancer cells were more sensitive to fucoxanthin treatments." | ( Du, DL; Jin, LJ; Wang, LL; Ye, GL, 2017) |
| "MATERIAL AND METHODS After human cervical cancer cell lines HeLa, SiHa, and CaSki were treated with fucoxanthin or TRAIL." | ( Jin, Y; Qiu, S; Shao, N; Zheng, J, 2018) |
| "In vivo, mice bearing breast or cervical cancer xenografts were treated with the GSH or TRX modulators and monitored using the mito-TEMPO spin probe." | ( Deglasse, JP; Desmet, C; Gallez, B; Gourgue, F; Jonas, JC; Jordan, BF; Kengen, J; Mignion, L; Neveu, MA, 2018) |
| "Highly glycolytic cervical cancers largely resist treatment by cisplatin and coadministered pelvic irradiation as the present standard of care." | ( Elhammali, AE; Floberg, JM; Huang, X; McCormick, ML; Patti, GJ; Rashmi, R; Schwarz, JK; Spitz, DR, 2018) |
| "Human cervical cancer cells HeLa and SiHa were divided into four group: Blank control group (control), everolimus group (Eve), paclitaxel group (Pac) and combined therapy group (Eve + Pac)." | ( Dai, S; Dong, P; Hao, F; Tian, L, 2018) |
| "Ninety-two patients with cervical cancer (stage IB-IVA, according to FIGO staging), were treated by curative radiotherapy from February 2012 to June 2015." | ( Chakrabandhu, S; Chitapanarux, I; Galalae, RM; Jayasvasti, R; Jia-Mahasap, B; Klunklin, P; Onchan, W; Sripan, P; Tharavichitkul, E; Tippanya, D; Wanwilairat, S, 2018) |
| "In patients with advanced stage cancer of the uterine cervix who undergo irradiation with curative intent, there is the necessity to treat all suspicious nodes on imaging." | ( Adam, JA; Arkies, H; Hinnen, K; Laan, JJ; Mom, CH; Stalpers, LJ; Stoker, J; van Eck-Smit, BL; van Os, R; van Waesberghe, JH, 2018) |
| "To find an anti-cervical cancer drug with high effects and low toxicity, luteoloside was used to treat the cervical cancer cell line Hela to investigate its effects on cell morphology, proliferation, apoptosis, and related proteins." | ( Dai, J; Li, L; Liang, H; Ling, X; Shao, J; Tang, H; Wang, C, 2018) |
| "HeLa, SiHa, C‑33A and CaSki cervical cancer cell lines were cultured and treated with osthole and/or irradiation and then subjected to 3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑-diphenyl‑tetrazolium bromide cell viability, colony formation, apoptosis, acridine orange/ethidium bromide fluorescence staining, wound‑healing, Transwell migration and invasion, immunofluorescence, Comet and western blot assays." | ( Che, Y; Li, J; Li, Z; Wang, S; Yan, Y; Zou, K; Zou, L, 2018) |
| "The rate of STAT3 over-expression in cervical cancer patients with no significant chemotherapy response was markedly higher than that with a significant response." | ( Huang, LL; Rao, W, 2018) |
| "A total of 480 patients with cervical cancer and treated with radiotherapy were included, 274 patients for Ir-192 group and 206 patients for Co-60 group." | ( Rongsriyam, K; Tantivatana, T, 2018) |
| "A case of stage IB2 cervical cancer at 27 weeks of pregnancy, treated with neoadjuvant chemotherapy followed by radical Cesarean hysterectomy with full pelvic and infra-mesenteric lymphadenectomy, and adjuvant chemo-radiation is described." | ( Cavaliere, AF; Cefalo, MG; De Vincenzo, R; Fagotti, A; Ricci, C; Scambia, G; Tortorella, L; Zannoni, GF, 2018) |
| "Advanced cervical cancer with a high Ki-67 PI expression responds better to cisplatin-based chemotherapy, thus resulting in a longer survival rate." | ( Apostolovic, MA; Cvetanovic, A; Golubovic, M; Jovic, Z; Krtinic, D; Mihailovic, D; Pesic, S; Rankovic, GN; Ristic, L; Stokanovic, D; Todorovska, I; Trandafilovic, M; Zivadinovic, A; Zivadinovic, B; Zivadinovic, R; Zivkovic, N, 2018) |
| "Treatment options in locally advanced cervix cancer (LACC) have evolved around radiation therapy (RT) and/or chemotherapy (CT), hypoxic cell sensitizers, immunomodulators (Imm), and locoregional moderate hyperthermia (HT)." | ( Bodis, S; Datta, NR; Gomez, S; Stutz, E, 2019) |
| "Our results showed that CSP3 is a cervical cancer targeting 12aa peptide with high specificity and sensitivity, and the CSP3 conjugated drug delivery system, CSP3-Lipo-DOX-miR101 has promising potential for development as an efficient drug system for the therapy of cervical cancer." | ( Cheng, S; Dong, J; Duan, W; He, H; Hou, Y; Jin, H; Li, J; Ma, N; Song, F; Song, X; Su, X; Xiao, L; Yang, Q; Zuo, R, 2019) |
| "Human cervical cancer cell line, HeLa cell, was treated with Metformin (5 mmol/l or 10 mmol/l) or/and carboplatin (25 mg/l or 50 mg/l) at different final concentrations, and divided into 8 groups." | ( He, DY; Qi, YX; Sheng, MJ; Tang, ZY; Wang, LY, 2018) |
| "A total of 39 studies including 88 cervical cancer patients with platinum administration during pregnancy were selected in this meta-analysis, and 64 women provided International Federation of Gynecology and Obstetrics stage information." | ( Lin, M; Liu, Y; Sheng, B; Song, Y; Zhu, X, 2019) |
| "In women with locally advanced cancer of the cervix (LACC), staging defines disease extent and guides therapy." | ( Anthes, M; Arsenault, J; D'Souza, D; Dayes, I; Dhamanaskar, K; Elit, LM; Filion, M; Fyles, AW; Gu, CS; Gulenchyn, KY; Levine, MN; Metser, U; Pond, GR; Samant, R; Thomas, G; Whelan, TJ, 2018) |
| "The primary obstacle to treat cervical cancer is its high prevalence of metastasis, which severely affects patients' quality of life and survival time." | ( Chen, J; Chen, X; Li, H; Qiu, J; Song, L; Sun, X; Yan, M; Zhang, W; Zhang, Y, 2019) |
| "Additionally, NUSAP1-induced cervical cancer cells metastasis and the cancer stem cell phenotype were abrogated with the Wnt/β-catenin signaling inhibitor XAV-939 treatment." | ( Chen, J; Chen, X; Li, H; Qiu, J; Song, L; Sun, X; Yan, M; Zhang, W; Zhang, Y, 2019) |
| "Patients with newly diagnosed cervical cancer underwent pre-treatment whole-body FDG-PET starting in 1997 at an academic institution." | ( Dehdashti, F; Grigsby, P; Lin, A; Ma, S; Markovina, S; Powell, M; Schwarz, J; Siegel, B, 2019) |
| "Conventional antitumor therapy for cervical cancer includes surgery, radiotherapy, and chemotherapy." | ( Guo, W; Jiang, G; Sun, C; Xin, Y, 2019) |
| "A total of 833 patients with cervical cancer treated with definitive radiotherapy or CCRT in our institute from January 2011 to December 2014 were included." | ( Hu, K; Liu, X; Meng, Q; Wang, W; Zhang, F, 2019) |
| "We retrospectively studied cervical cancer patients treated with definitive chemoradiation between 2009-2013 at a single institution with a baseline MRI with DWI and 18F-FDG positron emission tomography/computed tomography (FDG-PET) scan." | ( Allen, PK; Bhosale, PR; Cardenas, CE; Fang, P; Frumovitz, MM; Fuller, CD; Ho, JC; Jhingran, A; Klopp, AH; Mohamed, ASR, 2019) |
| "Enrolled 92 patients with stage IB2-IVB cervical cancer who received CCRT underwent 3-T BOLD MRI before treatment." | ( Gu, KW; Kim, CK; Lee, J; Park, W, 2019) |
| "Improved treatment for advanced cervical cancer is needed; currently, treatment options include combined chemotherapy and bevacizumab or pembrolizumab monotherapy for PD-L1 positive disease." | ( Campos, S; Dillon, D; Gray, KP; Konstantinopoulos, PA; Liu, JF; MacNeill, K; Matulonis, UA; Morrissey, S; Peralta, A; Whalen, C; Wright, AA, 2019) |
| "Patients with cervical cancer treated with radiotherapy or CCRT between January 2010 and December 2015 in our institute were reviewed." | ( Hu, K; Liu, X; Meng, Q; Wang, W; Zhang, F, 2019) |
| "A significant decrease in cervical cancer tumor volume was observed in this in vivo model, following treatment with CKD-602." | ( Baik, M; Choi, YJ; Ho, JY; Hur, SY; Ko, M; Lee, H; Lee, S; Lee, SU; Liu, JJ; Park, JY, 2019) |
| "Treatment for cervical cancer cost $1,345-$6,514, depending on stage." | ( Babigumira, JB; Chung, MH; Garrison, LP; Kosgei, RJ; Lee, F; Mugo, NR; Okech, TC; Sakr, SR; Stergachis, A; Vodicka, EL; Zimmermann, MR, 2019) |
| "Among women with cervical cancer, DEB-TACE achieved equal short-term efficacy, better tolerance, less hospital stay and medical costs, and higher resection rates as compared with synchronous radiochemotherapy." | ( Chen, M; Chen, W; Huang, L; Ji, J; Song, J; Tu, J; Zhao, Z; Zhou, H; Zhou, L; Zhu, X, 2019) |
| "Orthotopic cervical cancer xenografts were treated with RTCT (30 Gy in 2 Gy fractions and cisplatin) with or without concurrent, adjuvant or continuous plerixafor." | ( Chaudary, N; Han, K; Hill, RP; Lecavalier-Barsoum, M; Milosevic, M; Pintilie, M, 2019) |
| "HeLa, human cervical cancer cells were treated with various doses of CRE and changes in cell morphology and cell viability were assessed using microscopy and flow cytometry." | ( Cheng, ZY; Chueh, FS; Chung, JG; Kuo, CL; Lin, CH; Peng, SF, 2019) |
| "Inhibiting mTOR is cytotoxic to cervical cancer cells and creates a synergistic anti-tumor effect with conventional chemotherapy agents." | ( Han, JW; Lee, J; Lee, KR; Lee, MG; Nam, G; Nam, KH; Noh, JS; Oh, H; Park, HJ; Park, JH; Park, JW; Yi, SA, 2019) |
| "Treatment of cervical cancer cells with RAME promoted autophagy and apoptosis, decreasing cell survival rate." | ( Han, JW; Lee, J; Lee, KR; Lee, MG; Nam, G; Nam, KH; Noh, JS; Oh, H; Park, HJ; Park, JH; Park, JW; Yi, SA, 2019) |
| "Women aged ≥65 years with nonmetastatic cervical cancer treated with definitive external-beam RT and brachytherapy were identified in the SEER-Medicare database." | ( Kidd, EA; Xiang, M, 2019) |
| "Opioid-naive cervical cancer patients treated primarily with radiation and chemosensitization at a single institution, between January 2011 and December 2015, were identified." | ( Fischer, S; Lefkowits, C; Ramzan, A; Sheeder, J; Ward, K, 2019) |
| "Shp2 blockade may be a new strategy for cervical cancer treatment." | ( Cao, M; Duan, Y; Gao, D; Mujtaba, H; Wang, Y; Zhang, N, 2019) |
| "However, for cervical cancer, the role of neoadjuvant chemotherapy (NACT) on the local immune microenvironment is largely unexplored." | ( Bosse, T; de Kroon, CD; de Menezes, RX; Heeren, AM; Jordanova, ES; Kenter, GG; Kole, J; Lakeman, J; Pocorni, N; van Luijk, IF, 2019) |
| "Locally advanced stage cervical cancer diagnosed during pregnancy is a clinical challenge and requires skill in balancing maternal management, fetal care, and oncological treatment." | ( Bergamini, A; Candiani, M; Girardelli, S; Mangili, G; Petrone, M; Rabaiotti, E; Valsecchi, L, 2020) |
| "Siha and Hela cervical cancer cells were cultured and treated with 3% sevoflurane, 10 μmol/L DDP, or the co-treatment of sevoflurane and DDP, respectively." | ( Li, R; Song, Y; Xu, Y; Xue, F; Zhang, W; Zhu, X, 2019) |
| "145 patients with locally advanced cervical cancer were treated at our institution." | ( Cappiello, MA; Ferré, M; Gonzague, L; Houvenaeghel, G; Jauffret, C; Lambaudie, E; Mailleux, H; Minsat, M; Provansal, M; Rua, S; Tallet, A; Varela Cagetti, L; Zemmour, C, 2020) |
| "Patients with metastatic and recurrent cervical cancer (CC) have a poor prognosis with limited palliative treatment options." | ( Benedetti Panici, P; Di Donato, V; Fischetti, M; Giancotti, A; Monti, M; Musacchio, L; Muzii, L; Palaia, I; Perniola, G; Petrella, MC; Santangelo, G; Tomao, F, 2020) |
| "Treatment for cervical cancer consists of hysterectomy, radiotherapy, chemotherapy and targeted therapy in different combination based on stage at presentation." | ( Abrol, D; Bentrad, V; Bharat, RP; Bharti, SJ; Chakraborty, A; Dubey, A; Luther, A; Mandrelle, K; Patil, J; Saini, D; Shankar, A, 2020) |
| "Patients with recurrent cervical cancer in the apatinib-treated group were administered apatinib and carboplatin-paclitaxel as first-line chemotherapy." | ( Chen, J; Guo, Q; Kong, E; Li, M; Liu, N; Rao, L; Sun, L; Sun, Y; Wu, Q; Zhang, T, 2020) |
| "Human cervical cancer cell lines CaSki under hypoxic conditions were used to evaluate the cell viability by CCK-8 assay after the prodrug treatment." | ( Chen, HC; Chen, HY; Huang, J; Liu, XW; Rui, W; You, SY, 2020) |
| "After treatment for locally advanced cervical cancer, patients improved in most quality of life aspects." | ( Bonadio, R; da Costa, S; de Bock, GH; Del Pilar Estevez Diz, M; Dornellas, A; Nunes de Arruda, F; Pereira, D, 2020) |
| "The existing parenteral treatment of cervical cancer has high toxicity and poor distribution of drugs at the targeted site." | ( Arora, D; Kaur, H; Kaur, S; Khurana, B; Mishra, N, 2021) |
| "At present, cervical cancer is the fourth leading cause of cancer among women worldwide with no effective treatment options." | ( Caetano, W; César, GB; Consolaro, MEL; da Silva, VRS; Damke, E; Damke, GMZF; de Freitas Meirelles, LE; de Oliveira Silva, S; de Souza Bonfim-Mendonça, P; Gonçalves, RS; Hioka, N; Ratti, BA; Souza, RP, 2020) |
| "Given the few effective options for cervical cancer after platinum-based therapy failure, neratinib warrants further investigation in this molecularly defined patient population." | ( Alvarez, EA; Bidard, FC; Boni, V; Brana, I; Bryce, RP; D'Souza, A; Do, KTM; Eli, LD; ElNaggar, AC; Friedman, CF; Goldman, J; Hyman, DM; Keyvanjah, K; Lalani, AS; Meric-Bernstam, F; Monk, BJ; Oaknin, A; Passalacqua, R; Roman, LD; Santin, AD; Solit, DB; Xu, F, 2020) |
| "A large proportion of recurrent cervical cancer (RCC) patients present with poor performance status (PS) after comprehensive treatments, which usually prevents them from opting for clinical trials." | ( Jiang, SN; Shang, YP; Wang, ZM; Xu, XJ, 2020) |
| "Caski (cervical cancer cells) were cultured and followed by the treatment of various concentrations of organosulphur compounds (DADS and DAS), cell viability was measured by MTT assay." | ( Ahmad, A; Ahmad, I; Ansari, IA; Imran, MA; Saeed, M, 2021) |
| "Health system cost for different cervical cancer treatment modalities i." | ( Chauhan, AS; Ghoshal, S; Prinja, S; Rai, B; Singh, MP, 2020) |
| "The use of ICG to detect SLN in cervical cancer treated with open surgery allows a bilateral detection, sensitivity and negative predictive value comparable to minimally invasive surgery with potential advantages of ICG compared to other tracers." | ( Bizzarri, N; Carbone, MV; Chiantera, V; Fagotti, A; Fanfani, F; Fedele, C; Ferrandina, G; Gallotta, V; Gueli Alletti, S; Luigi, PA; Scambia, G; Teodorico, E; Zannoni, GF, 2021) |
| "Human cervical cancer cell lines SiHa and Ca Ski were treated with different concentrations of BBR." | ( Cui, L; Liu, L; Sun, L; Zheng, J, 2021) |
| "The HeLa and Caski cervical cancer cell lines were treated with different concentrations of TSA." | ( Cao, YM; Ding, J; Liu, JH; Pan, X; Rong, ZP, 2021) |
| "To solve this and to enhance cervical cancer treatment, a furin-responsive triterpenine-based liposomal complex (PEGcleavable Tf-CTM/L), with Tf-CTM (transferrin-modified tripterine-loaded coix seed oil microemulsion) in core, coated with a thermo-sensitive lipid and a kind of PEG shell modified with a furin-cleavable peptide was developed to improve tumor-specific accumulation and penetration." | ( Chen, Y; Guo, J; Guo, M; Liu, Y; Qu, D, 2020) |
| "The call for elimination of cervical cancer as a public health problem by the World Health Organization has led to intense focus on the burden of disease, available resources, and the possibility of introducing efficient systems for screening and treatment that allow effective cancer control in limited-resource settings." | ( Basu, P; Bhatla, N; Nessa, A; Oswal, K; Sebastian, P; Vashist, S, 2021) |
| "The treatment of recurrent cervical cancer, especially pelvic locoregional recurrence, is very challenging for gynecologic oncologists." | ( Chen, R; Cui, Y; Guo, S; Li, F; Ma, S; Wang, H; Wang, Y; Wang, Z; Wei, Y; Zhang, K, 2020) |
| "81 consecutive cervical cancer patients with pre-treatment staging MRI and [18F]-FDG PET/CT imaging were included." | ( Aboagye, EO; Arshad, MA; Barwick, TD; Bharwani, N; Gitau, S; Park, WE; Patel, NH; Rockall, A; Tam, H, 2021) |
| "For stage IIIB cervical cancer, treatment with CRT offers a significant benefit in DFS and OS compared with treatment with RT only." | ( da Costa Machado, H; Esteves, SCB; Fachini, AMD; Sarian, LO; Teixeira, JC; Zeferino, LC; Zuliani, AC, 2021) |
| "HeLa cervical cancer cells were cultured and subsequently treated with various doses of carvacrol." | ( Ahmad, A; Ansari, IA, 2021) |
| "Treatment of cervical cancer cells with the p53 activator Mithramycin A restored the levels of the endogenous ERBB2 inhibitor miR‑3184‑5p and may represent a novel treatment strategy for cervical cancer." | ( Guo, S; Li, Y; Liu, F; Liu, H; Liu, J; Wang, H; Wang, L; Wu, N; Zhang, J; Zhang, X; Zhang, Y, 2021) |
| "One of the important treatments for cervical cancer is radiation therapy." | ( Hidayat, YM; Laihad, BJ; Suardi, D; Susanto, H; Tobing, MDL; Wagey, F, 2021) |
| "The advanced cervical cancer patients were assigned to two groups: i) those who received curcumin + radiation therapy and ii) those who received placebo + radiation therapy." | ( Hidayat, YM; Laihad, BJ; Suardi, D; Susanto, H; Tobing, MDL; Wagey, F, 2021) |
| "Pre-treatment of cervical cancer cells with INI-43 at sublethal concentrations enhanced cisplatin sensitivity, evident through decreased cell viability and enhanced apoptosis." | ( Birrer, MJ; Chi, RA; Leaner, VD; van der Watt, P; Wei, W, 2021) |
| "MSUs are useful for providing cervical cancer screening services, using the 'screen and treat' strategy." | ( Baig, M; Basu, P; Joshi, S; Kand, S; Kulkarni, S; Kulkarni, V; Lucas, E; Mandolkar, M; Muwonge, R; Pardeshi, D; Rengaswamy, S; Surwase, K; Wankhede, S, 2021) |
| "Orthotopic cervical cancer xenografts derived from our patients were treated with RT (30 Gy; 2 Gy/d) and cisplatin (4 mg/kg/wk intraperitoneally) with or without concurrent X4-136 (100 mg/kg/d orally) for 3 weeks." | ( Chaudary, N; Hill, RP; Milosevic, M; Stulik, L, 2021) |
| "A total of 83 stage III cervical cancer patients with good performance status (ECOG PS 0, 1) were treated with three-dimensional conformal radiation therapy (3D-CRT) combined with chemotherapy (weekly cisplatin), followed by high-dose-rate (HDR) brachytherapy between January 2017 and March 2019 at Vietnam National Cancer hospital." | ( Dang, ATV; Nguyen, HT; Nguyen, LT; Phung, HT; Truong, MC; Vu, TH, 2021) |
| "The treatment of cervical cancer has reached a plateau in the last 20 years." | ( Chen, WJ; Ding, Y; Liu, H; Liu, YM; Sun, HL; Xu, YY; Ying, SP, 2021) |
| "When planning the treatment of cervical cancer, it is important to look for signs of metastasis before surgery, especially metastasis to the lymph nodes." | ( Adachi, S; Enomoto, T; Haino, K; Ishiguro, T; Ishii, S; Nishikawa, N; Soeda, S; Watanabe, T; Yamaguchi, M; Yoshihara, K, 2021) |
| "Despite advances in cervical cancer therapy, tumor recurrence and metastasis remain the leading causes of mortality." | ( Dai, T; Hao, X; Jiang, N; Sang, M; Sun, X; Sun, Y; Wang, X; Xie, L; Xu, H; Zhao, Q, 2021) |
| "Patients with cervical cancer stage I-IVA underwent radiotherapy alone or chemoradiotherapy using 3DCRT (n = 75) or VMAT (n = 30)." | ( Dröge, LH; Schirmer, MA; von Sivers, FF; Wolff, HA, 2021) |
| "Patients with recurrent or advanced cervical cancer, who agreed to take apatinib, were recruited into this single-center and retrospective study, and administrated apatinib with or without combination of chemo- or radio-therapy until progressive disease (PD) or unacceptable toxicity." | ( Chen, M; Mei, Z; Qiu, H; Xie, C; Yang, H; Zhou, Y, 2021) |
| "The immunologic interplay at work in cervical cancer development, progression, and treatment is complex." | ( Chiao, E; Geng, Y; Lakomy, DS; Lin, LL; Lombe, D; Montaner, LJ; Msadabwe, SC; Papasavvas, E; Wu, J, 2021) |
| "Despite various achievements for cervical cancer treatment, there are still shortcomings that lead to severe side effects." | ( Abbasinia, H; Abdollahi, V; Asnaashari, M; Javani Jouni, F; Zadehmodarres, S; Zafari, J, 2022) |
| "Recurrent cervical cancer is hard to treat when occurring in a previous radiated area and unresectable or distant metastasis." | ( Lai, CH; Liu, FY; Tung, HJ; Wang, CC, 2021) |
| "Patients with locally advanced cervical cancer (LACC) treated with chemoradiation often experience hematologic toxicity (HT), as chemoradiation can induce bone marrow (BM) suppression." | ( Corbeau, A; de Boer, SM; Godart, J; Hoogeman, MS; Horeweg, N; Kuipers, SC; Nout, RA, 2021) |
| "During a July 2018 cervical cancer screen-and-treat in Mwanza, Tanzania, participants were offered free cervical VIA screening, cryotherapy when indicated, and HIV testing." | ( Bera, KR; Bernstein, M; Chang, J; Chinn, JO; Cooper, EC; Crawford, EW; Dinicu, AI; Hari, A; Lucas, AN; Maher, JA; Naaseh, A; Pearre, DC; Runge, AS; Tewari, KS; Tewari, SE; White, KM; Zezoff, DC; Ziogas, A, 2021) |
| "Discovering compounds with anti-cervical cancer effect and clarifying their targets will help promoting the precise treatment of cervical cancer." | ( Duan, P; Huang, M; Huang, Q; Mei, J; Pan, L; Wang, D; Zhang, X, 2021) |
| "However, the prognosis of cervical cancer patients with metastasis remains unfavorable due to the fact that most of the cervical carcinomas are either resistant to anticancer drugs or show signs of relapse after initial treatment." | ( Chandrashekar, S; Devegowda, D; Nataraj, SM; Raja, S; Ramesh, PS; Udayakumar, SH, 2022) |
| "We retrospectively examined cervical cancer patients who underwent pelvic radiotherapy and 18F-FDG PET/CT between January 2014 and January 2021." | ( Cui, Y; Ji, Y; Shao, C; Shi, D; Su, N; Wang, Y; Zheng, J, 2021) |
| "WHO recommendation for cervical cancer screening in LMICs includes HPV testing as primary screening followed by visual inspection with acetic acid (VIA) and treatment." | ( Baleydier, I; Cattin, M; Enownchong Enow Orock, G; Foguem Tincho, E; Gervaix, A; Kenfack, B; Lemoupa Makajio, S; Makohliso, S; Petignat, P; Schönenberger, K; Thiran, JP; Tsuala Fouogue, J; Undurraga, M; Vassilakos, P; Viñals, R; Wisniak, A, 2021) |
| "Multi-modality treatment of cervical cancer is effective in low resource settings through coordinated care and pragmatic approaches." | ( Bazzett-Matabele, L; Bigirimana, JB; DeBoer, RJ; Katznelson, E; Nguyen, C; Nsabimana, N; Ntasumbumuyange, D; Paciorek, A; Ruhangaza, D; Shulman, LN; Shyirambere, C; Triedman, SA; Umutoni, V; Umwizerwa, A, 2022) |
| "There are nearly 40% of cervical cancer patients showing poor response to neoadjuvant chemotherapy that can be induced by autophagy, however, the underlying mechanism has not yet been fully clarified." | ( Guo, H; Han, Q; Huang, H; Li, Z; Liu, M; Lu, F; Shi, S; Wang, J; Xu, Q; Yang, X; Zhang, T; Zheng, H, 2021) |
| "In the search for effective anticervical cancer drugs, we discovered that β-estradiol (E2), a potent drug for estrogen deficiency syndrome treatment, displays the most potent cytotoxicity against HeLa cells." | ( Chan, M; Chen, J; Chen, L; Chen, S; Chung, C; Deng, L; Huang, Y; Lei, Y; Zhang, E; Zhong, Y, 2022) |
| "Patients with metastatic or recurrent cervical cancer treated with cisplatin-paclitaxel and bevacizumab or carboplatin-paclitaxel and bevacizumab were retrospectively evaluated in this study." | ( Arak, H; Bayram, S; Besen, AA; Bilici, A; Bozkurt, O; Coskun, HS; Dae, SA; Geredeli, C; Goktas Aydin, S; Ilhan, Y; Inanc, M; Kaplan, MA; Karaagac, M; Kargi, A; Korkmaz, M; Kose, F; Onder, AH; Oruc, Z; Ozdogan, M; Ozturk, B; Selvi, O; Sezgin Goksu, S; Tatli, AM; Teker, F, 2022) |
| "19 patients with cervical cancer that underwent pre-therapeutic PET imaging treated at our institution between January 2016 and April 2019 were included in the study." | ( Brambs, CE; Combs, SE; Hugo, C; Knorr, K; Scharl, S; Schüttrumpf, L; Weidenbaecher, CB, 2022) |
| "Advanced/recurrent cervical cancer has limited therapeutic options, with a median progression-free survival after the failure of systemic treatments ranging between 3." | ( Bini, M; Bogani, G; Chiappa, V; Conca, E; Indini, A; Raspagliesi, F; Ronzulli, D, 2023) |
| "There are limited data on management of cervical cancer in women living with HIV in the modern antiretroviral therapy era." | ( Chopra, S; Daddi, A; Deodhar, K; Engineer, R; Ghosh, J; Grover, S; Gulia, S; Gupta, S; Gurram, L; Mahantshetty, U; Maheshwari, A; Menon, S; Mohanty, S; Rekhi, B; Sawant, S; Shylasree, TS, 2022) |
| "Treatment of locally advanced cervical cancer (LACC) involves pelvic chemoradiotherapy, using an extended field in the case of para-aortic involvement." | ( Bourdon, A; Duraes, M; Ferrer, C; Khebbeb, S; Rathat, G; Serrand, C, 2022) |
| "To establish this, the cervical cancer cells were treated with the FSK compound which induced a dose dependent significant inhibition of COX-2 and DDX3 expression." | ( Dharmapuri, G; Lee, KW; Pasha, A; Pawar, SC; Rampogu, S; Ravinder, D, 2022) |
| "The most common treatment for cervical cancer involves the use of the drug cisplatin in conjunction with other therapeutics." | ( Gupte, R; Kraus, WL; Lea, JS; Lin, KY; Nandu, T, 2022) |
| "Patients with recurrent or metastatic cervical cancer have limited treatment options after platinum-containing treatment." | ( Cai, Y; Chen, H; Feng, J; Liu, P; Lou, H; Peng, J; Sun, Y; Tang, D; Wang, J; Wang, L; Yang, J; Zhou, Q; Zou, J, 2022) |
| "Patients with recurrent or metastatic cervical cancer who progressed during or after platinum-based therapy were enrolled to receive SHR-1701 at 30 mg/kg every 3 weeks." | ( Cai, Y; Chen, H; Feng, J; Liu, P; Lou, H; Peng, J; Sun, Y; Tang, D; Wang, J; Wang, L; Yang, J; Zhou, Q; Zou, J, 2022) |
| "Early-stage cervical cancer is mainly treated by surgery." | ( Deng, HT; Gu, YB; Huang, SM; Jiang, QQ; Li, SB; Ying, X, 2022) |
| "Here, SiHa epidermoid cervical cancer cells were treated with cholecalciferol (10-2600 nmol/L)." | ( Bhoora, S; Pillay, TS; Punchoo, R, 2022) |
| "A woman in her 30s with cervical cancer underwent postoperative chemotherapy and showed allergic reactions to multiple taxanes." | ( Ichikawa, G; Nakanishi, K; Okazaki, S; Suzuki, S, 2022) |
| "Data from 120 patients with cervical cancer who were treated with CCRT from January 2016 and December 2018 were retrospectively analyzed." | ( Chen, Q; Dong, Y; Lai, Q; Liu, G; Luo, Y; Pang, H; Song, Q; Tong, R; Yu, T, 2022) |
| "Patients with cervical cancer who received RRH treatment in our hospital from January 2016 to April 2019 were invited to participate in the study." | ( Li, Z; Ling, H; Wang, G; Yi, B; Zhu, S, 2023) |
| "Patients with cervical cancer are mainly treated with platinum compounds, which often cause severe toxic reactions." | ( Ke, XP; Li, JW; Li, L; Liu, P; Pei, JJ, 2023) |
| "A total of 414 patients with cervical cancer of International Federation of Gynecology and Obstetrics (FIGO 2009) stages IB2-IIA2 were included in the retrospective cohort study, who had received carboplatin-liposomal paclitaxel chemotherapy followed by radical surgery (NACT group) or primary radical surgery (PRS group) between 2007 and 2017 at our hospital." | ( Cai, J; Chen, L; Huang, Y; Sun, S; Wang, Z; Xiong, Z; Yang, L; Zhao, J, 2022) |
| "In chemotherapy applied against cervical cancer, non-specific cytotoxicity and drug resistance that develops over time are trying to be overcome." | ( Altun, A; Şahin İnan, ZD; Yulak, F, 2022) |
| "Women with cervical cancer may require counselling and time to enable them to deal with the disease and its treatment." | ( Chaluvarayaswamy, R; Malila, N; Sastry, NB; Somanna, SN, 2022) |
| "Further, we observed that Dkk1-depleted cervical cancer cells induce senescence under Cisplatin treatment instead of apoptosis, suggesting that Dkk1 levels can strongly influence the phenotypic response of these cells toward Cisplatin." | ( Frensemeier, K; Holzer, A; Hoppe-Seyler, F; Hoppe-Seyler, K, 2022) |
| "Patients with locally advanced cervical cancer treated with chemoradiation at our institution between November 2015 and August 2020 were retrospectively identified." | ( Kotha, NV; Marra, KV; Mayadev, JS; McHale, M; Mell, LK; Williamson, CW, 2022) |
| "Obese patients with cervical cancer have been reported to have superior outcomes following chemoradiotherapy, suggesting that free fatty acids (FFA) might enhance response to radiotherapy." | ( Cho, K; Huang, Y; Jayachandran, K; Markovina, S; Muhammad, N; Patti, GJ; Rashmi, R; Ruiz, F; Schwarz, JK; Stanley, J; Zahner, MC; Zhang, J, 2022) |
| "The cost of delayed diagnosis of cervical cancer and its treatment is overwhelming, and the rural population takes the worst hit." | ( Dandpat, A; Khanna, D; Vikraman, SM, 2022) |
| "The second case is a 54-year-old cervical cancer patient, who had received concurrent chemoradiation therapy and further systemic therapy with cisplatin, paclitaxel, and bevacizumab." | ( Chen, HH; Hsiao, SM; Hsieh, CH; Tseng, LM; Wu, CY, 2022) |
| "The second case is a 54-year-old cervical cancer patient, who had received concurrent chemoradiation therapy and further systemic therapy with cisplatin, paclitaxel, and bevacizumab." | ( Chen, HH; Hsiao, SM; Hsieh, CH; Tseng, LM; Wu, CY, 2022) |
| "The second case is a 54-year-old cervical cancer patient, who had received concurrent chemoradiation therapy and further systemic therapy with cisplatin, paclitaxel, and bevacizumab." | ( Chen, HH; Hsiao, SM; Hsieh, CH; Tseng, LM; Wu, CY, 2022) |
| "Despite invaluable advances in cervical cancer therapy, treatment regimens for recurrent or persistent cancers and low-toxicity alternative treatment options are scarce." | ( Chrabąszcz, K; Kwiatek, WM; Paluszkiewicz, C; Pięta, E; Pogoda, K; Suchy, K, 2023) |
| "Despite invaluable advances in cervical cancer therapy, treatment regimens for recurrent or persistent cancers and low-toxicity alternative treatment options are scarce." | ( Chrabąszcz, K; Kwiatek, WM; Paluszkiewicz, C; Pięta, E; Pogoda, K; Suchy, K, 2023) |
| "Recurrent high-grade neuroendocrine cervical cancer has a very poor prognosis and limited active treatment options." | ( Bhosale, P; Chisholm, GB; Flores-Legarreta, A; Frumovitz, M; Gonzales, NR; Hillman, RT; Jhingran, A; Ramalingam, P; Salvo, G, 2023) |
| "Recurrent high-grade neuroendocrine cervical cancer has a very poor prognosis and limited active treatment options." | ( Bhosale, P; Chisholm, GB; Flores-Legarreta, A; Frumovitz, M; Gonzales, NR; Hillman, RT; Jhingran, A; Ramalingam, P; Salvo, G, 2023) |
| "Moreover, cervical cancer risk was considerably reduced in those treated with a high dose (>1,200,000 mg) or for an extended period (≥2,000 days) compared to non-users (HR, 0." | ( Kang, MJ; Kim, HM; Song, SO, 2022) |
| "Women with cervical cancer referred for curative radiotherapy and who underwent two PET-CT scans (before treatment and approximately 7 months post-treatment) were included." | ( Bjurberg, M; Markus, M; Sartor, H; Trägårdh, E, 2023) |
| "Detection of lymph node metastases in cervical cancer patients is important for guiding treatment decisions, however accuracies of current detection methods are limited." | ( Benbrook, DM; Conrad, R; Deng, W; Gold, MA; Husain, S; Jackson, AL; Mathews, CA; Moore, K; Rai, R; Spirtos, N; van der Wel, H; West, CM; Zakhour, M, 2023) |
| "After the diagnosis of cervical cancer at an advanced stage, treatment such as chemotherapy and radiation therapy become too much costly along with having many side effects such as hair loss, loss of appetite, nausea, tiredness, etc." | ( Al-Najjar, MAA; Alam, MS; Zeyaullah, M, 2022) |
| "Locally advanced cervical cancer (LACC) is frequently treated with neoadjuvant chemotherapy (NACT), which includes paclitaxel and platinum." | ( Guo, L; Wang, S; Wang, W; Xie, X; Zhang, Y, 2023) |
| "Sixty-nine patients with cervical cancer treated with curative or postoperative adjuvant therapy received weekly cisplatin concurrent chemotherapy (CCT) and intensity-modulated radiation therapy (IMRT)." | ( Bao, Z; Chen, M; Mei, Z; Qiu, H; Sun, S; Wang, D; Xiang, Q; Xie, C; Yang, C; Yang, H; Yi, Z, 2023) |
| "Mortality from cervical cancer has declined steadily in the United States over the past several decades due to widespread screening for precancerous and early-stage cervical cancer (ECC), which are significantly easier to treat compared with late-stage cervical cancer (LCC)." | ( Montealegre, JR; Oluyomi, AO; Sokale, IO; Thrift, AP, 2023) |
| "Women with advanced/recurrent cervical cancer after ≤1 prior chemotherapy regimen, measurable disease and ECOG performance status ≤2 were treated with eribulin (1." | ( Aldana, M; Brunette-Masi, LL; Ciccone, MA; Dong, T; Facio, G; Garcia, AA; Garcia-Sayre, J; Groshen, SG; Lin, YG; Louie, S; Matsuo, K; Mhawech-Fauceglia, P; Muderspach, LI; Pham, HQ; Roman, LD; Tsao-Wei, DD; Yessaian, AA, 2023) |
| "However, more effective treatment for cervical cancer is needed." | ( Guo, W; Jing, W, 2023) |
| "GA-Fe@EMB can target cervical cancer marker SLC16A1/3 to regulate glycolysis and redox pathways, synergistically with photothermal therapy, which provides a new avenue for the synergistic treatment of malignant cervical cancer." | ( Akram, Z; Li, Y; Li, Z; Sun, S; Xie, Z; You, S; Yu, L; Zhang, J; Zhao, N, 2023) |
| "An important cervical cancer prevention strategy in low- and middle-income countries (LMICs) has been single-visit screen-and-treat (SV-SAT) approach, using visual inspection with acetic acid (VIA) and ablative treatment with cryotherapy to manage precancerous lesions." | ( Barnabas, RV; Baynes, C; Fridah, H; Gimbel, S; Heitner, J; Kerubo, MB; Mugo, NR; Ngure, K; Oluoch, LM; Pinder, LF; Shin, MB; Thomas, KK, 2023) |
| "Patients diagnosed with advanced cervical cancer (CC) have poor prognosis after primary treatment, and there is a lack of biomarkers for predicting patients with an increased risk of recurrence of CC." | ( Chen, M; He, J; Kong, X; Li, L; Lu, Q; Xiong, Y; Xue, M, 2023) |
| "The human cervical cancer cells were treated with STA-9090, Venetoclax, and Sta-9090 plus Venetoclax for 48 h, and cell viability was measured using the XTT assay." | ( Karademir, D; Özgür, A, 2023) |
| "We evaluated cervical cancer program for women living with HIV (WLHIV) to determine program screening rate, primary case finder screening accuracy and treatment and post-treatment screening rate among screen-positive patients." | ( Ajayi, OA; Akinro, Y; Amoo, B; Ayoka-Ikechukwu, R; Ifechelobi, C; Ogunsola, OO; Ojo, TO; Okonkwo, P; Olumeyan, OO; Osayi, E; Wudiri, K, 2023) |
| "A ten-month review of cervical cancer program data among WLHIV aged 15-49 years on HIV care across forty-one comprehensive ART sites, supported by APIN (a PEPFAR implementing partner) for cervical cancer screening and treatment in Nigeria, was conducted from October 2020 to July 2021." | ( Ajayi, OA; Akinro, Y; Amoo, B; Ayoka-Ikechukwu, R; Ifechelobi, C; Ogunsola, OO; Ojo, TO; Okonkwo, P; Olumeyan, OO; Osayi, E; Wudiri, K, 2023) |
| "Survival outcome of patients with cervical cancer who show residual 18F-fluorodeoxyglucose uptake on initial PET/CT after treatment, but reach complete metabolic response on follow-up PET/CT, is not inferior compared with survival of patients who show complete metabolic response on initial PET/CT 3 months after treatment." | ( Baruch, Y; Even-Sapir, E; Grisaru, D; Kerzhner, K; Laskov, I; Michaan, N; Peleg-Hasson, S; Rabin, T; Raz, Y; Safra, T; Wenkert, A, 2023) |
| "In locally advanced cervical cancer (LACC), adding cisplatin to radiotherapy (RT) improves survival but increases toxicity." | ( Antonio, L; Bacorro, W; Baldivia, K; Canlas, R; Dancel, E; Gonzalez, G; Mariano, J; Ortin, TS, 2023) |
| "Modulation of AMPK may have a role in cervical cancer treatment." | ( Beduk Esen, CS; Canpinar, H; Gedik, ME; Gultekin, M; Gunaydin, G; Yedekci, FY; Yildiz, F, 2023) |
| "The emergence of chemoresistance in cervical cancer is extremely challenging in chemotherapy." | ( Chen, J; Chen, S; Chen, Y; Li, H; Li, Y; Liu, C; Liu, X; Shen, C; Sun, H; Wang, X; Wang, Y; Yang, Z; Zhang, C; Zhou, L, 2023) |
| "Nanomedicine for cervical cancer introduces several novel aspects that distinguish it from previous treatment options such as tailored delivery system, precision targeting, combination therapies, real-time monitoring and diverse nanocarriers to overcome the limitations of one another." | ( Das, PP; Kumar, D; Sagar, R; Sengupta, S; Sharma, S; Yadav, R, 2023) |
| "The survival of patients with cervical cancer who are treated with cisplatin in conjunction with the topoisomerase I inhibitor topotecan is enhanced when compared with patients treated with only one of these chemotherapeutics." | ( Arens, R; de Graaf, JF; Melief, CJM; Pardieck, IN; van der Burg, SH; van der Maaden, K; van der Sluis, TC; van Duikeren, S; van Haften, FJ; Vleeshouwers, W, 2023) |